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9, 3 and 10 cases. Adjuvant therapy was administrated in 61 patients while 33 patients 
needn’t. Depth of invasion limited to partial pleura or intercostal soft issue in 60 cases, 
infiltrated into rib in 44 patients. Of 66 CT available cases, tumor’s location arrived at 
spine was found in 19 and away from in 47 cases. furthermore, distance to transverse 
process was more far than 5cm in 28 while closer in 19. There were 4(3.85%) 
perioperative mortalities caused by PE or respiratory failure. Overall 5 year survival was 
41.6%. Local-regional recurrence occurred in 5 patients with 45 patients developing 
systemic recurrence. The adjuvant therapy (yes versus no,p=0.0005), depth of 
invasion(rib versus other, p<0.0001), tumor size(≤3 versus >3cm, p=0.017) and tumor’s 
location(arrival versus away, p=0.034; near versus far, p=0.019)(fig. 1) were found as 
prognostic factors in univariate analysis. I have to mention that the near goup can 
surprisely better the suvival as opposite to what we have historically thought. Two 
independent factors affecting long term survival are adjuvant therapy（p=0.002）and 
depth of invasion(p=0.028) according to multivariate analysis. 
fig.1: A: arrival; B: away; C: near; D: far. Conclusion: Adjuvant therapy and depth of 
invasion are independent factors influencing prognosis of en-bloc resected chest wall 
involving non-small cell lung cancers, the role of tumor’s location needs more 
investigations.  
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PUB004 Primary Tumor Resection Showed Survival Benefits for Non-Small-Cell 
Lung Cancers with Unexpected Malignant Pleural Dissemination 
Yijiu Ren, Yunlang She, Chenyang Dai, Gening Jiang, Ke Fei, Pengqing Ying, Chang Chen 
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of 
Medicine, Shanghai/China
Background: Although non-small-cell lung cancer (NSCLC) with malignant pleural 
nodules is generally contraindicated for surgery, there is no consensus concerning 
on-site operative decisions for unexpectedly intra-operatively encountered malignant 
pleural disseminations. The rationale underlying the primary tumor removal and other 
aggressive interventions remains controversial. Methods: All surgical NSCLC cases of 
Shanghai Pulmonary Hospital between January 2005 and December 2013 were reviewed. 
Among them, 83 cases met the definition of “unexpected” malignant pleural nodules, 
despite routine preoperative evaluations for tumor metastasis. No pleural effusion was 
visualized in 52 cases during operations, and 31 had pleural effusion in minimal volume. 
Survivals were calculated with Kaplan–Meier method and risk factors were evaluated 
by the log-rank test. Results: The overall 3- and 5-year survival rates were 36.1% and 
16.8%, respectively. The median survival time (MST) after surgery was significantly 
longer in the group without pleural effusion (37 months) compared to group with pleural 
effusion (22 months, p=0.005) (Fig 1). Patients with primary tumor resection had 
significantly better outcome compared to biopsy (MST: respectively, 35 vs. 17 months, 
3-year survival 45.8% vs. 11.8%, p=0.001) (Fig 2). No baseline differences emerged
in characteristics between biopsy (n=21) and primary tumor resection (n=62) groups
including targeted therapy. Multivariate analysis showed that primary tumor resection
(HR: 3.678, p=0.014), no pleural effusion (HR: 3.409, p=0.001), N0/1 status (HR: 5.937, 
p=0.002), and adenocarcinoma (HR: 5.481, p=0.002) were favorable prognostic factors 
in patients with malignant pleural nodules.
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PUB001 EGFR TKI Erlotinib in Patients with Advanced Squamous Cell 
Carcinoma of the Lung: A Retrospective Analysis from India Devavrat Arya, 
Manish K. Singhal Medical Oncology, Fortis International Oncology Centre, Noida, Uttar 
Pradesh/India
Background: Erlotinib has proven efficacy in patients with advanced non-small cell lung 
cancer, especially adenocarcinoma which harbour activating EGFR mutations. In squamous 
cell carcinomas, it has been used in second line treatment and beyond, especially in 
patients with poor performance status. The aim of this study was to evaluate the efficacy of 
erlotinib in patients with advanced squamous cell carcinoma of lung (SCC). Methods: We 
retrospectively reviewed medical records and serial chest images of lung cancer patients 
with SCC histology and history of erlotinib treatment. The primary objective was to 
assess overall response rate (ORR) and disease control rate (DCR) and the secondary 
objective was to assess progression-free survival (PFS) and overall survival (OS). 
Results: A total of 20 patients were analyzed (18 men and 2 women, median age of 63 
years).Seventeen patients were current or former smokers and three were non smokers. 
Ninety percent of patients had a poor performance status (Eastern Co-operative 
Oncology Group Performance Status 2 or 3). Three patients achieved partial response 
and 7 had stable disease. The ORR was 15 % and the DCR was 50%. The median PFS 
was 4.3 months (range, 1.0 – 8.0 months). Overall Survival (OS) data was not mature at 
the time of reporting. EGFR mutation status of three patients subjected to EGFR analysis 
were all negative. The PFS was longer in patients who were non smokers as compared 
to those who gave a history of current or former smoking (median PFS, 5.3 vs. 4.1 
months). Five patients (25%) had PFS more than six months. Conclusion: A significant 
proportion of lung SCC patients derive a clinical benefit from erlotinib treatment. 
This needs further evaluation that includes testing for activating EGFR mutations 
in these patients particularly those who have longer progression free survivals. 
Keywords: Erlotinib, Squamous Cell Carcinoma Lung, Disease Control Rate, Progression 
Free Survival
PUB002 Accidental Intrathoracic Disseminated pM1a - Distinguished Lung 
Cancer with Favorable Prognosis Wei Li, Wen-Zhao Zhong, Xue-Ning Yang, Ri-Qiang 
Liao, Qiang Nie, Song Dong, Xu-Chao Zhang, Yi-Long Wu Guangdong Lung Cancer 
Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, 
Guangzhou/China
Background: In the 7thedition of lung cancer TNM stage, the prognosis of the pM1aⅣ 
is better than pⅢB. Subgroups of lung cancer patients who underwent incomplete 
resection (R1/R2) gain favorable prognosis. This study compares the prognosis 
between accidental local residue and intrathoracic disseminated pM1a after incomplete 
resection. Methods: Patient characteristics, histological and molecular profiles of lung 
cancer patients who receiving accidental incomplete resection were retrospectively 
collected. All patients were divided into local residual group and intrathoracic 
disseminated pM1a group. Progression-free survival (PFS) and overall survival(OS) 
were evaluated by Kaplan–Meier and Cox regression. Results: From 2008 to 2013, 
1483 lung cancer patients received thoractomy in Guangdong Lung Cancer Institute. 
58 patients receiving incomplete resection(R1/R2) were enrolled, including 38 patients 
of local residue(2.6%) and 20 patients of disseminated pM1a (1.3%). Compared to 
local residual group, disseminated pM1a group includes more female(P=0.002), more 
patients younger than 60 years old(P=0.01), more non-smokers(P=0.037), higher R2/
R1 resection ratio(P=0.013), less patients with lymph nodes metastasis(P=0.013), 
higher stage Ⅳ/ⅢB ratio P<0.001), more adenocarcinomas( P<0.001), more 
adenocarcinomas with lepidic pattern(P<0.001), higher EGFR mutation rates(P<0.001), 
lower EGFR expression（P=0.022）. Median PFS of local residue and disseminated 
pM1a were 8.7 and 18.8 months(P=0.120), and median OS were 11.9 and 36.0 
months(P=0.002), respectively. Cox regression analysis revealed that group (local 
residue vs. disseminated pM1a) was the only independent prognostic factor(P=0.005) 
for OS. Conclusion: Accidental intrathoracic disseminated pM1a is a distinguished lung 
cancer subtype with favorable prognosis comparing to patients of local residue. The 
prolong PFS and OS might contribute to the natural history of the distinguished subtype 
and the favorable response to EGFR-TKI.
PUB003 Prognostic Analysis of High Selected En-Bloc Resected Chest Wall 
Involving Non-Small Cell Lung Cancers Rui Mao, Chang Chen Department of Thoracic 
Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai/China
Background: Factors influencing long term survival of NSCLC invading chest wall have 
been under debates. Considering the advances in examinations and treatments during 
the past several decades, this study is an attempt to investigate the possible prognostic 
factors of this group of patients. Methods: We reviewed data of all patients with NSCLC 
invading chest wall, who underwent complete(R0) surgical treatment of en-bloc resection 
at our hospital from 1994 to 2014. Superior sulcus tumors, neoadjuvant therapy 
receivers and patients need vertebrectomy and reconstruction were excluded. All 
patients were classified according to the current TNM classification. Results: One 
hundred and four patients were included. Adjuvant therapy(chemoradiotherapy or 
chemotherapy) was administered according to the various advises of referring physicians, 
so no uniform protocol was employed. All tumors received en-bloc resection. Complete 
resection was achieved in all cases. There were 61 IIB tumors(T3N0) and 41 IIIA tumors 
(T3N1, 18 patients; T3N2, 22 patients; T4N1, 1 patients) and 2 IIIB(T4N2) tumors 
according to the current TNM classification. Lobectomy, bilobectomy, pneumonectomy, 
wedge/segmentctomy and sleeve lobectomy/plastic lobectomy were required in 80, 2, 
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Meanwhile, the pathological and electron microscopic morphological change with pleural 
carcinomatoid tissue, as well as paraneoplastic normal tissue were observed after 
ICHPC. Results: The symptoms such as dyspnoea, shortness of breath disappeared. 
And MPEs were effectively controlled with total response rate of 100%. All patients KPS 
exceeded seventy. Moreover, the concentration of CEA CYFRA21-1 NSE dramatically 
descended with tolerably adverse effects. Mass necroses with pleural carcinomatoid 
were observed in post-treatment microscope. And chromatin condensation、apoptotic 
body occurrence and nuclear fragmentation in tumor cells were also found in post-
treatment electron microscope. Conclusion: ICHPC has the evident therapeutical effect 
on MPE with less adverse reactions and invasiveness. And it is also suitable for the old 
and rigid patients with MPEs. We think it would be highly valued in controlling the MPEs 
Keywords: Video-assisted thoracic surgery, intrapleural perfusion hyperthermic 
chemotherapy, lung cancer, malignant pleural effusion
PUB006 The Efficacy and Safety of Higher-Dose Icotinib in Non-Small Cell Lung 
Cancer Patients after Progression with Normal Dose Xiaoqing Liu1, Weixia Wang1, 
Chuanhao Tang1, Xiaoyan Li1, Jianjie Li1, Wanfeng Guo1, Haifeng Qin1, Lili Qu1, Hongjun 
Gao1, Fenlai Tan2, Lieming Ding2 1Department of Pulmonary Oncology, 307 Hospital of the 
Academy of Military Medical Sciences, Cancer Center, Beijing/China, 2Betta Pharmaceuticals 
Co.Ltd., Hangzhou/China
Background: Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumor 
activity and favourable toxicity in clinical trials. A phase III clinical study revealed icotinib 
was non-inferior to gefitinib in efficacy with favorable safety. Phase I trials established that 
icotinib anti-tumor efficacy increases with dose escalation. The objective of this study is 
to investigate the efficacy and safety of higher-dose icotinib in non-small cell lung cancer 
(NSCLC) patients after disease progression with normal-dose icotinib. Methods: Patients 
with NSCLC would be administered with higher-dose icotinib (250 mg three times 
per day) after disease progression with 125-mg icotinib, until second progression or 
intolerable toxicity. The primary endpoint was progression-free survival (PFS1) following 
progression at standard dose of icotinib (125 mg), secondary endpoints included 
objective response rate (ORR), disease control rate (DCR) and safety. The safety and 
efficacy of 375-mg icotinib will also be explored in those patients experiencing a second 
progression. This study is registered at ClinicalTrial.gov as NCT01465243. Results: A 
total of 32 NSCLC patients were enrolled, mostly stage IV (29/32), ECOG score 0-1 
(32/32), adenocarcinoma (29/32) and non-smokers (21/32). The median PFS of 125-mg 
icotinib (PFS0) was 150.0 days (95% CI 111.0 - 267.0 days). All 32 patients experienced 
disease progression and thereafter were given 250-mg icotinib three times daily. All 
patients had progressed disease and were evaluable for efficacy. Median PFS in icotinib 
250 mg tid extension period (PFS1) was 64.0 days (95% CI 50.0-103.0 days). Six patients 
were further given 375-mg icotinib after disease progression with 250-mg icotinib with a 
median PFS2 (PFS in 375-mg extension period) of 68.5 days (95% CI 30.0 ~ 117.0 days). 
In the extension period of 250mg and 375mg, the ORR was 15.6% (5/32) and 0% (0/0), 
DCR was 62.5% (20/32) and 66.7%(4/6), respectively. The PFS1 was significantly longer 
in patients with PFS0 > 3 months, compared to patients with PFS0 < 3 months (91.0 vs. 
43.0 days, long-rank p = 0.0046). Thirty-two patients were included in safety analysis, 
the incidence of overall adverse reactions (ADR) was 56.3% (18/32). The most common 
ADRs were rash (34.4%), diarrhea (9.4%), and transaminase elevation (18.8%). Only one 
serious adverse event (SAE) was reported (grades 3 urine leukocytosis), which was 
unrelated to drug by investigator evaluation. No interstitial lung disease (ILD) or treatment-
related deaths were reported. Conclusion: Higher-dose icotinib continuation was well 
tolerated with favorable efficacy in NSCLC patients after disease progression with normal 
dose, especially for patients with a median PFS more than 3 months in 125-mg period. 
Keywords: higher dose, icotinib, non-small cell lung cancer, progression
PUB007 TTF-1 Expression Is Significantly Associated with Mutations in Exon 
21 of the EGFR Gene in Chinese Patients with Lung Adenocarcinoma Ying Li, 
Hongyu Liu, Qingchun Zhao, Yongwen Li, Jun Chen Tianjin Medical University General 
Hospital, Tianjin/China
Background: Non-small cell lung cancers (NSCLCs) make up 85% of lung cancers, with 
a 5-year survival rate of only 15%–17%. Adenocarcinoma of the lung is one of the main 
subtypes of NSCLC. With the identification of epidermal growth factor receptor (EGFR) 
gene mutations in NSCLCs and the development of the EGFR tyrosine kinase inhibitors 
(TKIs), such as gefitinib and erlotinib, the survival and quality of life of adenocarcinoma 
patients have improved greatly. Along with EGFR mutations, thyroid transcription factor-1 
(TTF-1), a biomarker for lung adenocarcinoma, was reported to have a much higher rate 
of expression in the lung adenocarcinoma specimens of Asian, female, and nonsmoking 
lung cancer patients. The NEJ 002 clinical trial also found that the rate of EGFR mutations 
was significantly higher in lung adenocarcinoma specimens that were positive for TTF-1 
expression than in specimens that were TTF-1 negative. Therefore, clarifying whether there 
is a relationship between EGFR mutations and TTF-1 positivity in lung adenocarcinomas 
and whether TTF-1 can be a biomarker of EGFR mutation status is essential, especially for 
some patients with advanced lung cancer with inadequate specimens for evaluating EGFR 
status. Methods: There were 200 lung adenocarcinoma patients who were enrolled in 
this study. Tumor specimens of these patients were investigated for TTF-1 expression 
using immunohistochemistry and mutations in EGFR were determined by a liquidchip 
platform for DNA analysis of slides with sections of formalin-fixed, paraffin-embedded 
specimens. Results: The rates of TTF-1 expression and EGFR mutations were 81.5% and 
45.5%, respectively, in the lung adenocarcinoma specimens of recruited patients. Among 
female nonsmokers (n = 72), 93.1% of specimens were positive for TTF-1 expression, and 
63.9% had EGFR mutations. Of 89 patients with EGFR mutations, 83 (50.9%) specimens 
were simultaneously positive for TTF-1 expression. Kaplan-Meier analysis of all patient 
specimens found that postoperative survival time was not significantly associated with 
 
 
Conclusion: Patients with malignant pleural nodules but without pleural effusion had 
better survival compared to those with effusions. Primary tumor resection had survival 
benefits for patients with unexpected intra-operatively proven malignant pleural nodules. 
Keywords: lung cancer, Surgery, Malignant pleural dissemination, Prognosis
PUB005 Therapeutical Effect of Intrapleural Circular Hyperthermic Perfusion 
Chemotherapy on Malignant Pleural Effusion under VATS Feng Xing1, Hong 
Jiang1, Shenglin Ma2 1Department of Thoracic Surgery, Hangzhou First People’S Hospital, 
Hangzhou, P. R. China, Hangzhou/China, 2Department of Radiation Oncology, The First 
People′S Hospital of Hangzhou Medical Group, Hangzhou/China
Background: Malignant pleural effusion (MPE) is defined as the identification of malignant 
cells in plural fluid or on pleural biopsy, which is often caused by primary pleural malignancy 
and tumors with pleural extension. It is a common complication of advanced malignant 
disease. According to the recently UICC revised staging system, the presence of MPE 
was upstaged from T4 to M1a with poor prognosis. The 30-day mortality is 29 to 50% and 
the median survival is 3 to 12 months. Given these considerations, the management of 
MPE is usually palliative, with promptly relieving of symptoms, reducing discomfort, and 
raising the patient’s quality life. There is no standard treatment for patients with these 
malignancies. And the therapeutic outcomes remain to be unsatisfactory. Recent reports 
have demonstrated the effectiveness of hyperthermic pleural perfusion with cisplatin. 
But only few MPE patients had adopted the therapy in several institutions reports. The 
true long-time therapeutic effect, toxic side reactions, and the patient’s remaining days 
were still to be greatly expected. The purpose of this study is to assess the feasibility, 
toxicity, and final results of intrapleural circular hyperthermic perfusion chemotherapy 
on MPE under VATS Methods: Between February 1999 and March 2012, eighty patients 
with symptomatic MPEs were performed on ICHPC under video-assisted thoracoscopic 
surgery (VATS). All had been proved to be as pleural spreads with malignant effusion 
due to primary or pleural malignancy. After breaking up the pleural adhensions under 
VATS, the 43℃ distilled water 3000ml containing cisplatin (200 mg/m2) was circularly 
perfused into the pleural cavity for one hour through extracorporeal circulation unit. The 
improvement on patient’s symptoms - the change for Karnofsky score(KPS)、the effect 
on MPEs, and the adverse reaction were observed after the treatment. The concentration 
change of carcino-embryonic antigen (CEA), cytokeratin-19 fragments(CYFRA21-1), 
neuron-specific enolase(NSE) were compared before and after the treatment. 
S763Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
grade 3 toxicity( 2 pneumonitis and 1 esophagitis, and no late grades 3-5 toxicity After 
EBRT the airway obstruction was improved to some degree in 58 patient (80.6%) on 
chest X-ray. The median time for maximum obstruction resolution was 23 days (range; 
3-86) from the commencement of EBRT. The rate of improvement in obstruction was 
significantly higher in SCLC (89.5%) than the NSCLC (77.3%) patients (p=0.02). Time 
to maximum resolution was also significantly shorter in SCLC than the NSCLC patients 
(5 vs. 28 days; p=0.02). The median survival was only 2.3 months (rang: 1.1-3.5) in 
non-responder patients which was significantly lower than the 8.9 months (rang: 4.2-
13.6) achieved in responders (p=0.007). The largest diameter of obstructive lesion 
less than 5.3 cm (p=0.02) the biologically effective dose (BED10) of ≥ 39 Gy (p=0.002) 
were factors associated with better resolution of the airway obstruction. On multivariate 
analysis only the SCLC histology and BED10 ≥ 39 Gy retained their significant association 
with better response. Conclusion: EBRT is a relatively safe and effective treatment 
option in relieving tracheal and/or bronchial obstruction without severe toxicities 
in acute and chronic phase in metastatic NSCLC and SCLC patients. Higher EBRT 
doses (BED10 ≥ 39 Gy) should be preferred inorder to achieve superior response rates. 
Keywords: Radiotherapy, Airway obstruction
PUB010 Factors Associated with Brain Metastasis Development in Radically 
Treated Stage IIIB Non-Small Cell Lung Cancer Patients Erkan Topkan, Berna 
Akkus Yildirim, Ozan C. Guler, Yurday Ozdemir Radiation Oncology, Baskent University 
Faculty of Medicine, Adana/Turkey
Background: We retrospectively investigated the factors associated with brain 
metastasis (BM) development following radical concurrent chemoradiotherapy (C-CRT) 
in stage IIIB non-small cell lung cancer (NSCLC) patients. Methods: Institutional 
records of 767stage IIIB NSCLC patients with available pretreatment brain MRI and 
treated between January 2007 and December 2012 were analyzed. FDG-PET-CT was 
the standard staging procedure either during diagnsis or as a re-staging method 
prior to thoracic radiotherapy. All patients received at least 1 cycle of platinum-
based doublet chemotherapy during the course of 3D-conformal 60-66 Gy (2 Gy/fr) 
thoracic radiotherapy. Primary endpoints were the incidence of BM following C-CRT 
and associated risk factors. Results: Median follow-up was 24.7 months (range, 2-61 
months). Two-year survival rate was 31%. One-year incidence of brain metastasis was 
28.7%. In univariate analysis showed that patients younger than 60 years of age had 
more brain metastases than older patients (36% vs 15%, p= 0.01). Brain was more 
frequently thefirst site of metastases in younger patients than >60years (22% vs 9%, p> 
0.05). Histology also significantly affected the development of brain metastasis (43.2% 
in adenocarcinoma, 16.4% in epidermoid carcinoma, p= 0.004). On multivariate analysis, 
only age was found to be significant prognostic factor (p= 0.01). Conclusion: Age 
and histology significantly effects development of brain metastasis in locally 
advanced NSCLC. Younger age was the only significant variable for brain metastasis. 
Keywords: Brain metastasis, Stage IIIB Non-Small Cell Lung Cancer
PUB011 Comparison of Maintenance Therapy in EGFR Mutation Negative and 
EGFR Mutation Positive NSCLC Patients Amit Joshi1, Vanita Noronha1, Abhishek 
Mahajan2, Amit Janu2, Anuradha Chougule1, Nirmala Jambhekar3, Rajeev Kumar3, Kumar 
Prabhash1 1Medical Oncology, Tata Memorial Hospital, Mumbai/India, 2Department of 
Radiodiagnosis, Tata Memorial Hospital, Mumbai/India, 3Department of Pathology, Tata 
Memorial Hospital, Mumbai/India
Background: Platin based doublet is standard of care in locally advanced and metastatic 
NSCLC. Maintenance pemetrexed and tyrosine kinase inhibitior both have shown to improve 
outcomes in patients with favourable response to induction therapy. Methods: Data 
of patients with locally advanced and metastatic non squamous NSCLC who received 
induction pemetrexed platin doublet were retrieved from prospectively maintained lung 
cancer database registered between June 2011 and March 2014.Patients who received 
maintenance pemetrexed and maintenance TKI being EGFR mutation negative and 
positive respectively were chosen for final analysis. Kaplan Meir survival analysis was 
used for Progression free survival and overall survival. Log rank test was used to evaluate 
and compare factors affecting outcome. Results: Median follow up is 16 months. Out of 
268 patients who had favourable response to induction pemetrexed platin doublet, EGFR 
mutation result was available in 238 (89%) patients. Patients who were EGFRF mutation 
negative and received maintenance pemetrexed were 138, while those with EGFR mutation 
negative and received maintenance TKI were 80.Median PFS with maintenance TKI in EGFR 
mutation positive patients was significantly better than that of maintenance pemetrexed in 
EGFR mutation negative (11 months versus 8 months; p=0.01), while the overall survival 
was 19 months and 20 months respectively. Older age, females, non smoker, no baseline 
effusion and partial response to induction did better with maintenance TKI. Conclusion: 
Maintenance TKI in EGFR mutation positive non squamous NSCLC delays disease 
progression more than maintenance pemetrexed in EGFR mutation negative NSCLC. 
Both option fare favourably to improve outcomes after response to induction therapy. 
Keywords: Maintenance, Tyrosine kinase inhibitors, pemetrexed.
PUB012 The National Lung Matrix Trial: Multi-Drug, Genetic Marker-Directed, 
Multi-Arm Phase II Trial in Non-Small Cell Lung Cancer Gary Middleton1, Sanjay 
Popat2, Ian Walker3, Clive Mulatero4, James Spicer5, Yvonne Summers6, Timothy A. 
Yap7, Laura R. Crack8, Lucinda J. Billingham9 1School of Cancer Sciences, University 
of Birmingham, Birmingham/United Kingdom, 2Royal Marsden Hospital, London/United 
Kingdom, 3Strategic Partnerships, Cancer Research UK London/United Kingdom, 4Leeds 
Teaching Hospitals NHS Trust, Leeds/United Kingdom, 5Guy’S & St. Thomas’ NHS Trust; 
King’s College London, London/United Kingdom, 6Department of Medical Oncology, The 
TTF-1 expression and the presence of EGFRmutations. However, patients with stage III-
IV disease whose tumors were positive for TTF-1 expression and EGFR mutations had 
better postoperative survival than similar patients whose tumors were negative for TTF-1 
expression and EGFRmutations. Conclusion: Our study showed a significant association 
between TTF-1 positivity and the presence of EGFR mutations (exon 21) in the lung 
adenocarcinomas of Chinese patients. In clinical practice, TTF-1 expression may be a 
marker for planning therapy for certain patients with lung adenocarcinomas, especially 
for selection of EGFR TKIs.
PUB008 The Impact of Continued Cigarette Smoking on Prognosis in Lung 
Cancer Patients Receiving Chemotherapy Serap Hastürk, Fatma I. Uzel, Sezin 
Altunbay Pulmonary Medicine, Yedikule Chest Diseases and Thoracic Surgery Training 
Hospital, Istanbul/Turkey
Background: Lung cancer is one of the leading causes of mortality worldwide. Cigarette 
smoking is the most important etiologic risk factor, but there are discordant and scarce 
data on the impact of continued smoking during and after chemotherapy on prognosis in 
lung cancer patients. The aim of our study was to investigate the effects of cigarette 
smoking during and after chemotherapy on prognosis in patients with lung 
cancer. Methods: We reviewed the medical records of lung cancer patients who received 
chemotherapy at our hospital between January 2012 and December 2012. Results: Of 
the 209 patients 26 (12.4%) were female, 183 (87,6%) were male with the mean age of 
58±8,4 years. Histologic distribution was as follows: 56 ( 26,8%) adenocarcinoma, 85 
(26,7%) squamous cell carcinoma, 19 (9,1%) small cell carcinoma, 49 (23,4%) unclassified 
non-small cell carcinoma. 22,5% of patients were never-smokers, 56,9% were former 
smokers, 8,1% were them who quitted smoking during treatment, 12,4%were current 
smokers. No relationship was detected between smoking during and after treatment and 
gender, comorbidities, stage of the disease, histology, performance status and former 
smoking habit. The survival time was not different in the same stage disease according 
to smoking status. The mean survival time in patients who were smoking during and after 
treatment was 19±4 months, who were nonsmokers was 33±6 months, who quitted 
smoking 33±14 months and who were long time quitters was 36 months (p=0,69). 
Although these differences did not prove to be statistically significant, patients who 
continued smoking had remarkable shorter survival times.
 
Conclusion: We did not detect any statistically significant prognostic influence of 
smoking during and after chemotherapy in lung cancer patients. As the survival time in 
patients who continued smoking was remarkably shorter than nonsmokers, we 
recommend to incourage patients to quit smoking. Keywords: lung cancer, smoking, 
Prognosis, chemotherapy
PUB009 Effective Resolution of Lung Cancer Related Tracheal and/or 
Bronchial Obstruction with External Beam Radiotherapy Erkan Topkan1, Berna 
Akkus Yildirim1, Yurday Ozdemir1, Ozan C. Guler1, Fatih Kose2 1Radiation Oncology, 
Baskent University Faculty of Medicine, Adana/Turkey, 2Medical Oncology, Baskent University 
Faculty of Medicine, Adana/Turkey
Background: We retrospectively evaluated the efficacy of external beam radiotherapy 
(EBRT) in relieving lung cancer related tracheal and/or bronchial obstruction and 
associated factors. Methods: Medical records of 72 patients with metastatic lung 
cancer and a mass obstructing the trachea and/or bronchi treated with EBRT were 
analyzed. Fifty-three (73.6%) and 19 (26.4%) patients had non-small cell lung- (NSCLC) 
and) small-cell lung cancer (SCLC), respectively. EBRT dose was 8 to 40 Gy (median; 
30 Gy) administered in 1 to 13 fractions (median; 10 fractions). The primary end point 
was the rate of resolution of obstruction after EBRT which was assessed with the 
changes in between the radiographic findings and/or subjective symptoms between 
the pre- and post-EBRT evaluations. Overall survival and EBRT toxicity rates constituted 
the secondary end points. Results: The median follow-up duration was 5.6 months 
(range; 1.3-17.8). Treatment was relatively well tolerated with only 5 (6.9%) acute 
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Results: Not applicable Conclusion: Not applicable Keywords: national clinical trial, 
precision medicine
 
Christie NHS Foundation Trust, Manchester/United Kingdom, 7Royal Marsden NHS Foundation 
Trust, London/United Kingdom, 8Cancer Research UK Clinical Trials Unit, University of 
Birmingham, Birmingham/United Kingdom, 9Cancer Research UK Clinical Trials Unit, 
University of Birmingham, Birmingham/United Kingdom
Background: Management of NSCLC has been transformed by precision medicine. 
There are an increasing number of potentially actionable targets and a pressing need 
to efficiently test the activity of targeted therapies aimed at these actionable changes. 
The National Lung Matrix Trial (NLMT) is a large country level study investigating genetic 
biomarker/targeted therapy combinations. Each arm is non-randomised with the primary 
objective in most cases being objective response rate in order to screen for biomarker-
drug combinations with high signals of activity. CR-UK’s Stratified Medicine Programme 
2 will undertake large volume national molecular pre-screening integrated with the NLMT, 
funded by CR-UK, in partnership with AstraZeneca/MedImmune and Pfizer. The trial opened 
to recruitment in March 2015. The multi-centre trial will be open at all UK Experimental 
Cancer Medicine Centres and will be carried out under a single clinical trial protocol 
and regulatory submission. Key translational analyses include ctDNA for emergence of 
resistance, and whole genome analysis, if content permits, for predictive biomarkers. 
This will be complemented by pre-treatment DNA/RNA analysis for biomarker discovery 
and post-treatment biopsies for resistance mechanisms. Methods: In the NLMT there 
are currently 8 targeted drugs and 23 different drug-biomarker combinations. The 
aim is to determine whether there is sufficient signal of activity in any drug-biomarker 
combination to warrant further investigation. We have chosen to use a Bayesian adaptive 
design that gives a more realistic approach to decision-making and flexibility to make 
conclusions without fixing the exact sample size. The screening platform for the NLMT 
is an adaptable 28-gene Nextera Next Generation Sequencing platform designed by 
Illumina. This covers the range of molecular abnormalities being targeted in the trial. 
The NLMT is an adaptive design allowing new biomarker-drug combinations to be tested 
via incorporation by substantial amendment. The pre-clinical data supporting each 
arm has been rigorously assessed and the implications incorporated into selection of 
biomarkers for each drug. In the FGFR arm we are only including mutations that have 
been specifically demonstrated to be transforming and tumourigenic. In the AKT inhibitor 
arm we are excluding patients with concomitant KRAS mutations as repression of 4E-BP1 
is also driven by ERK activation. In the CDK4 inhibitor arm we are clinically testing the 
synthetic lethality concept in KRAS mutant adenocarcinoma of the lung; we are excluding 
all concomitant abnormalities which can activate AKT/MTOR signalling as this has been 
shown to inhibit KRAS driven oncogene induced senescence.
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PUB015 Clinical Investigation into the Initial Diagnosis and Treatment of 539 
Patients with Ⅳ Stage Lung Cancer Bin J. Li, Qian Shao Department of Radiation, 
Shandong Cancer Hospital and Institute, Jinan/China
Background: The aim of the present study was to analyse clinical data obtained from 
Ⅳ stage lung cancer patients, including the initial clinical symptoms upon diagnosis, 
duration of patient delay in presenting to a doctor, pathological classification, 
transferred organs, treatment strategy and prognosis. Methods: A retrospective 
analysis was conducted of the clinical features of 539 lung cancer patients(Ⅳ stage) 
who were initially diagnosed and treated at Shandong Cancer Hospital and Institute 
(Jinan, China) in 2009. the clinical features of 539 cases of patients, including male 
351 cases（65.1%）, female 188 cases (34.9%).The maximum and minimum age were 
88 and 19 years old, respectively. The average age was 58.51and the median age was 
59, but the age less than 60 years old was 282 cases (52.3%).The main symptoms 
were cough, sputum, blood in phlegm, chest pain, chest tightness, holding breath, fever 
and extrapulmonary symptoms. The shortest duration of patient delay in presenting 
to a doctor was 3 days and the longest was 24 months, the average time was 2.36 
months and the median time was 2.0 months. The pathological type and/or cytology: 
adenocarcinoma, squamous carcinoma, small cell carcinoma, large cell carcinoma, 
Adenosquamous carcinoma and other types were respectively 377 cases (69.9%), 95 
cases (17.6%), 50 cases (9.3%), 9 cases (1.7%), 5 cases (0.9%) and 3 cases (0.6%).
The metastases from one single organ and multiple organs were 393 cases (72.9%), 
146 cases (27.1%), respectively. Single organ metastasis such as pleura, brain, bone, 
lung, liver, adrenal metastasis is respectively 112 cases (28.5%), 100 cases (25.4%), 
78 cases (19.8%), 60 cases (15.3%), 29 cases (7.4%), 14 cases (3.6%). The Kaplan 
Meier method and multivariate Cox regression analysis were performed to analyse the 
influence of age, predominant symptoms, pathological classification, transferred organs, 
treatment strategy on patient’s overall survival. Results: The 1, 2 and 3 year survival 
rates were 64.2% (346 cases), 19.7% (106 cases) and 1.5% (8 cases),respectively. 
The liver metastases were poor prognosis and the bone metastases were relatively 
well. The prognosis of single brain metastasis is relatively better than that of multiple 
brain metastases. The radiotherapy doses of brain metastases tumor were positively 
correlated with survival, and radiation dose more than 6000cGy was better than that 
of less than 6000cGy. Multi-factor analysis showed that the patient’s age, different 
organs transferred, The number of transferred organs and treatment were independent 
risk factors on survival. Conclusion: The clinical symptoms of patients with Ⅳ stage 
lung cancer are diversiform and have no specificity. The duration of patient delay in 
presenting to a doctor and the prognosis is poor. The patient’s age, different transferred 
organs, the number of organs transferred, and treatment affect patient’s survival. 
Keywords: diagnosis, Therapy, Prognosis, Carcinoma, lung
PUB016 Bevacizumab Combined Chemotherapy Significantly Improved PFS 
and ORR of Patients with Advanced Non-Small Cell Lung Cancer Hua R. Guo, Yi 
X. Lu, Cheng C. Xiang Oncology, The First Affiliated Hospital of Nanjing Medical University, 
Nanjing/China
Background: This study aimed to explore whether bevacizumab concomitant with 
pemetrexed and platinum could offer benefits for patients with advanced NSCLC 
by observing their influence on the clinical antitumor efficacy, survival time and 
safety. Methods: Patients with stage IIIB/IV, recurrent, or metastatic histologically- or 
cytologically- confirmed non-squamous non-small cell lung cancer (ns-NSCLC), 25-76 
years of old, performance status 0-2, were treated with platinum-based pemetrexed 
(500 mg/m2) and bevacizumab (7.5 mg/kg) on day 1 of a 21-day cycle until disease 
progression, unacceptable toxicity occured, or patients asked for treatment withdrawal. 
The primary end point of this study was the response rate (RR) and disease control 
rate (DCR). Results: Between October 2011 and November 2014, 33 patients were 
enrolled (72.7% male, 93.9% adenocarcinoma, median age was 56 years), out of 
whom thirty-two patients were included in the response analysis. Combination therapy 
was delivered for a median time of 4.35 cycles (95%CI=3.14-5.57cycles), overall 
response rate was 50% (95%CI=31.9%-68.1%) and disease control rate (CR+PR+SD) 
was 90.625% (95%CI=75.0%-98.0%). Median Progression-free survival (PFS) was 6.23 
months (95 % CI 4.80–7.66 months). All patients were evaluable for toxicity analysis. 
Grade 3 or higher adverse events included leukopenia (3.03%), anemia (6.06%), bleeding 
(3.03%), infection (6.06%) and anorexia (3.03%). No patient experienced drug-related 
deaths. Conclusion: The addition of bevacizumab to chemotherapy of pemetrexed and 
platinum can significantly improve PFS and ORR in treatments of advanced NSCLC, with 
an acceptable risk of bleeding events, hypertension and proteinuria. However, whether 
bevacizumab plus pemetrexed and platinum can prolong OS need further validation. 
Keywords: NSCLC, bevacizumab, chemotherapy
PUB017 A New Approach for Management of EGFR TKI’s Skin Rash Toxicities 
Alberto Fulvi1, Maria C. Romano2, Serena Ricciardi1, Maria R. Migliorino1 1Department 
of Respiratory Disease, San Camillo-Forlanini High Specialization Hospitals, Rome/
Italy, 2Dermatological Unit, San Camillo-Forlanini High Specialization Hospitals, Rome/Italy
Background: EGFR tyrosine kinase inhibitors (EGFR-TKIs) are commonly associated with 
a large number of skin adverse events. Strategies to manage those adverse effects 
are essential to increase patient’s compliance, quality of life, and overall outcome of 
the treatment. Through a proper and early management, EGFR TKIs may provide a less 
PUB013 Identification of Existing Targeted Drugs That Inhibit NTRK and ROS1 
in Lung Cancer Curtis Chong1, Dalia Ercan1, Marzia Capelletti1, Magda Bahcall1, Taebo 
Sim1, Lynette Sholl2, Mizuki Nishino-Habatu3, Bruce E. Johnson1, Nathanael Gray1, 
Pasi A. Janne1 1Medical Oncology, Dana-Farber Cancer Institute, Boston/United States of 
America, 2Department of Pathology, Brigham and Women’S Hospital, Boston/MA/United 
States of America, 3Radiology, Brigham and Women’S Hospital, Bosston/MA/United States 
of America
Background: Patients with oncogenic driver mutations in non-small cell lung 
cancer (NSCLC) who are treated with a targeted agent will eventually develop 
resistance. Methods: In an effort to identify inhibitors of NTRK1 and ROS1, which 
are inappropriately activated in some patients with NSCLC, we created and screened 
a library of existing targeted drugs against Ba/F3 cells transformed with these 
oncogenes. Results: This screen identified the FDA-approved drug cabozantinib (XL184) 
as a potent inhibitor of CD74-ROS1 (IC50 = 9 nM), including the crizotinib-resistant mutants 
G2032R (IC50 = 26 nM) and L2026M (IC50 = 11 nM), with no inhibition of the parental BaF3 
cells (IC50 > 10 uM). AP26113, a dual ALK/EGFR inhibitor undergoing phase I/II clinical 
trials, also potently inhibited CD74-ROS1 (IC50 = 30 nM), including the crizotinib-resistant 
mutants G2032R (IC50 = 170 nM) and L2026M (IC50 = 220 nM), with weak inhibition 
of the parental BaF3 cells (IC50 > 1 uM). Both cabozantinib and AP26113 inhibited 
ROS1 autophosphorylation and downstream ERK activation in CD74-ROS transformed 
Ba/F3 cells and in the SLC-ROS1-rearranged NSCLC cell line HCC78. The FGFR3 
inhibitor dovitinib, which is in phase III clinical trials for renal cell carcinoma, potently 
inhibited NTRK1 transformed compared to parental Ba/F3 cells (IC50 = 69 nM vs > 1 uM), 
and blocked NTRK1 autophosphorylation and ERK activation in transformed 3T3 cells. A 
patient with metastatic ROS1-rearranged NSCLC with progression on crizotinib was treated 
with cabozantinib and experienced a partial response. This patient had a novel ROS1-
rearrangement with RNPC, which encodes RNA binding protein 40, a component of the 
U12-dependent (minor) spliceosome. Conclusion: While acquired resistance to targeted 
therapies is a major clinical problem, this study highlights other existing agents that 
may overcome resistance, and identifies several promising candidates for clinical trials. 
Keywords: Drug repurposing, cabozantinib, ros1
PUB014 Survival Impact of Concomitant Medications in Advanced Lung 
Cancer Mahender Yellu1, Shuchi Gulati2, Nabeela Siddiqi1, Jane Pruemer1, Changchun 
Xie3, Nagla A. Karim1 1Internal Medicine, Universitty of Cincinnati, Cincinnati/OH/United 
States of America, 2Internal Medicine, Universitty of Cincinnati, Cincinnati/United States of 
America, 3Environmental Sciences, Universitty of Cincinnati, Cincinnati/OH/United States of 
America
Background: Limited and conflicting data is available regarding the impact of non-
chemotherapy drugs such as antidepressants, low molecular weight heparin (LMWH) 
and statins on overall survival (OS) in advanced stage lung cancer. We conducted a 
retrospective study to investigate the impact of individual and combined effect of 
these medications followed by a subgroup analysis for LMWH. Methods: Retrospective 
analysis of patients with advanced stage lung cancers including non-small cell lung 
cancers (NSCLC), small cell lung cancers (SCLC) and rare histopathologic types was 
conducted at the University of Cincinnati (UC) between January 2004 and June 2013. 
Patients with early stage lung cancer and those without a tissue diagnosis were excluded 
from the study. Antidepressants (comprising of duloxetine, trazodone, and mirtazapine) 
other than tricyclic antidepressants (TCAs) and selective serotonin receptor inhibitors 
(SSRIs) were grouped separately. Patients not on any of the above medications were used 
as control arm. Death was the end point. Kaplan-Meier method was used to calculate 
median OS with 95% confidence intervals (CI). Cox model was used to test the treatment 
effect adjusted for age and gender. Data was analyzed using SAS (Ver 9.4). Results: A 
total 200 patients were included in the study, 40 patients were on antidepressants, 
28 on LMWH, and 42 on statins. Median age of the study population was 61 years and 
median OS was 539 days (CI 376-839). A trend towards protective effect (cox model) 
was noted in SSRIs (HR 0.836, P 0.590) and other antidepressants (HR 0.840, P 0.660), 
while inferior survival was noted in patients receiving TCAs (HR 1.943, P 0.163). Similarly 
statins have showed a trend towards protective effect (HR 0.840, P 0.513). Therapeutic 
LMWH used for patients with thrombosis had negative effect on OS (HR 1.335, P 0.339), 
but better OS was observed when used as prophylaxis (HR 1.202, P 0.751). None of 
these results achieved statistical significance.
Drug OS in study arm (days)
OS in control 
arm (days) P value
Hazard 
ratio
TCAs 307 560 0.163 1.943
SSRIs >463 539 0.590 0.836
Other antide-
pressants 805 531 0.660 0.840
LMWH 460 539 0.339 1.335
Statins 648 539 0.513 0.840
 
Conclusion: Our study demonstrated a protective effect of SSRIs, other 
antidepressants and statins although statistical significance was not achieved. 
For unknown reasons TCAs and LMWH increased the risk of death. Since our 
sample size is small and also a retrospective analysis, a larger prospective 
study would help determine the impact of these medications on OS. 
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PUB020 Systemic and CNS Activity of Combined RET and mTOR Inhibition 
in RET Re-Arranged NSCLC Vivek Subbiah1, Michael Roxas2, Siraj M. Ali3, Zhenya 
Zhenya2, John V. Heymach2 1Investigational Cancer Therapeutics, UT MD Anderson Cancer 
Center, Houston/United States of America, 2MD Anderson Cancer Center, Houston/United 
States of America, 3Foundation Medicine, Boston/MA/United States of America
Background: In-frame fusion RET transcripts have been characterized in 1-2% of 
non-small cell lung cancers and are known oncogenic drivers. The RET tyrosine 
kinase inhibitor, vandetanib, suppresses fusion-induced, anchorage-independent 
growth activity. A retrospective evaluation of RET biomarker status and outcome to 
vandetanib monotherapy in four phase III randomized NSCLC trials failed to show any 
differential advantage in RET fusion patients. We hypothesized that combined RET 
and mTOR pathway inhibition may overcome the innate and/or acquired resistance 
to RET-targeted monotherapy.Moreover,in vitro studies with a co-administration of 
vandetanib and everolimus was shown to enhance the brain accumulation of vandetanib 
by modulating P-gp/Abcb1- and Bcrp1/Abcg2-mediated efflux. We designed a phase 1 
trial combining vandetanib and everolimus. Methods: Fluorescence in situ hybridization 
(ISH) of paraffin-embedded tissue sections was performed using a clear-view FISH RET 
dual-color breakapart probe from Cymogen DX. Hybridization capture of 315 cancer-
related genes plus introns from 28 genes often rearranged or altered in cancer was 
applied to >50 ng of DNA extracted from samples and sequenced to high, uniform 
coverage in a CLIA certified lab ( Foundation medicine, Boston, MA). Therapy was given 
in the context of a phase I clinical trial vandetanib (300 mg Q daily) and everolimus 
(10 mg Q daily) ClinicalTrials.gov Identifier (NCT01582191). Results: Among > 50 
patients with NSCLC screened for RET rearrangement, a deletion of 5’-RET (red signal) 
was observed in four patients with NSCLC, indicating a RET gene rearrangement. 
Comprehensive genomic profiling confirmed RET fusions in 3 patients (KIF5B-RET n=2; 
CCD6-RET,N=1). Druggable co-occurring alterations included AKT2 amplification 
in 1 patient and full homozygous loss of CDKN2A/B in 2 patients. Patients have been 
enrolled on the vandetanib/everolimus clinical trial and have tolerated therapy (G1 
diarrhea, G1 mucositis). The patient with co-occurring AKT2 amplification completed 
2 cycles. Re-staging MRI brain showed a decrease in the intracranial disease burden 
and PET/CT showed systemic response. Re-staging 3 patients is pending. Biopsies 
at the time of progression are planned. Conclusion: The combination of vandetanib 
and temsirolimus demonstrated both cns and systemic activity in a patient with ret 
fusion NSCLC. Further evaluation of this regimen is ret fusion NSCLC is in progress 
Keywords: Everolimus, RET, mTOR, Vandetanib
PUB021 Bone Metastasis in EGFR Mutant Non-Small Cell Lung Cancer 
Shu-Mei Huang1, Jin -Ji Yang2, Yi-Sheng Huang2, Hua-Jun Chen2, Xiao-Yan Bai2, Qing 
Zhou2, Han-Yan Tu2, Yi-Long Wu2 1Guangdong Lung Cancer Institute, Guangdong General 
Hospital ,Second Clinical Medical Committee, Southern Medical University, Guangzhou/
China, 2Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong 
Academy of Medical Sciences, Guangzhou/China
Background: To elucidate factors affecting overall survival (OS) and skeletal related 
events (SREs) on EGFR mutant NSCLC patients with bone metastasis. Methods: Data of 
patients from Guangdong General Hospital who were diagnosed EGFR mutant advanced 
stage NSCLC between June 1st 2002 and May 31st 2012 were retrospectively collected. 
Patients were excluded who were confirmed secondary primary carcinoma within two 
years of the diagnosis of advanced stage NSCLC. Variables were collected including 
age at diagnosis, gender, performance status, smoking status, histology, EGFR mutation 
status, treatment strategy for entire patients and location, amount, property, SREs and 
zoledronic acid for patients with bone involvement. Patients were stratified by initial 
diagnosis into three cohorts: extraosseous metastasis, both bone and extraosseous 
metastasis, and only bone metastasis. Kaplan-Meier survival curve was conducted for 
survival and Log-rank analysis was conducted for cohort comparison. Univariate and 
multivariate analysis of survival were conducted by a backward Wald Cox-regression 
model. Risk factors of SREs were analyzed using a backward Wald logistic regression 
model. Results: Throughout disease courses, 55.9% (287 of 513 patients) were found 
bone involvement, of which 17.8% with extraosseous metastasis, 57.8% with both bone 
and extraosseous metastasis and 24.4% with only bone metastasis. 40.8% of bone 
lesions were osteoblastic (117 of 287 cases) Both bone and extraosseous metastasis 
at diagnosis was related to a significantly decreased survival (for the three cohorts, 
mOS (95% CI), 29.0m（24.5m,33.5m), 17.0m (14.8m,19.2m) , 24.0m (19.5m,28.5m), 
respectively; p<0.001 )) (Figure 1) In multivariate analysis using Cox-regression, male 
gender and both bone and extraosseous metastasis at diagnosis (HR for both bone and 
extraosseous at diagnosis 1.982[95%CI 1.381, 2.846];p<0.001) indicated a poorer 
prognosis of overall survival for patients with bone metastasis In multivariate analysis 
using logistic regression , bone symptoms at diagnosis, and osteolytic lesions (OR for 
osteolyticlesions 2.164 [95%CI 1.200, 3.903];p=0.010 ) indicated higher risks of SREs, 
and EGFR-TKIs treated as first line had a lower risk of SREs (OR for EGFR-TKIs treated as 
first line 0.579 [95%CI 0.322, 1.041]; p=0.068 ), administration of zoledronic acid (63 of 
287 cases) was of no statistical significance in both univariate and multivariate analysis 
 
toxic treatment option for patients suffering from advanced NSCLC. Methods: Between 
January 2014 and March 2015, 42pts with common EGFR mutation (exon 19 and 21) 
were treated with TKI’s, 35 with irreversible inhibitors and 7 with reversible. Skin’s 
toxicity of each patient is carefully monitored every 15 days in our DH through periodic 
checks carried out by a multidisciplinary team, which includes a dermatologist, in order 
to prevent skin toxicity grade 3-4. The inflammation and the alteration of the corneum 
stratum was treated with water- free unguents, made from vegetable oil (containing 
no mineral oil (petroleum) or steroids) as well as antibiotic local cream. We use oral 
antibiotic and steroid only very occasionally. Skin’s toxicity was evaluated according 
to the System of CTCAE 2014. We evaluated the skin’s toxicity of our patients with a 
proactive approach from the beginning to the end of the TKI’s treatment, as well its 
modification over the course of time. Results: Rash has appeared in all pts within 
2 wks as of the beginning of the treatment. G3 skin toxicity was detected in 3% of 
the pts treated with irreversible TKI and in 1% of the other group. No pts had to stop 
the treatment for more than 3 days because of dermatological toxicity. Conclusion: 
Our observation has demonstrated that a proactive dermatological approach 
could reduce the percentage of treatment suspension and skin’s toxicity grade. 
Strategies to improve the management of EGFR TKI related adverse events should 
improve clinical outcomes, compliance, and QoL in patients with advanced NSCLC. 
Keywords: Skin Toxicity TKIs
PUB018 The Efficacy of Erlotinib as Molecularly Targeted Maintenance 
Therapy in Advanced (NSCLC) Case Reports in Western Iran Mehrdad Payandeh, 
Masoud Sadeghi, Edris Sadeghi KUMS, Kermanshah/Iran
Background: In developing countries, majority of cancer patients have low income. 
Therefore, we could hardly do maintenance therapy about the number of patients with 
non-small-cell lung cancer and other cancers. Maintenance therapy for advanced non-
small-cell lung cancer (NSCLC) refers to the use of an effective agent in the absence 
of disease progression following platinum-based combination chemotherapy to improve 
progression-free survival. In our Clinic, we identified three cancerous patients with 
metastasis for lung cancer. The Epidermal Growth Factor Receptor mutation on exon 
19 started erlotinib therapy for several courses. After a short time, in all patients, 
lesions decreased and patients became stable. Methods: Case reports Results: of the 
study suggested that first of all, these case reports show that maintenance therapy 
with erlotinib according to molecular markers (TTF-1 and kind of EGFR mutation) can 
help survival rate in patients. Second, in this report illustrates erlotinib may to cross 
the blood-brain barrier. Conclusion: Our department of oncology is in Kermanshah 
province, which is one of western provinces in IRAN, and neighbor with Iraq country. 
In 2009, a study [8] showed that health care payments in western Iran, compared with 
other developing countries in Asia, are very high. Majority of peoples this province and 
surrounding provinces are rural and living in (IRAN-IRAQ) war zone. In 2012, Rostaei S 
et al. [9] reported that 43% of people in Kermanshah city are below the poverty line. 
Therefore, majority of cancer patients may have low income ($35 - $150 per month). 
In recent years, due to sanctions on Iran, and since majority of patient samples should 
be sent to Tehran (capital of Iran) for further evaluation, diagnosis, treatment and drug 
costs have had a huge increase. Despite financial limitations for majority of patients, 
because of appropriate clinical facilities in Kermanshah province compared to the 
neighboring provinces, the number of patients referred to our clinic is very high, and over 
a few past years we could do maintenance therapy for the number of wealthy cancer 
patients. In this way, so we could stable lung cancer for three patients (top case reports). 
Keywords: Brain blood barrier, EGFR mutation, Maintenance therapy, NSCLC, TTF-1
PUB019 Randomized Study of Two Schedules of Oral Vinorelbine in Advanced 
NSCLCr Patients Unfit for Platinum-Based Chemotherapy Filippo De Marinis1, 
Renan Fougeray2, Carole Levrault2, Marcello Riggi2 1European Institute of Oncology, Milan/
Italy, 2Pierre Fabre Medicament, Boulogne Billancourt/France
Background: Chemotherapy with a single agent is an appropriate therapeutic option 
suitable for a large number of patients with advanced NSCLC who are unfit for a 
platinum-based chemotherapy because of comorbidities, cardio-vascular problems, 
creatinine clearance decrease and age when it is correlated with functional impairment 
.Among available drugs, oral vinorelbine (NVB) at weekly doses is suitable for patients 
unfit for platinum-based chemotherapy. Oral metronomic NVB has been tested in phase 
I trials at 50 mg three times a week (Monday-Wednesday-Friday), highlighting the 
excellent safety of this scheme. On the basis of these grounds, patients with advanced 
NSCLC unfit for platinum-based chemotherapy are randomized to receive either 
metronomic or weekly oral NVB as first-line single agent treatment. Methods: Open 
label, prospective, multicentre, randomized Phase II study (1:1), with 83 randomised 
NSCLC patients per arm defined unfit for a platinum-based chemotherapy based 
on at least one or more of the following criteria: Previous adjuvant platinum-based 
chemotherapy for resected NSCLC; Creatinine Clearance < 60 ml/min; Heart Failure 
NYHA class II-III; Hearing Loss > Grade 2 ; Medical condition impairing platinum-based 
chemotherapy according to physician’s opinion. Primary Objective is Progression Free 
Survival (PFS) without Grade 4 toxicity (G4PFS) in both arms. Arm A: metronomic 
schedules: Oral vinorelbine 50 mg three times weekly. Arm B: weekly schedules: Oral 
vinorelbine: 60 mg/m2 weekly, for cycle 1, then 80 mg/ m2 weekly. Both treatments 
are delivered until progression. The study accrual is planned to start on T3/2015 
for a duration of 24 monthsResults: not applicable Conclusion: not applicable 
Keywords: Advanced NSCLC, Chemotherapy, Metronomic
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Conclusion: Surgical treatments for NSCLC M1a patients demonstrated better 
survival status than that described in the most of previously publications and might be 
adopted in well selected patients who were in good performance status. Nonsmoking 
histology may be regarded as a benefi cial predictor to survival time in these patients. 
Keywords: Local metastasis, non-small cell lung cancer, Surgical resection
PUB023 Survival of Patients with Non-Small Cell Lung Cancer and Its Relation 
with Clinical Trial Enrollment Carlos A. Carmona1, Eleazar O. Macedo2, Laura-
Alejandra Ramírez-Tirado3, Oscar Arrieta Rodriguez4 1Internal Medicine, Medica Sur 
Foundation and Clinic, Mexico/Mexico, 2Unit of Thoracic Oncology, Department of Medical 
Oncology, Instituto Nacional de Cancerología México D, F., México Distrito Federal/
Mexico, 3Laboratory of Experimental Oncology, National Cancer Institute, Mexico, Df/
Mexico, 4Laboratory of Experimental Oncology and Thoracic Oncology Unit, National Institute 
of Cancer, Mexico City/Mexico
Background: Lung cancer remains the leading cause of cancer-related death for both 
genders worldwide. Oncological up-to-date management has been made, traditionally, 
through the development of Randomized Clinical Trials (RCT). Therefore, treatment 
within clinical trials have also been seen as another promising therapeutic alternative 
for patients as it has been strengthened the scientifi c evidence on the limited antitumor 
effi cacy of the traditional chemotherapeutic approaches. The clinical effect of patients 
due to the enrollment on clinical trials has been a subject poorly studied. However, the 
results with respect to clinical benefi t associated with whether or not patients have 
been enrolled on a trial have been inconsistent. The aim of this study was to analyze 
the survival of patients with non-small cell lung cancer and its relation to clinical trial 
enrollment. Methods: Patients from the Thoracic Oncology Unit at Instituto Nacional 
de Cancerologia of Mexico were included in the study. Data was collected from medical 
records included demographic and clinical characteristics, participation in a clinical 
trial. Comorbidities, chemotherapy treatment, disease stage, histology, presence of 
brain metastasis, and survival details were collected from medical records and were 
updated over time. Multivariable survival analyses using Cox regression were conducted 
to determine the association between enrollment in a clinical trial and survival adjusting 
for age, comorbidities, presence of brain metastasis, stage IIIB versus IV, and cancer 
histology. Results: There were 1042 patients of which, 295 were on a clinical trial 
and 747 outside of it, there were no statistically differences when comparing age, 
gender, disease stage, ECOG-PS, wood smoke exposure and Kras status. There were 
statistically signifi cant differences in adenocarcinoma histology (p= 0.001), Tobacco 
use (p= 0.004), EGFR mutation (p= 0.001) and the presence of brain metastases (p= 
<0.001). For the whole group, median OS at one-year survival were 22.1 months (18.6 
- 25.7). The differences in median OS at one-year between the groups were signifi cant 
(18mo (14.5–21.6mo) vs. 30.1mo (21.0-40.3mo)p=0.0001) in favor to on-trail patients. 
When multivariate analysis was conducted the patients enrolled in a trial showed HR 
of 2.22 [95% CI 1.38 - 3.58] p=≤0.0001. For the whole group, patients who received 
second line chemotherapy had better OS (p=≤0.0001). More patients in the trial 
group received second line chemotherapy (p=0.0004). The difference in the median 
OS between the groups continued to be signifi cant even after patients who received 
second line chemotherapy were censored (p= 0.001). Conclusion: Patients with 
lung cancer who participate in clinical trials at our institution have improved survival 
compared with those who are treated with standard therapies. No other factors 
examined were associated with treatment completion or survival. Improved survival. 
Despite the signifi cant difference in the presence of EGFR mutation that could explain 
differences in survival outcomes, being enrolled in a RCT has a signifi cant improved 
survival after multivariate analysis. So patients with cancer should be encouraged 
to enroll in clinical trials on the basis that those enrolled has better outcomes. 
Keywords: Survival, NSCLC, enrollment, clinical, trial
Conclusion: Both bone and extraosseous metastasis at diagnosis is a poor prognostic 
factor for overall survival. EGFR-TKIs treated as fi rst line decreases the risk of SREs. 
Keywords: skeletal related events, non-small cell lung cancer, EGFR mutation, bone 
metastasis
PUB022 Survival of M1a Non-Small Cell Lung Cancer Treated Surgically 
Tieqin Liu, Hongxu Liu Thoracic Surgery, First Affi liated Hospital China Medical University, 
Shenyang/China
Background: Stage IV non-small cell lung cancer (NSCLC) usually has a poor prognosis 
and surgical procedure is rarely success. This study aimed to retrospectively investigate 
the effectiveness of surgical treatments to these patients. Methods: The outcomes of 
80 NSCLC M1a patients with a median age of 58 years (range 38 to 80 years) were 
analyzed retrospectively after surgery. Eight parameters were used for assessment 
including age, gender, smoking, current drinking, metastatic location, pathology type, 
resection condition status, and adjuvant treatment which may impact the survival time of 
patients.
 
Results: Eighty patients (49 males, 61%) with a median age of 58 (range, 38–80) were 
included. Metastatic sites included: pleural nodules with or without effusion metastasis 
(51, 63.8%), pleural effusion without nodules (7, 8.8%), contralateral lung (9, 11.3%), 
diaphragm nodules metastasis (5, 6.3%), and pericardium nodules metastasis (8, 10%). 
Histology was adenocarcinoma in 55, squamous-cell carcinoma in 16, large cell in 5 
and other in 4 patients. Types of lung resection performed for primary tumors were 
complete resection in 43 and limited resection in 37 patients. Survival at 5 years for the 
overall population reached 31% (95% confi dence interval, 19.4–43%). The median overall 
survival time was 34.3 months. Ten (12.5%) patients survived for more than 5 years. 
Smoking status and postoperative adjuvant treatment were independent prognostic 
factors (p =0.006 and 0.013). There was no impact on survival for the other six variables.
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PUB027 Surgery vs SBRT for Early-Stage Non-Small Cell Lung Cancer: A 
Meta-Analysis Melina Shoni1, Michiel Ijsseldijk2, Charles Siegert3, Jan Seegers2, Ton 
Van Engelenburg2, Thomas Tsai1, Richard Ten Broek2, Abraham Lebenthal1 1Surgery, 
Brigham and Women’S Hospital, Boston/United States of America, 2Surgery, Slingeland 
Hospital, Doetinchem/Netherlands, 3Surgery, Brigham and Women’S Hospital, Boston/AL/
United States of America
Background: Lobar resection (LR) is considered the standard of care for patients 
diagnosed with early-stage (I and II) non-small cell lung cancer (NSCLC). Recent 
studies indicate that less invasive treatment options, such as sublobar resection (SR) 
(segmentectomy or wedge resection) and stereotactic body radiation therapy (SBRT) 
may have similar oncologic efficacy. Elderly and medically ‘inoperable’ patients pose 
a therapeutic challenge and may benefit from limited therapy. To overcome the high 
heterogeneity of studies published on this matter, we conducted a systematic review 
and meta-analysis to properly compare the oncologic and survival outcomes of LR, SR 
and SBRT in stage I-II NSCLC. Methods: A systematic search of published literature 
was conducted using the main databases [MEDLINE, PubMed, EMBASE, Web of 
Knowledge Search and Cochrane Central Register of Controlled Trials (CENTRAL)] to 
identify pertinent clinical trials and cohort studies published up to December 2014. Two 
independent researchers performed the screening and selection of the eligible studies, 
utilizing the early review organizing software (EROS). We only considered peer-reviewed 
articles studying cohorts with ≥ 20 patients, ≥ 85% biopsy-proven treated lesions, ≥ 24 
months follow up time and reporting relevant survival data. Articles published prior to 
2000, non-English, including neo-adjuvant therapies, as well as conference abstracts 
were excluded. The inverse variance method and the random effects method for meta-
analysis were utilized to assess the pooled overall survival (OS) estimates of individual 
studies and their corresponding 95% confidence interval (CI). Results: A total of 5230 
non-duplicate records were identified by the original search strategy. After screening 
by title and abstract, 720 potentially eligible records were identified. Only 141 articles 
finally met the inclusion criteria and underwent subsequent analysis. Pooled data for the 
surgical arm included 26373 patients with a median age of 65.5 years undergoing LR, 
and 6616 patients with a median age of 70.6 years undergoing SR. Pooled data for the 
SBRT arm included 2151 patients with a median age of 74.5 years and treated with a 
total radiation dose range of 36-72.5 Gy. The 3-year OS was: 79% for LR (95% CI: 75%-
84%), 79% for SR (95% CI: 61%-96%), and 63% for SBRT (95% CI: 55%-71%). Statistical 
significance was seen only between LR and SBRT arms. The survival gap significantly 
widened for 5-year survival: LR 73% (95% CI: 59%-86%), SR 64% (95% CI: 45%-83%), 
SBRT 44% (95% CI: 31%-57%). These differences were maintained when controlled for 
age. Conclusion: In early-stage NSCLC, our meta-analysis demonstrates an unequivocal 
survival superiority of LR over SBRT at 5 years. To date, the best pooled results of SBRT 
at 3 years are still inferior to LR at 5 years. Thus, SBRT should be only offered to patients 
who are medically unfit as a possible alternative to surgery.
PUB028 How Does 4DCT Spare Normal Tissues in NSCLC Radiotherapy by 
Defining ITV? Jian Zhu, Yong Yin Radiation Oncology Physics, Shandong Cancer Hospital 
& Institute, Jinan/China
Background: To investigate how does the four-dimensional CT (4DCT) technique 
spare normal tissues in non-small cell lung cancer (NSCLC) radiotherapy by defining 
individualized internal target volume (ITV). Methods: GTV and CTV were contoured on 
all 10 respiratory phases of 4DCT scans in 10 patients with peripheral NSCLC. Both 
3D and 4D treatment plans were performed for each patient using PTV3D (derived 
from a single CTV plus conventional margins) and PTV4D (derived from ITV4D, which 
included all 10 CTVs plus setup margins). DVH and NTCP values were compared for 
lung, heart and spinal-cord between 3D and 4D treatment plans. Results: The average 
PTV volume of the 4D plans (127.56±70.79) was less than 3D plans (147.65±76.89). 
The 4D plans spared more surrounding normal tissues than 3D plans, especially 
lung. Compared with 3D plans, V5, V10, V20 and V30 of total lung decreased from 
41.25%, 37.75%, 24.25%, 17.00% to 38.13%, 33.00%, 21.25%, 15.13% respectively. 
Without increasing the NTCP of lung significantly, the 4D plans allowed to increase 
the average prescription dose from 60Gy to 66.00±4.62Gy. Conclusion: The 
4DCT based plans can reduce the target volumes, spare more normal tissues 
and allow dose escalation compared with 3D plans in NSCLC radiotherapy. 
Keywords: internal target volume, dosimetry, non-small cell lung cancer, 4DCT
PUB029 Manage of Vascular Injury in VATs LOBECTOMY Yun Li Department of 
Thoracic Surgery, People’s Hospital of Peking University, Beijing/China
Background: Bleeding caused by vascular injury is one of the most critical intra-
operative complications associated with minimally invasive surgery[1]. Thoracoscopic 
lobectomy is attracting more and more interest in the field of thoracic surgery in this 
representative minimally invasive procedure, this problem is more prominent[2-5]. The 
main procedure is completed by anatomic dissection of the blood vessels. The thoracic 
blood vessels have relatively thin and brittle walls compared to the blood vessels in 
other anatomic sites of human body. Therefore, vascular injury and subsequent 
intra-operative bleeding is a concern for every thoracic surgeon[6,7]. Intra-operative 
bleeding is difficult to handle and there have been no specialized reports regarding 
the management of intra-operative bleeding caused by vascular injury during thoracic 
lobectomy. We collected data from 1006 consecutive cases in our hospital over a 
period of approximately 6 years and analyzed various causes of vascular injury and 
corresponding treatment measures. Methods: From September 2009 to April 2013, 
125 patients that the blood loss in VATs lobectomy were exceed 400ml (male=82, 
PUB024 Bone Metastases in Non-Small Cell Lung Cancer: A Retrospective 
Study Puneet K. Bagri, Saurabh Samdariya, Puneet Pareek Radiation Oncology, AIIMS, 
Jodhpur/India
Background: Bone is one of the most common sites of metastasis in patients with 
advanced cancer. Bone metastases often cause skeletal-related events (SREs). Despite 
advances in the treatment of primary lung cancer, SREs still affect many patients. 
The aim of this retrospective study to investigate the clinical impact of SREs, and to 
compare differences in the therapeutic outcome between patients with and without bone 
metastases or SREs. Methods: 512 patients with histologically proved nonsmall cell 
lung cancer (NSCLC) who consulted the department of Oncology at Regional cancer 
institute between May 2009 and July 2011. We assessed their TNM stage, presence 
of bone metastases (on bone scan, CT/MRI, and plain X-ray films), and outcome 
parameters such as SREs, analgesic use, and survival. Results: A total of 164 patients 
(32.03%) were found to have skeletal metastases during their clinical course and 96 
patients (58.54%) out of all 164 patients had SREs. Among 315 stage IV patients, a 
total of 147 (46.67%) had bone metastases, and 72 of these 147 patients (48.98%) 
had SREs. The most common SREs were the need for radiotherapy (48%). Patients 
with SREs tended to have worse survival, while no significant difference of survival 
was observed between patients with and without bone metastases. Conclusion: It 
seems to be important to prevent SREs during the treatment of NSCLC, so further 
studies evaluating bisphosphonates in combination with chemotherapy are warranted. 
Keywords: NSCLC, Bone metastasis, Skeletal-related events
PUB025 Effect of the Newcastle Disease Virus with NP Regimen for Patients 
with NSCLC Ying Hua1, Xiujuan Tao2 1Shandong Cancer Hospital and Institute, Jinan/
China, 2Oncology, Liaoning Cancer Hospital, Shenyang/China
Background: not applicable’ Methods: A total of 140 patients with advanced 
NSCLC were enrolled in the study. The patients were randomized to experimental 
and control groups. Newcastal disease virus combined with NP regimen was given 
to the experimental group, and the NP regimen only was given to the control group 
.The chemotherapy was performed for four cycles every 28 days. The therapeutic 
efficacy was evaluated every 2 cycles.The following indications were observed : level 
of hemoglobin, white blood cell ,platelet, Tcell subpopulation ,as well as short-term 
sfficacy, adverse effects, and QOL. Results: The response rate in the experimental and 
control group were 50.68% and 41.10%, respectively. The CD4/CD8 ratio increased in 
the experimental group but decreased in the control group. Conclusion: The newcastle 
disease virus combined with the NP regimen showed a better therapeutic effect. 
Keywords: carboplatin, newcastle disease virus, NSCLC, drug therapy
PUB026 The Value of Intraoperative Frozen Section of Lymph Nodes in the 
Surgery of Non-Small Cell Lung Cancer Wei Li, Wen-Zhao Zhong, Xue-Ning Yang, 
Song Dong, Ri-Qiang Liao, Qiang Nie, Yi-Long Wu Guangdong Lung Cancer Institute, 
Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou/China
Background: This paper discusses the value of intraoperative rapid pathology of the 
lymph nodes in non-small cell lung cancer(NSCLC) treatment. Methods: From 2010 to 
2014, 2057 lung cancer patients received thoracotomies at the Guangdong Lung Cancer 
Institute (GLCI). Patients had their first station (station N1) draining lymph nodes screened 
according to the location of the tumor and/or suspected metastatic lymph nodes with 
the naked eyes for frozen pathology. Analysis of the preoperative radiological staging 
(cN), intraoperative frozen pathological stage (sN), postoperative pathological staging 
(pN), pseudo operation mode, actual operation mode, intraoperative lymphadenectomy 
or lymph node sampling was conducted. The corresponding rate of preoperative, 
intraoperative, and postoperative N staging and the effects of lymph node frozen 
pathology on the operation mode of non-small cell lung cancer were explored. Results: In 
74 lung cancer patients with submitted frozen lymph nodes, the coincidence rate of 
preoperative imaging cN staging and intraoperative frozen pathological sN staging 
was 62.2% (46/74); the coincidence rate of preoperative imaging cN staging and 
postoperative paraffin pathological pN staging was 63.5% (47/74); the coincidence rate 
of intraoperative frozen pathological sN staging and postoperative paraffin pathological 
pN staging was 71.6% (53/74); and the positive rate of intraoperative lymph node rapid 
pathology was 18/74 (24.3%). According to the frozen lymph node results combined with 
pulmonary function in patients with other diseases, the operation process, intrathoracic 
adhesions and operation strategy were adjusted in 18 cases (five cases of sN positive, 
13 cases of sN negative) during the operation. Among these patients, nine had a lung 
parenchyma resection, including five patients with an enlarged pulmonary parenchymal 
resection range (one case of left pneumonectomy, one case of right middle and lower 
lobectomy, and three cases of right upper and middle lobectomy) and four patients with a 
reduced lung parenchyma resection (one case of left upper lung lymph node sampling + 
R2 resection, one case of left pulmonary lobectomy, and two cases of pulmonary wedge 
resection). Nine patients had changed the scope of lymph node dissection (the scope 
of the lymph node dissection was narrowed in all cases). Conclusion: Pathological 
examination of frozen lymph nodes may change the range of pulmonary parenchyma 
resection and the degree of lymph node cleaning, Which needs further exploration.
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Conclusion: Anatomical lung resection can be performed safely in selected high risk 
patients based on pulmonary function without significant increase in morbidity or 
mortality. The majority of patients had an uneventful post-operative period or developed 
only minor surgical complications. Length of stay as expected was slightly longer than 
the average for all comers although this was lower following thoracoscopic surgery. 
Given that complications following lung resection are multi-factorial, fitness for surgery 
should be thoroughly assessed in all patients with resectable disease within a multi-
disciplinary setting. High operative risk by pulmonary function tests alone should not 
preclude surgical resection. This approach combined with further research into sub-lobar 
resection may allow improved resection rates for non-small cell lung cancer. 
Keywords: Thoracic Surgery, Pulmonary function tests, lung cancer
PUB032 Prognostic Factors in Resected Pathological Right Middle Lobe Non-
Small Cell Lung Cancer Tieqin Liu1, Hongxu Liu2 1Thoracic Surgery, First Affiliated 
Hospital China Medical University, Shenyang/China, 2China Medical University, Shenyang/
China
Background: Patients (pts) with right middle lobe non-small cell lung cancer (NSCLC) 
were not well studied. This study analyzed the prognostic factors in resected pathological 
right middle lobe NSCLC. Methods: 76 pts with completely resected right middle lobe 
NSCLC were stratified on age, gender, smoking status, tumor diameter, metastatic 
status of lymph nodes and histologic subtype. The status of hilar /interlobar lymph nodes 
was assessed according to the seventh edition of the TNM classification for lung cancer. 
Overall survival (OS) as the primary endpoint was defined as the interval between surgery 
and death from the tumor or the most recent follow-up. Outcome was computed using 
Kaplan-Meier curves and correlation was assessed via Cox regression. Results: The 
median follow-up was 47 months. Overall, 28(36.8%) pts died during follow-up. The 1-, 3- 
and 5-year overall survival rates were 90.8%, 71.1% and 47%, respectively. No significant 
differences were noted in the age, gender and histologic subtype. There was a trend 
towards worse overall survival in those with larger tumor size (p=0.087). The lymph node 
metastases and active smoking inversely correlated with OS (50 vs. 34 month; p<0.001 
and 41 vs. 38 month; p=0.029, respectively). There were 31 pts found to have hilar /
interlobar zone lymph nodes metastases. This subgroup included 14 node 2 (N2) pts and 
17 N1 pts. In N1 possive pts, the median overall survival was 40 months for the Hilar/
Interlobar zone positive cohort while 32 months for the negative cohort (P=0.123). In 
multivariate analyses, the presence of lymph node metastases (p<0.001) and smoking 
status (p=0.031) were revealed to be significant independent prognostic factors. 
female=43). The lobectomy consist of 42 right upper lobe, 9 right middle lobe, 19 
right lower lobe, 40 left upper lobe and 15 left lower lobe. The procedure consist of 99 
simple lobectomy, 4 lobectomy combine with partial chest wall resection, 16 compound 
lobectomy, 3 sleeve lobectomy with bronchoplasty and 3 pneumonectomy. The main 
procedure was completely video-assisted anatomical lobectomy with mediastinal 
lymphadenectomy. Results: Among 125 cases with > 400 ml of blood loss, there 
were 3 injury of pulmonary vein, 2 were repaired endoscopiclly and 1 case conversed 
to open thoracotomy to control bleeding and repair the vein. There were 13 injury of 
pulmonary artery, in 2 cases that the proximal trunk of ipsilateral pulmonary artery 
was blocked endoscopically and repaired artery endoscopiclly; in 11 case, conversed 
to open thoracotomy to control bleeding and repair the artery. There were 22 cases 
need blood transfusion in the operation or post-operation. All patients recovered 
well, 47 patients (36.0%) experienced a minor complication. Conclusion: injury of 
blood vessels was common and troublesome in completely thoracotomy lobectomy, 
and always lead to conversion to thoracotomy. The surgeon should deal with it 
based on the character of vessles, condition of injury and experience of the surgeon. 
Keywords: injury of blood vessls, VATs lobectomy, bleeding
PUB030 Sequence of Vessel Interruption in VATs Lobectomy for Early-Stage 
NSCLC Yun Li Department of Thoracic Surgery, People’s Hospital of Peking University, 
Beijing/China
Background: Surgical treatment is optimal for early lung cancer, but there are still 
40-50% of patients who would suffer metastasis after the operation. How to improve 
the methods, reduce the incidence of metastasis, promote the surgical curative 
effect are the direction of thoracic surgeons. Besides, the effect of the cut order of 
blood vessels on the dissemination and accelerating metastasis is always the focus 
of discussion. Recently, most doctors suggest to cut vein first, and then artery, in 
the process of lung lobectomy. They think in this way dissemination will be reduced, 
which is matching the principles of surgery. However, there is no final conclusion yet. 
In contrast, those scholars who think should cut artery first, believe that it can reduce 
the bleeding. But some studies show that the two methods have the similar impact on 
cancer dissemination. The studies are all in a thoracotomy lobectomy, with relatively 
short follow-up time, fewer cases in the group, lack of hierarchical analysis, excessive 
interference factors in the control group, no strong enough markers.As a result, the 
conclusions remain to be further confirmed. This article is to study the curative effects 
of pulmonary arteriovenous cut order on stage Ⅰ～Ⅱ non-small cell lung cancer in the 
completely thoracoscopic lobectomy. Methods: From September 2006 to June 2013, 
1337 patients underwent lobectomy in our hospital, including 334 cases of patients 
underwent completely thoracoscopic(VATs) lobectomy who were identified as stage Ⅰ
～Ⅱ non-small cell lung cancer(NSCLC). They were divided into 3 groups according to the 
order of cutting the blood vessels, including vein cut first group (Group V) with 174 cases, 
artery cut first group (Group A) with 93 cases and Mixed group (Group M) with 67 cases,. 
The preoperative condition, operative factors and the prognosis of the three groups 
were reviewed. We compare with the survival and recurrent the patients. Results: All 
procedures were uneventful, with a median operative time of 181.7 min and a median 
blood loss of 128.0 mL. The three groups were similar in the age, main complication, 
cancer history, diameter, preoperative tumor markers and preoperative lung function, 
with fewer smokers and more lung Infestor in Group A. The average operative bleeding 
during operation was 105.1ml in Group A, which is more than Group V (148.3ml) and 
Group M (107.0ml). The three groups have the similar complication during and after 
the operation. The recurrent in three groups are all far distance metastasis. And 
there is no significant difference in disease free survival (DFS) and overall survival 
(OS). Conclusion: For the treatment of stage Ⅰ～Ⅱ non-small cell lung cancer in total 
thoracoscopy, to cut the pulmonary artery first could reduce the blood loss during VATs 
lobectomy, but it did not influence the surgical difficulty and postoperative complications. 
The sequence of blood vessels interruption has no influence in recurrence and prognosis. 
Keywords: Sequance of Pulmonary vessel Inerruption, VATs lobectomy, NSCLC
PUB031 Outcomes following Anatomical Resection for Lung Cancer in High 
Risk Patients Henrietta Wilson, Tom Routledge, Karen Harrison-Phipps Thoracic 
Surgery, Guy’s Hospital, London/United Kingdom
Background: Surgery remains the gold-standard for patients with resectable non-small 
cell lung cancer. Unfortunately, though improving, resection rates in the UK remain low 
(between 18 and 25%). Current guidance identifies patients with an estimated post-
operative predicted (ppo) FEV1 or TLCO of less than 40% to fall within a high-risk cohort. 
Advances in surgical techniques and peri-operative care have however allowed surgeons to 
offer resection to selected patients within this group. The aim of this study was to 
determine the outcomes of anatomical resection in patients deemed high risk based on 
pulmonary function. Methods: A retrospective review of patients undergoing lobectomy or 
pneumonectomy between January 2013 and January 2015 was performed. Patients with a 
ppo FEV1 or TLCO of less than 40% were included. The main outcomes were post-operative 
complications (graded based on the Ottawa TM&M classification), admission to ITU, length 
of stay and 30 day in-hospital mortality. Results: Surgery was performed in 53 patients 
with a ppo TLCO or FEV1 less than 40% (median ppo TLCO 35%, median ppo FEV1 54%). 
Twelve patients had both ppo FEV1 and TLCO less than 40%. The median age was 70yr 
(range 39-86) with 57% (n=30) being female. Forty six patients underwent lobectomy with 
52% performed thoracoscopically. Three patients underwent bilobectomy and four 
pneumonectomy. There was no operative mortality. Sixty four percent had no complications 
(n=34), twenty-six percent had one or more minor complication (n=14) and 9% had a major 
complication (n=5) as shown in table 1. Nine patients required admission to ITU with three 
being planned electively. Median length of stay was 7 days in the whole cohort and 5 days 
in the thoracoscopic group. One patient was discharged home on oxygen. 
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including patient demographics and operative outcomes were collected and compared 
between the two groups. Operating efficiency was compared by surgical time. The 
rating scale of musculoskeletal discomfort (score ranging from 0 (uninfluenced) to 
100 (maximum fatigue, cease to rest)) was record preoperatively and postoperatively 
to evaluated the surgeons’ working fatigue. Results: Two groups were comparable 
in patient demographics (age, gender, body mass index, ASA score, tumor location, 
histological type and clinical stage). There were 2 cases had conversion to thoracotomy 
(one in each group). In terms of operative features, four-incision group had a little shorter 
surgical time than three-incision (92±26 min versus 97±25 min, p=0.274), though no 
significant difference was confirmed. Besides, the clinical outcomes between two groups 
were similar, including blood loss (three-incision group vs four-incision group: 91±64ml 
vs 97±63ml, p=0.610), number of lymph nodes harvested (14.2±3.6 vs 14.0±3.6, 
p=0.722), postoperative hospital stay (6.7±2.5d vs 6.9±2.4d, p=0.545) and total 
complications (10.4% vs 11.3%, p=0.878). No 30-day mortality occurred in two groups. 
In terms of surgeons’ fatigue evaluation, the increased score after surgery was much 
higher in three-incision group than four-incision group (left upper limb: 65.4±19.2 versus 
42.4±14.2, p=0.000; right upper limb: 61.0±19.9 versus 55.3±13.4, p=0.018; shoulder-
back: 39.1±12.5 versus 25.5±8.4, p=0.000).Conclusion: The study shows that both 
procedures are safely and effective for VATS lobectomy plus mediastinal lymph node 
dissection, though four-incision procedure could provide better ergonomic condition and 
less working fatigue for surgeons, compared with three-incision procedure. Therefore, 
surgeons could make their choice according to their own experience and habits. 
Keywords: Video-assisted thoracoscopic surgery, lobectomy, mediastinal lymph node 
dissection, Ergonomic Evaluation
PUB034 Weight Loss before Radical Chemoradiotherapy Is Associated with 
Poorer Survival Outcomes in Overweight Locally Advanced NSCLC Patients 
Erkan Topkan1, Berna Akkus Yildirim1, Yurday Ozdemir1, Ozan C. Guler1, Ozgur Ozyilkan2 
1Radiation Oncology, Baskent University Faculty of Medicine, Adana/Turkey, 2Medical 
Oncology, Baskent University Faculty of Medicine, Adana/Turkey
Background: Presence of weight loss (WL) has been demonstrated to be associated 
with poor outcomes in locally advanced nonsmall-cell lung cancer (LA-NSCLC) patients. 
However, data regarding the impact of presentation with WL before radical C-CRT is 
scarce. Therefore, we aimed to investigate the impact of WL in radically treated 
overweight (body mass index>25 kg/m2) LA-NSCLC patients. Methods: Medical records 
of 192 stage III NSCLC (squamous cell- or adenocarcinoma) patients with BMI>25 kg/
m2 those underwent platinu-based C-CRT between January 2007 and December 2014 
were retrospectively analyzed. All patients received 60-66 Gy (2 Gy/fx; 5 days a week) 
three-dimensional conformal radiotherapy. Patients were dichotomized into 2 groups 
according to presence (WL+) and absence (WL-) of WL for comparative analysis. Primary 
end point was the overall survival difference between two groups. Results: Median age 
was 62 years (range: 36-74), 129 (67.2%) patients were male, 77% had stage IIIB disease, 
and 55.8% had squamous cell carcinoma.Median follow-up was 23.2 months (range: 4.7-
83.2). Median and 5-year overall survival (OS) rates for overall study population were 
23.6 months and 16.8%. Sixty-seven (34.9%) patients had WL before onset of C-CRT. 
(Patients with WL had significantly shorter median OS time (17.8 vs. 27.8 months; 
p< 0.001) and lower 5-year OS rates (3.8% vs. 21.3%; p< 0.001) than those patients 
without. This difference was significant across the stage (A vs. B), histology (squamous 
cell- vs. adenocarcinoma), and ECOG performance status (0-1 vs. 2). Multivariate 
analysis revealed that the presence of WL before C-CRT was independently associated 
with poorer survival in overweight LA-NSCLC (p<0.001). Conclusion: Presence of 
weight loss prior to C-CRT in overweight LA-NSCLC patients is associated with poorer 
survival outcomes indicating the importance of prevention of malnutrition and early 
use of nutritional support in such patients in an effort to preventor at least prolong the 
progress of anorexia-cahexia complex, and therefore, to prolong survival outcomes. 
Keywords: Overweight, Locally advanced NSCLC, Poorer Survival
PUB035 Phase III Study of Concurrent DDP with Pemtrexed or Vinorelbine and 
LACHRT Based on Normal Tissue for Unresectable Stage III NSCLC Baosheng 
Li1, Qian Zhao2, Zhenying Wu3, Shuzheng Yu4, Qiang Wang5, Zhongtang Wang1 1Radiation 
Oncology, Shandong Cancer Hospital, Jinan/China, 2Shandong Cancer Hospital, Jinan/
China, 3Dezhou Cancer Hospital, Dezhou/China, 4Liaocheng People Hospital, Liaocheng/
China, 5Linzi People Hospital, Zibo/China
Background: Concurrent chemoradiotherapy hasbeen the stadard management 
for unresectable stage III NSCLC. However, the outcome is not satisfactory yet. This 
phase III study was designed to evaluate cisplatin with pemtrexed or vinorelbine with 
concurrent late course accelerated hyperfractionated radiotherapy (LCAHRT) for 
the disease. Methods: Eligible patients were randomly assigned to two concurrent 
regimens: NP arm with cisplatin (DDP) at 25 mg/m2 on days 1-3, 22-24 and vinorelbine 
at 25 mg/m2 on days 1, 8 and 22, 29 with concurrent LCAHRT based on bilateral 
lungs V20 = 33%; DDP at 25 mg/m2 on days 1-3, 22-24 and pemtrexed at 500 mg/
m2 on days 1 and 22 with the same radiotherapy protocol in PP arm. The primary 
endpoint was overall survival (OS) and secondary endpoints included progression-
free survival (PFS) time and toxicities. Results: A total of 105 patients were enrolled 
in this study, and 100 ones analyzed for efficacy and safety. The median survival 
time (95% CI) was 27.0 (18.9-35.0) and 31.0 (13.8-48.1) months for NP and PP arm 
respectively. The PFS and 2-, 3-year survival rates were 12.0 months and 57.6%, 38.9% 
in NP arm, 19.0 months and 56.9%, 49.1% in PP arm. The median survival time (MST) 
of squamous cell carcinoma was 25.5 months, while non-squamous cell carcinoma 
was not reached in PP arm (p = 0.163). The incidences of grade 3 to 4 neutropenia, 
hemotoblatin, and radiation pneumonitis were significantly higher in NP arm than 
those in PP arm regimen. Conclusion: Current study demonstrated that there was no 
 
 
 
 
Conclusion: In a single institution cohort, we validate lymph nodal 
involvement and active smoking inversely correlated with OS in resected 
right middle lobe NSCLC. However, in N1 possive pts, the presence of Hilar/
Interlobar lymph node metastases maybe protective predictor for survival. 
Keywords: Right middle lobe NSCLC; Lymph node metastasis; Hilar/interlobar zone 
metastases.
PUB033 Three-Incision versus Four-Incision Procedure of Video-Assisted 
Thoracoscopic Surgery Lobectomy for NSCLC: Ergonomic Comparison 
Chu Zhang1, Binjun He2, Haiyong Wang2, Jian Cui2, Guangmao Yu2 1Cardiothoracic 
Surgery, Shaoxing People’S Hospital, Zhejiang, China, Shaoxing/China, 2Cardiothoracic 
Surgery, Shaoxing People’S Hospital, Zhejiang University, China, Shaoxing/China
Background: Presently, both three-incision and four-incision procedure are applied for 
video-assisted thoracoscopic surgery (VATS) lobectomy plus mediastinal lymph node 
dissection for non-small cell lung cancer. However, which procedure is superior remains 
uncertain. In this study, we aim to compare the two procedures from the aspect of 
ergonomic evaluation (operating efficiency, clinical outcomes and surgeons’ working 
fatigue). Methods: From January 2014 to February 2015, a total of 129 patients with 
NSCLC who underwent VATS lobectomy plus mediastinal lymph node dissection were 
enrolled in this study. And 67 cases were performed in three-incision procedure (one 
surgeon and one thoracoscope holder), while 62 cases in four-incision procedure (one 
surgeon, one assistant and one thoracoscope holder). All operations were completed 
with the same type of operative devices by experienced surgeons. Clinical characteristics 
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easy and reliable to use and more importantly needs no time for simultaneous data 
entry. Methods: The most important feature of the program is the automatically 
entrance of patients’ demographic data, medical history, co-morbidity, operative 
notes, laboratory and the radiological findings into the database program. Moreover, 
the death time of the patient are also automatically added from the national population 
registration system so clinical follow-up calculations can securely be performed. When 
this program is also being used by other clinics; recurrence, metastasis and treatment 
modalities can easily be monitored in real time. Results: In this study, 1320 patients 
of non small cell pulmonary carcinoma who were operated in our clinic, between the 
years 2005-2014 are recorded and followed-up in this database program. Unresectabl 
cases, early mortalities, T0 tumors owing to neoadjuvant therapy and patients lacking 
data were excluded. Overall 1056 cases were included in the study. 22 datas such as 
demographics, comorbidities, tumor attributes, cell type, differentiation, the number 
of metastatic lenf nodes and stations as well as the TNM staging were included and 
evaluated statistically in the study. All analyses were performed with SPSS 22.0. In 
analyzing the datas, ROC (Receiver Operating Curve), the Kaplan-Meier (product limit 
method), Cox Regression, Spearman’s rho and Fisher’s Z transformation were used. 
Firstly, significant risk factors associated with mortality and survival were determined by 
Kaplan-Meier method. Then these factors are statistically evaluated with Cox regression 
test to estimate the probability of death. The hazard function was calculated for each 
patient using this method. New database system has been succesfully used in this study. 
It is found that the most important variables in determining the survey, in addition to 
the TNM staging were adjuvant chemotherapy and radiotherapy, tumor location and the 
presence of additional tumors. When the probability of death basing on these factors 
was correlated with the survey, a strong negative correlation (r = - 0.802) was observed 
(p<0.001). The probability of death explained 64.3% (r2) of the surveillance. A weak and 
significant negative correlation was determined between the staging and surveillance (r 
= -0130). According to this, the stage described 1.7% (r2) of the surveillance. When the 
probability of death-surveillance r value is compared with the stage-surveillance r value 
with the Fisher Z method, probability of death-surveillance r value was significantly higher 
than the stage-surveillance r value statistically (z = 14.874). Conclusion: According 
to our results, the current staging system is important in assessing the treatment 
modalities but it is found insufficient in estimating surveillance. The variables adjuvant 
chemotherapy and radiotherapy, tumor location and the presence of additional tumors 
when analised with the ’Survival function evaluate at the current case’, it is found that 
these variables are more accurate than TNM staging in predicting the prognosis. 
In conclusion our study is a pilot study, and has learning algorithms that could easily 
be integrated in the structure. Finally we aimed to take a step for the “personalized 
staging” that all the prognostic factors are calculated individually. At present, while 
genome analysis has begun to show the way to personalized treatment, the importance 
of “personalized staging” is obvious. Available in the future we believe that software 
systems will be transformed into artificiel intelligency and current staging system 
will change to individually “personalized staging” that a lot of factors to be analised. 
Keywords: database, Personalized staging, lung cancer
PUB039 Dividing Procedures of Right Upper Lobectomy as aB-VA Indicate 
Better Operative Outcomes for Patients with Lung Cancers Hao-Ran Zhai1, 
Wen-Zhao Zhong2, Xue-Ning Yang2, Song Dong2, Qiang Nie2, Ri-Qiang Liao2, Qing Zhou2, 
Jin-Ji Yang2, Yi-Long Wu2 1Guangdong Lung Cancer Institute, Guangdong General Hospital 
and Guangdong Academy of Medical Sciences; Southern Medical University., Guangzhou/
China, 2Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong 
Academy of Medical Sciences, Guangzhou/China
Background: The most common location of primary lung cancers is right upper 
lobe(about 30.0%) and procedures of right upper lobectomy(RUL) vary frequently. Rare 
analyses of thoracoscopic RUL focus on clinical benefits from different procedures with 
a traditional order of dividing right upper pulmonary vein-artery branches-right upper 
bronchus(VA-B or AV-B) versus an innovational order of posterior ascending branch of 
the pulmonary artery-bronchus-pulmonary veins and artery branches(aB-VA). This study 
aimed to address advantages of operative outcomes and technical feasibility of RUL 
with a dividing order of aB-VA over VA-B/AV-B. Methods: A total of 198 consecutive 
patients with primary lung cancers undergoing RUL assisted by video-assisted thoracic 
surgery(VATS) at Guangdong General Hospital from January 2013 to December 2014, 
were analyzed retrospectively. Two grouping factors were included: procedures of aB-VA 
and VA-B/AV-B as P1 and P2, respectively; surgical team of Team 1 and Team 2 Surgery 
as T1 and T2, respectively. Since no P1 was conducted in T2, there were three groups 
in this study: one, 78 patients in P1T1; two, 56 patients in P2T1; three, 64 patients 
in P2T2. Operative outcomes and surgical complications were compared between 
groups. Results: Clinical characteristics of age, gender and TNM staging were well 
balanced among groups, except for smoking index, pathological types and the number 
of ports during surgeries. Most patients with adenocarcinoma(89.9%,70/78) and less 
patients with squamous cell carcinoma(5.1%, 4/78) were included in P1T1. The average 
operative time and estimated blood loss in three groups were 168±59 minutes vs. 211±61 
minutes vs. 233±87 minutes(P<0.001) and 94±84 mL vs. 171±215 mL vs. 109±107 
mL(P=0.001), respectively. The rates of conversion to open thoracotomy were 0% 
(0/78) vs. 23.2%(13/56) vs. 3.1%(2/64) (P=0.001), respectively. The number of staplers 
during surgeries was 5±2 vs. 6±2 vs. 8±2 (P<0.001), respectively, although total costs 
of staplers were not statistically significant (P=0.810) . Tube duration of patients in three 
groups were 3.4 ±2.7 days vs.3.7±2.9 days vs. 6.3±5.8 days (P<0.001), respectively. 
Surgical costs per patient in P1T1 were less than that in other groups (3.80±0.85 ten-
thousand-yuan RMB vs. 3.90±0.97 ten-thousand-yuan RMB vs. 4.33±1.01 ten-thousand-
yuan RMB, P<0.001). Even though, complication rate in P1T1 was lower than other groups 
without significance (15.4% vs. 25.0% vs. 28.1%, P=0.161); the same circumstances in 
length of hospital stay after surgery (P= 0.210). In the subgroup analysis, 46.2%(36/78) 
patients in P1T1 received RUL during which pulmonary veins and artery branches were 
divided using a same stapler, resulting in significant decrease of operative time(P<0.001) 
statistically significant difference in OS between the NP and PP regimens. However, 
the PP regimen resulted in significant reduction of toxicity and a trend in improvement 
of PFS in Chinese population with inoperable stage III NSCLC regardless of pathology. 
Keywords: chemotherapy, non-small cell lung cancer, Radiotherapy
PUB036 Study on Predictive Factors of Anti-Angiogenesis Therapy Combined 
with Neoadjuvant Chemotherapy for Phase IIIA Non-Small Cell Lung Cancer 
Changli Wang Department of Thoracic Oncology, Tianjin Medical University Cancer Institute 
& Hospital, Tianjin/China
Background: To explore the therapeutic predictive factors of anti-angiogenesis therapy 
combined with neoadjuvant chemotherapy in the treatment of phase IIIA non-small cell lung 
cancer (NSCLC). Methods: Twenty-four patients with phase IIIA (N2) NSCLC were divided 
into trial group (n=16) and control group (n=8) according to the proportion of 2：1. Trial 
group was treated with NP+Endostar, while control group with NP chemotherapy alone. 
Administration method: Endostar (7.5 mg/m2), intravenous dripping, d1～14; vinorelbine 
(25 mg/m2), intravenous dripping, d1 and d8; DDP (75mg/m2), intravenous dripping, d1
～3, 28 days as one cycle. The efficacy was assessed after two cycles. Therapeutic 
evaluation indexes primarily include response rate (RR), clinical benefit rate (CBR) and 
tumor regression rate (TRR), and secondary indexes were disease-free survival (DFS) 
and overall survival (OS). Results: Compared with control group (40%, 60%, 9.1%), the 
overall RR of trial group increased by 10%, total CBR by 27.5% and TRR by 10%. After 
treatment, the blood flow (BF), permeability surfaces (PMS) and microvessel density 
(MVD) in serum vascular endothelial growth factor (VEGF) and CT perfusion indexes went 
down dramatically in trial group by comparison to treatment before (P<0.05). Significant 
differences were presented regarding VEGF and MVD before and after treatment (P<0.05). 
Endothelial progenitor cells (EPC), VEGF, BF, PMS and MVD in patients with clinical benefit 
(BF) in trial group changed dramatically before and after treatment, in which the changes 
of BF, PMS and MVD were the most significant (P<0.01). But compared with control 
group, the changes of EPC and MVD were more evident before and after treatment. 
The change rates of EPC, PMS and MVD in trial group were all correlated with tumor 
regression rate (TRR) positively (P=0.009; P=0.012; P=0.000), and those of EPC and 
PMS also had a positive correlation with MVD (P=0.049; P=0.022). Conclusion: Anti-
angiogenesis therapy combined with neoadjuvant chemotherapy can improve the CBR 
of patients with phase IIIA NSCLC and reach the purposes of clinical down-staging and 
increased operation resection rate. Both PMS and EPC of CT perfusion imaging may 
be more effective and easier therapeutic predictive factors for combined therapy. 
Keywords: anti-angiogenesis; neoadjuvant chemotherapy; non-small cell lung cancer; 
Endostar, predictive factors
PUB037 Age-Related Risk Assessment for Lung Cancer Surgery in Elderly 
Patients Nazar Lukavetskyy, Taras Fetsych Oncology, Lviv Medical University, Lviv/
Ukraine
Background: The elderly population is heterogeneous, ranging from healthy seniors 
with no disability and few comorbidities to frail seniors who are disabled and have 
multiple comorbidities. This makes the assessment and management of this population 
challenging, especially when deciding on cancer treatment modalities. The purpose of 
the present study was to identify preoperative risk factors related to age of the patients 
focusing on comorbidities.The elderly population is heterogeneous, ranging from healthy 
seniors with no disability and few comorbidities to frail seniors who are disabled and have 
multiple comorbidities. This makes the assessment and management of this population 
challenging, especially when deciding on cancer treatment modalities. The purpose of 
the present study was to identify preoperative risk factors related to age of the patients 
focusing on comorbidities. Methods: Retrospective review of the clinical records of all 
patients operated on thoracic department in 2000-2003. A comparison was carried out 
between patients with lung cancer 70 years and older (38 patients), and younger lung 
cancer patients (44patients) who underwent curative open operation. The influence of 
comorbidity (cardiac, pulmonary, second primary cancer, anemia, diabetes mellitus 
etc) in postoperative complication were also analyzed. None of the patient received 
preoperative chemo and/or-radiotherapy. Type of surgery, histology type of tumors 
was compared in both groups. Results: No significant difference was observed in the 
comorbidities between elderly and young patients. The 30-day operative mortality rates 
were 6.25% in elderly population, postoperative morbidity was “ 40.0% - significantly 
higer in elderly lung cancer population (p0.05). Conclusion: Elderly patients undergoing 
curative surgery for lung cancer have a higher risk of developing postoperative 
complications, but mortality rates is equal to younger population. Age or the presence 
of comorbidity should not be considered contraindications for lung resection. Additional 
functional evaluation is indicated in specific subgroup of elderly lung cancer patients. 
Keywords: risk assessment, Elderly patients, lung surgery
PUB038 New Practical Database: Personalized Staging Seyda Ö. Kaya, Demet 
Yaldiz, Kenan C. Ceylan, Tevfik İ. Akçam, Özgür Öztürk Thoracic Surgery, Dr.Suat Seren 
Thoracic Surgery and Chest Diseases Training Hospital, Izmir/Turkey
Background: Hence the importance of regionel and national cancer database is growing, 
establishment of cancer survival datas and evaluation of results is extremely important 
for the treatment and follow-up. There isn’t still a national cancer database system in 
our country. In the current database programs, all datas of the patients are needed 
to be entered manually into these programs and most of the datas are not numerical. 
Studies show that the clinicians are needed to seperate their 50-60% of average daily 
overtime to enter patient datas. Therefore, we performed a database software that is 
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and the number of staplers; but no statistical significances were observed on other 
operative outcomes. Conclusion: Procedures of RUL as posterior ascending branch 
of the pulmonary artery-bronchus-pulmonary veins and artery branches for patients 
with lung cancers could reveal more benefits of operative outcomes and is quite 
technically feasible. Shorter operative time and tube duration, and less estimated blood 
loss were observed. No significance existed when dividing pulmonary veins and artery 
branches separately or together, except for shorter operative time and less staplers. 
Keywords: Right upper lobectomy, Video-assisted thoracic surgery, Primary lung 
cancers
PUB040 Learning Curve of Uniportal Lobectomy for NSCLC. How Many Cases 
Are Needed to Reach Competence under Guidance? Hongjun Chu, Rujian Lu 
Cardiothoracic Surgery, Nantong Third People’S Hospital, Nantong University, Nantong/China
Background: Uniportal video assisted thoracoscopic lobectomy plus mediastinal lymph 
node dissection is an innovative technique shown to be less minimally invasive for the 
treatment of early non-small cell lung cancer (NSCLC), though it is quite technically 
difficulty. This study aimed to describe the learning curve for this minimally invasive 
surgery with guidance by experienced consultant surgeon. Methods: From January 
2014 to March 2015, a total of 45 patients with early NSCLC underwent uniportal 
VATS lobectomy plus mediastinal lymph node dissection in our low-volume center. 
The procedures were guided by experienced consultant surgeons. The patients were 
divided into three groups. Group A included the first 15 cases. Group B comprised 
the middle 15 cases, and Group C included the final 15 cases. The demographic 
characteristics and the intra- and postoperative data were collected retrospectively and 
analyzed. Results: There was no significant difference found among the three groups 
in age, gender, body mass index, ASA score, tumor location, histological type and 
clinical stage. No postoperative death occurred. Three patients required conversion (1 
cases in Group A converted to open surgery; 1 cases in Group A and 1 case in Group B 
convered to three-port VATS lobectomy). Compared with group A, a significant decrease 
in intrathoracic operative time (146±29min vs 215±41min; P=0.000), blood loss 
(138±73ml vs 214±105ml; P=0.006), but more retrieved nodes (12.0±2.9 vs 9.5±3.2; 
P =0.040) was observed in group B, while the postoperative hospital stay was similar 
(8.6±3.7days vs 9.3±4.1 days; P=0.276). AND compared with group B, the last 15 
patients (group C) involved less intrathoracic operative time (131±23min vs 146±29 
min; P=0.193), less blood loss (98±55ml vs 138±73ml; P=0.000), more retrieved 
nodes (14.4±3.2 vs 12.0±2.9, p=0.045) as well as a shorter postoperative hospital stay 
(6.5±2.5days vs 8.6±3.7days; P=0.033). A decline in the overall morbidity from group 
A to group C (46.7%, 33.3%, 13.3%, P=0.117) was also observed. Conclusion: This 
study suggests that at least 30 cases were needed to reach the plateau of uniportal 
VATS lobectomy plus mediastinal lymph node dissection for early NSCLC. The guidance 
of experiened consultant surgeons might be meaningful to reduce the learning curve. 
Keywords: learning curve, uniportal lobectomy, NSCLC
PUB041 CAP1 Is Associated with the Metastasis of Lung Cancer Changhui Wang, 
Shuanshuan Xie Department of Respiratory Medicine, Shanghai Tenth People Hospital, 
Tongji University, Shanghai 200072, Peoples R China, Shanghai/China
Background: This study was designed to predict non-small cell lung cancer metastasis 
and explore mechanism of lung cancer cell proliferation, metastasis and migration in 
vitro and vivo. Methods: Firstly, Adenylate cyclase-associated protein 1, CAP1 were 
determined by real-time PCR and western blot analysis and IHC in 82 lung cancer 
specimens. Secondly, BM group (n =50) and non-BM group (n =70) were treated and 
followed up by 4 years. Thirdly, we characterized the expression of CAP1 in lung cell by 
using Western blot and RT-PCR analyses. In addition, Si-CAP1, empty vector, over-CAP1 in 
cultured A549,95-C,95-D by using MTT, wound Healing, Transwell invasive, Western blot, 
and IHC analyses and nude mouse. Results: We provided evidence that overexpression 
of CAP1 in lung cancer cells, particularly at BM [figure1] . In addition, these findings 
suggest that CAP1 promotes the lung cancer cell proliferation and migration in vitro as 
well as its growth and metastasis in vivo via LIMK/cofilin I [figure2]. 
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mutation information was used for enrollment in the treatment arms of the CUSTOM 
trial. Results: From February 2011 to December 2012, 264 patients were enrolled 
and underwent molecular profiling. KRAS was the most frequently mutated gene in 
NSCLC with a frequency of 25.6%, followed by TP53 at 21.9%, and PTEN at 18.8%. 
EGFR mutations were detected in 17.4%, and BRAF in 2.4%. In SCLC, TP53 was the 
most commonly mutated gene at 21.4%, followed by NOTCH1 at 16.7, and PIK3CA at 
6.7%. In thymic malignancies, no tested mutations were positive. Overall survival was 
defined by individual mutation; patients with EGFR mutations had the longest survival 
times of 1.83 years. Genetic mutation information was used to enroll patients into 
the CUSTOM clinical trial treatment arms. Twenty-five percent of patients with NSCLC 
had actionable mutations. Five patients were enrolled in the treatment arm of the 
CUSTOM trial. Conclusion: We report on a single institution’s experience with multiplex 
genotyping for multiple histologic types of thoracic malignancies. Information regarding 
genomic aberrations was used to guide treatment with well-known genetic-based agents, 
like erlotinib, as well as enrollment into the CUSTOM clinical trial, where patients were 
assigned treatment based on specific mutations. Multiplex genotyping from patients with 
metastatic non-small cell lung cancer, small cell lung cancer, and thymic malignancies 
is feasible, informs treatment decisions, and facilitates clinical trial enrollment. 
Keywords: oncologic drivers, multiplexed assays, non-small cell lung cancer, small cell 
lung cancer
PUB044 Comparison between 5-Aminolevulinic Acid Based Photodynamic 
Therapy on Human Lung Adenocarcinoma Cells Grown in Monolayers and 
Spheroids Haydee Fukuda1, Maria J. Teijo2, Berenice A. Diez2, Alcira M.D.C. Batlle2 
1Biological Chemistry, Faculty of Sciences, University of Buenos Aires, Buenos Aires/
Argentina, 2Conicet, Cipyp, Buenos Aires/Argentina
Background: Photodynamic therapy (PDT) is a therapeutic modality for the treatment of 
obstructive or microinvasive lung cancer. After the administration of a photosensitising 
drug (PS) which selectively accumulates in the tumor cells, irradiation with an appropriate 
wavelength light triggers photochemical reactions inducing Reactive Oxygen Species 
(ROS) production with the consequent cellular damage, which ultimately lead to cell death. 
Porphyrins are the only PSs endogenously synthesized by means of incubation with the 
biological precursor, 5- aminolevulinic acid (ALA). Methods: ALA-PDT was performed on 
A 549 human lung adenocarcinoma cells, growing in monolayer or multicellular spheroids 
(MCSs), by incubation with 1mM ALA for 3h, followed by irradiation with two fluorescent 
lamps (Osram L36W/10) for different times, and within 1 h analyzed for PDT-induced 
events. MCSs were initiated by seeding 5.104 cells/ml on 3% agar : RPMI (1:1) coated 
wells and harvested after 7 days with periodic fresh medium renewal (MCSs are three-
dimensional compact cellular aggregates that mimic micro-tumors with no vascular 
irrigation, representing a suitable model for the study of PDT-induced cell death, since 
tumor vasculature has a controversial role in tumor eradication by PDT). Porphyrins were 
extracted from the cells with 5% HCl and quantified spectrofluorometrically. Effects of PDT 
treatment were analyzed by the MTT and the APH assay, and by acridine orange/ethidium 
bromide staining and AnnexinV-FITC/propidium iodide labelling, visualized under optical 
and confocal microscopy, and analyzed by flow cytometry. Results: Porphyrin synthesis 
was not significantly different between monolayers and MCSs, neither quantitatively 
(monolayers: 0,109±0,1 pg/cell; MCSs: 0,09±0,1 pg/cell) nor qualitatively, since PpIX 
fluorescence distribution was uniform along all sections of the spheroids analyzed 
Conclusion: CAP1 is associated with metastasis of NSCLC especially in BM patients and 
promotes the lung cancer cell proliferation and migration in vitro and vivo by limk1-cofilin. 
Keywords: lung cancer, metastasis, Adenylate cyclase-associated protein 1
PUB042 Involvement of Protein Kinase CK2 in the Radioresistance of Lung 
Cancer Cells Qianwen Li, Gang Wu, Rui Mng Cancer Center, Union Hospital, Tongji 
Medical College, Huazhong University of Science and Technology, Wuhan/China
Background: As radiotherapy is the main treatment of advanced non-small cell 
lung cancer, resistance to radiotherapy becomes a key limitation for the treatment. 
To overcome this problem, we investigated the correlation between lung cancer 
radioresistance and Protein kinase CK2, a constitutively active serine/threonine kinase, 
which is widely overexpressed in human cancers. Protein kinase CK2 is involved in many 
cellular processes including proliferation, survival and viability, and also proved to be 
linked to DNA damage response through phosphorylation of and interaction with several 
key molecules. Methods: Clonogenic assays were performed to assess the effect of a 
CK2 inhibitor, Quinalizarin, on the radiosensitivity of A549 and H460 cells. The effect 
of the combination of Quinalizarin and X-ray irradiation on apoptosis and cell cycle of 
A549 and H460 cells was measured by Flow cytometry. Immunofluorescence assays 
were performed to detect the expressions of γ-H2AX and 53BP1, and the average 
fluorescent values were obtained. The protein expression of DNA-pk was measured by 
Western Blotting assays. Results: We found that A549 and H460 exposed to Quinalizarin 
have an increased radiosensitivity, decreased proliferation and impaired DNA repair. 
Down-regulation of CK2 results in significant increase of γ-H2AX foci and reduction of 
53BP1 foci and DNA-PK protein expression in cells after ionizing radiation. In addition, we 
observed an extended G2/M arrest but not increased apoptosis after ionizing radiation 
in the absence of CK2. Conclusion: In conclusion, inhibition of protein kinase CK2 might 
be a promising way to increase the radiosensitivity of non-small lung cancer cells, and 
further experiments need to be conducted to elucidate its underlying mechanisms. 
Keywords: non-small cell lung cancer, Protein Kinase CK2, radiosensitivity, Quinalizarin
PUB043 Using Multiplexed Assays of Oncologic Drivers to Select Targeted 
Drugs Elizabeth Cathcart-Rake1, Christopher Corless2, Alan Sandler1, Carol Beadling1, 
Andrea Warrick2, Beth Wilson2, Andrea Burt1, Grant Roesler2, Ariel Lopez-Chavez1 
1Knight Cancer Institute, Oregon Health and Science University, Portland/United States of 
America, 2Knight Cancer Institute, Oregon Health and Science University, Portland/OR/United 
States of America
Background: Multiplex genotyping from patients with metastatic adenocarcinomas 
of the lung is feasible, informs treatment decisions, and facilitates clinical trial 
enrollment. Identification of certain genomic alterations may also potentially impact 
survival. We describe a single institution experience with multiplex genotyping of 
patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and 
thymic malignancies. Methods: Patients with advanced NSCLC, SCLC including lung 
neuroendocrine tumors, and thymic malignancies were enrolled from Oregon Health 
and Science University. Biopsies of tumors were obtained and screened concurrently 
for over 200 genetic alterations using the Sequenom MassArray and / or Ion Torrent 
platforms. Mutation frequencies and overall survival data were calculated. Genetic 
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PUB047 The Increased Serum Norepinephrine Is Associated with Poor 
Prognosis in Non-Small Cell Lung Cancer and Contributes to Cancer Cell 
Metastasis Wei Zhao, Bin Zhang, Xiaoyuan Wu Central Laboratory, Nanjing Chest 
Hospital, Nanjing/China
Background: Lung cancer is the most common cancer worldwide. Non-small cell 
lung cancer (NSCLC) accounts for 85% of lung cancer. Norepinephrine (NE) regulates 
tissue response to stimulation through binding to receptors, which locate on cell 
surface. Recently, NE was reported to promote ovarian cancer, melanoma, breast 
cancer, colon cancer and prostate cancer program. Methods: Serum NE was 
detected in 58 NSCLC patients and 70 healthy controls by Elisa kit. The associations 
between serum NE level with patient’s prognosis and survival were analyzed by 
SPSS 17.0 statistical software. Add NE and/or NE β1 receptor blocker into NSCLC 
cell medium, MTT and transwell assays were employed to measure proliferation and 
metastasis changes, respectively. Results: Serum NE is significantly higher in NSCLC 
patients, compared to the healthy controls (P < 0.003). In addition, High level of 
serum NE was correlated with tumor size (P = 0.012) and N stage (P = 0.026). Kaplan-
Meier analysis indicated that patients with higher serum dopamine had a poor overall 
survival (P = 0.0311). Additional NE promoted NCI-H322 proliferation and metastasis, 
whereas NE β1 receptor blocker reversed NE effect to NSCLC cell. Conclusion: Our 
data indicates that NE regulates NSCLC cell proliferation and metastasis through β1 
receptor and blockage of NE might be a novel therapeutic strategy in NSCLC patients. 
Keywords: non-small cell lung cancer, norepinehrine, proliferation, metastasis
PUB048 Demographic Profile of Lung Cancer in India Conjeevaram S. Pramesh1, 
George Karimundackal2, Sabita Jiwnani2, Parveen Yadav3 1Surgical Oncology - Thoracic 
Surgery, Tata Memorial Centre, Mumbai/India, 2Department of Surgical Oncology, Tata 
Memorial Hospital, Mumbai/India, 3Artemis Hospital, New Delhi/India
Background: Lung cancer is a common problem worldwide and an important public 
health problem in India. There are over 1.8 million cases of lung cancer worldwide 
with 1.6 million deaths per year, a large proportion of which occurs in the developing 
world. Lung cancer is one of the commonest cancers in India, is a major public health 
problem and a leading cause of cancer related deaths. While there are direct links 
with smoking, there has been an increase in the non-smoking lung cancers worldwide. 
The clinico-pathological profile of lung cancer has also changed considerably over 
the last two decades. The epidemiology has changed from a predominant squamous 
histology to adenocarcinoma which is now the most common.Published literature as 
well as unpublished observations indicate that the features of lung cancer in India like 
prevalence, incidence, aetiopathogenesis and presentation vary markedly from the 
west. We performed a prospective study to evaluate the unique demographic features 
of lung cancer in India, with specific emphasis on smoking and histopathological 
trends. Methods: We performed a prospective study between Dec 2012 and Dec 2014 to 
study the demographic and clinic-pathological profile of lung cancer patients registered 
in the thoracic oncology services of India’s largest tertiary referral cancer centre. Data 
was collected directly from patients’ paper and electronic medical records. All patients 
of histologically proven lung cancer were included. Data of patients who did not consent 
was excluded. The study was initiated after approval from the Institutional Review Board 
of the Tata Memorial Hospital. Data was entered into Statistical Program for Social 
Sciences (SPSS version 18 for Windows) software and analysed as percentages and 
as descriptive data. Results: A total of 2085 patients were included in the database 
of which 44 patients were excluded for significant missing data. There were 1512 male 
(74.1%) and 529 women (25.9%) with a M:F ratio of 3:1. Over half (50.6%) patients 
were active or past smokers, while 45.3% patients had not been exposed to active or 
passive smoking. Beedi (local rolled tobacco) smoking was more common (29.7%) than 
cigarettes (15.1%) while 2.8% smoked both; exclusive chewed tobacco use was seen in 
8.3% while combined use of chewed and smoked tobacco was seen in 3.1% patients. 
The proportion of women never-smokers with lung cancer was significantly higher (87%) 
compared to men (32%). More than two-thirds patients (67.7%) presented with metastatic 
disease.Amongst patients with a definitive cytohistological diagnosis, the prevalence of 
adenocarcinomas was highest (70.3%) followed by squamous (20.8%), small cell (5.8%) 
and NSCLC NOS (3.2%). Conclusion: The demographic profile of patients with lung 
cancer in India is unique with a much higher proportion of never smokers, especially in 
women. Most patients present with metastatic disease with significant epidemiological 
trends towards a predominant adenocarcinoma histology. Urgent studies are 
required to analyse these epidemiological trends especially in non-smoking women. 
Keywords: never-smoker, lung cancer, demography, India
PUB049 Downregulated the Non-Coding RNA AK126698 Promotes Cisplatin 
Resistence in Non-Small-Cell Lung Cancer by Targeting FZD8 Xiao Fu, Hui Li 
Department of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, 
Beijing/China
Background: Cisplatin is one of the widely used chemotherapeutic drug for the 
treatment of patients with advanced lung cancer. However, chemoresistance to 
cisplatin is common in patients with lung cancer. In our previous study, we have 
demonstrated that lncRNA AK126698 regulated A549 cells cisplatin resistance partly 
through Wnt/β-catenin signaling. However, the precise molecular mechanism is not 
yet fully understood. Methods: LncRNA AK126698 expresion was detected in NSCLC 
cell lines A549, NCI-H520, A549/DDP and NCI-H520/DDP, and then the effects of 
AK126698 on the proliferation and chemosensitivity of cancer cells was investigated, 
using both gain- and loss-function studies. The correlation between AK126698 level and 
under confocal microscopy. However, in the monolayer a plateau in the porphyrin 
synthesis was attained at 0.5 mM ALA concentration, and in the MCSs, at 1 mM. With 
incubation times longer than 3 h, kinetics of porphyrin biosynthesis was faster in the 
monolayer. Survival curves after performing ALA-PDT showed that DL50 (irradiation 
time producing 50% of cell death) in MCSs was 2 min higher than in the monolayer, and 
according to these results, a higher percentage of viable cells when 20 min-irradiation 
PDT was performed, was observed in the MCSs (66,57±6,5%) compared to monolayers 
(3,5±0,2%). Moreover, caspase-3 expression and cytochrome c release were also lower 
in MCSs. Conclusion: With normal PpIX synthesis and distribution, the limiting factor on 
ALA-PDT efficacy in the 3D growing cells, could be the light penetration into the inner 
section of the MCSs, or the lower oxygen availability conditioning the generation of ROS. 
Keywords: aminolevulinic acid, Lung adenocarcinoma cells, photodynamic therapy
PUB045 Activating Mutant EGFR Upregulates HIF-1α to Promote a Hypoxic 
Phenotype Independent of Hypoxia in Non-Small Cell Lung Cancer Dianren Xia1, 
Matthew H. Matthew H. Herynk1, Li Xu2, Tina Cascone2, Petro Nikolinakos2, Monique 
Nilsson2, Maria I. Nunez3, Pierre Saintigny2, Li Zhang4, Luc Girard5, Adi F. Gazdar6, 
John Minna7, Ignacio I. Wistuba3, John V. Heymach2 1Thoracic, Head and Neck Medical 
Oncology, The University of Texas MD Anderson Cancer Center, Houston/United States of 
America, 2Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson 
Cancer Center, Houston/TX/United States of America, 3Pathology, The University of Texas 
MD Anderson Cancer Center, Houston/TX/United States of America, 43Bioinformatics and 
Computational Biology, The University of Texas MD Anderson Cancer Center, Houston/
TX/United States of America, 5Pharmacology, The University of Texas Southwestern 
Medical Center, Dallas/TX/United States of America, 6Pathology, The University of Texas 
Southwestern Medical Center, Dallas/TX/United States of America, 7Pharmacology, The 
University of Texas Southwestern Medical Center, Dallas/United States of America
Background: Activating EGFR mutations L858R and del19 define a subset of lung 
adenocarcinomas that are addicted to EGFR signaling for growth and survival. Clinical 
and pre-clinical data have demonstrated that the activating EGFR mutations confer 
sensitivity to EGFR tyrosine kinase inhibitors, such as erlotinib and gefitinib, in non-small 
cell lung cancer (NSCLC). The mechanism by which the activating mutant EGFR renders 
the receptor more sensitive to the effects of the inhibitors has not been well defined. We 
investigated the impact of activating mutant EGFR on hypoxia-inducible factors (HIFs) and 
cellular response. Methods: Protein expression was examined using either western 
blotting, ELISA, or IHC. mRNA expression was examined using real-time PCR 
or cDNA microarray. Transcription activity was measured using corresponding 
promoter-driven luciferase expression. Functional analysis of genes was performed 
by gene set enrichment analysis. Xenograft study was performed in mice to examine the 
effects of VEGF inhibitor bevacizumab on lung cancer cells with either wild-type EGFR 
or activating mutant EGFR. Results: In NSCLC cells bearing EGFR-activating mutations, 
canonical hypoxic response was diminished and EGFR was a dominant regulator of HIF-1a 
and, to a lesser extent, HIF-2a via affecting their mRNA expression and protein stability. 
Microarray analysis of 53 NSCLC cell lines demonstrated elevatedHIF-1a and HIF-
2a mRNA and enrichment of HIF-regulated genes in cells with activating mutant EGFR, 
indicating that these mutants result in constitutive, ligand-independent upregulation of 
HIF- and hypoxia-regulated genes in normoxia, leading to a hypoxic phenotype. Inhibition 
of EGFR activity reduced the level of VEGF, a well-characterized HIF-responsive gene, in 
cells with activating mutant EGFR but not in cells with wild-type EGFR, and these effects 
were independent of oxygen level. Xenografts with activating mutant EGFR were more 
sensitive to VEGF inhibition than xenografts with wild-type EGFR. Conclusion: Together, 
our results suggest that cells expressing activating mutant EGFR uncouple HIF expression 
and hypoxia, providing an important mechanism through which cells can upregulate HIF 
and its target genes in the absence of hypoxia, thereby hijacking an important cellular 
response regulating invasiveness and tumor aggressiveness. Our results also suggest 
that patients with activating mutant EGFR will benefit from VEGF inhibition related therapy. 
Keywords: VEGF, lung cancer, EGFR, HIF1A
PUB046 Prognostic Stratification of Patients with Lung Cancers by EMT-
Related 4-Gene Signature Bangrong Cao, Lin Feng, Yu Liu, Xiangyang Liu, Kaitai 
Zhang, Shujun Cheng, Yanning Gao Cancer Institute & Hospital, Cams, Beijing/China
Background: This study aimed to investigate the association between epithelial-to-
mesenchymal transition (EMT) molecular events in morphologically normal tumor-adjacent 
tissues and the outcome of lung cancer patients. Methods: EMT was induced in an 
immortalized human bronchial epithelial cell line by TGF-β1. Gene expression of the EMT-
induced cells and morphologically normal tumor-adjacent tissues derived from 60 patients 
with squamous cell carcinoma (SCC) in lung was profiled by microarray and real-time PCR. 
An independent cohort of 50 lung SCC patients was applied to validate the prognostic 
value of the candidate gene signature by real-time PCR. Results: A 4-gene signature that 
was related to EMT in vitro was activated in morphologically normal tumor-adjacent tissues 
from the 60 lung SCC patients, and associated with lymph nodes metastasis. Up-regulated 
expression of the 4-gene signature in tumor-adjacent tissues was also significantly 
associated with poor overall survival in the independent cohort of lung SCC (N=50, 
P=0.009). Conclusion: An EMT-related 4-gene signature expressed in tumor-adjacent 
morphologically normal tissues is associated with outcome in lung cancer patients. 
Keywords: tumor-adjacent tissue, EMT, Gene signature, Prognosis
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Results: Expression of t-type calcium channels is significantly correlated with poorer 
overall survival in the patients included in the Glans Look Lung Cancer Database with a 
p-value of 0.0339. Conclusion: T-type calcium channel expression was seen in 18 of 163 
NSCLC tumor samples from patients included in the Glans Look Lung Cancer Database. 
In all these patients, expression was only found within the tumor and not in adjacent 
healthy tissue. Furthermore, overall survival was significantly worse in patients with t-type 
calcium channel expression. Previous research by other groups has shown depressed 
proliferation of ovarian, esophageal and breast carcinomas using t-type calcium channel 
blockers. These blockers may potentially provide a targeted treatment for NSCLC given 
that t-type calcium channels are expressed in the malignant tumors of patients and not in 
the healthy tissues. Further work must be done to determine the influence of t-type 
calcium channels in NSCLC tumors, specifically their affect on proliferation, which could 
lead to targeted therapy with minimal side effects. 
Keywords: t-type calcium channels, Targeted therapy
PUB052 JAK2 Participates in Lung Cancer Progression Yanjun Xu, Yun Fan 
Chemotherapy, Zhejiang Cancer Hospital, Hangzhou/China
Background: Lung cancer ranks as the first most common cancer and the first leading 
cause of cancer-related death in China and worldwide. Due to the difficulty in early 
diagnosis and the onset of cancer metastasis, the 5-year survival rate of lung cancer 
remains extremely low. JAK2 has emerged as pivotal participant in biological processes, 
often deregulated in a range of cancers, including lung cancer. Recently we found that 
JAK2 might play an important role in lung cancer pathogenesis as an oncogene. While our 
understanding of JAK2 in the onset and progression of lung cancer is still in its infancy, 
there is no doubt that understanding the activities of JAK2 will certainly secure strong 
biomarkers and improve treatment options for lung cancer patients. Methods: The 
expression of JAK2 protein level was assayed using the Western Blot assay. MTT assay, 
Scratch-wound healing assay, Transwell migration and invasion assay were conducted to 
study the proliferation, migration and invasion abilities of lung cancer cells independently. 
The RNAi and over expression plasmids were conducted. Results: JAK2 is up-
regulated in lung cancer tissues when compared with their adjacent non-tumor tissues. 
Downregulation of JAK2 inhibits the proliferation, migration and invasion abilities of lung 
cancer cells. Moreover, over expression of JAK2 induced the proliferation, migration 
and invasion abilities of lung cancer cells. Conclusion: These findings demonstrate 
that JAK2, whose expression is up-regulated in lung cancer, may participate in lung 
cancer progression by regulating cancer cells proliferation, migration and invasion. 
Keywords: JAK2, lung cancer
PUB053 Primary Lung Cancer in Morocco: Results of a Retrospective Study 
Hinde Hami1, Amine Arfaoui2, Faouzi Habib3, Abdelmajid Soulaymani1, Abdelrhani 
Mokhtari1, Ali Quyou1 1Laboratory of Genetics and Biometry, Faculty of Science, Ibn Tofail 
University, Kenitra/Morocco, 2Department of Life Sciences, Royal Institute of Executive 
Education, Salé/Morocco, 3Al Azhar Oncology Center, Rabat/Morocco
Background: Lung cancer is one of the most common cancers in the world, accounting 
for 13% of all cancers. It is the third most common cancer and the third most common 
cause of cancer death in both men and women in Northern Africa, with an estimated 
14 506 new cases of lung cancer and 12 940 cancer deaths in 2012 (GLOBOCAN 
chemoresistance was further investigated in clinical NSCLC specimens. Results: LncRNA 
AK126698 levels were dramatically downregulated in the cisplatin-resistent cell lines 
A549/DDP and NCI-H520/DDP compared with their respective parental cell lines. 
Overexpression of AK126698 also could increase the sensitivity of A549/DDP and 
NCI-H520/DDP cells to cisplatin in vitro. Furthermore, we showed that AK126698 
inversely regulates FZD8 expression in NSCLC cell lines. The results also show that 
LncRNA AK126698 increasing chemosensivity was associated with inhibition of 
cell proliferation, induction of G0/G1 cell-cycle arrest and apoptosis enhancement 
through regulation of FZD8 expression along with decreased activity of Wnt pathway. 
Importantly AK126698 expression levels were significantly lower in NSCLC tissues with 
high levels of FZD8 and ERCC1, a marker for cisplatin-resistance. Conclusion: Our 
findings suggest that downregulation of LncRNA AK126698 contributes to the cisplatin 
resistence of NSCLC cells, at least in part, through the regulation of FZD8 expression. 
Keywords: long non-coding RNA, NSCLC, FZD-8, cisplatin resistence
PUB050 Clinical Significance of Reduced GPRC5A Expression in Surgically 
Resected Non-Small-Cell Lung Cancers Er Jin1, Wenzhe Wang2, Wei Wang1, Mengdie 
Fang2, Hong Zhou1, Ruifei Xie1, Jian Ye1, Rujun Xu1 1Affiliated Hangzhou Hospital of Nanjing 
Medical University, Hangzhou/China, 2Center for Molecular Medicine, Zhejiang Academy of 
Medical Sciences, Hangzhou/China
Background: GPRC5A (G protein-coupled receptor, family C, group 5, member 
A) was initially identified as a retinoid-inducible gene, while retinoid plays a pivotal 
role in regulation of many physiological and pathological processes, including 
cell growth and differentiation. GPRC5A has been characterized as a lung cancer 
suppressor gene, although clinical significance of GPRC5A in NSCLC remains to 
be determined. Methods: This study detected GPRC5A expression in NSCLC for 
association with clinical significance of NSCLC patients. GPRC5A messenger RNA 
(mRNA) and protein were assessed by using quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR) and Western blot, respectively in 30 NSCLC 
and matched normal tissue samples. Immunohistochemistry was to detect GPRC5A 
expression in 110 NSCLC and 60 para-tumor tissues. Results: The data showed that 
levels of GPRC5A mRNA and protein in NSCLC tissues were significantly lower than those 
in corresponding noncancerous tissues (P<0.001). Loss of GPRC5A expression was 
associated with tumor histological type (P=0.008), poor tumor differentiation, lymph 
node metastasis, and tumor-node-metastasis (TNM) stage (P<0.001). Furthermore, 
Kaplan-Meier curve analysis revealed that patients with low GPRC5A expressed tumor 
had shorter survival than patients with GPRC5A expressed tumor (P=0.010), while the 
multivariate Cox analysis revealed that lost GPRC5A expression was an independent 
prognostic factor for NSCLC patients (P<0.001). Conclusion: The data from the current 
study demonstrated that detection of GPRC5A expression might serve as a valuable 
biomarker for prediction of NSCLC differentiation and survival of NSCLC patients. 
Keywords: NSCLC, biomarker, GPRC5A
PUB051 T-Type Calcium Channels and Non-Small Cell Lung Cancer 
Allison Childers1, Lars Petersen1, Shannon Otsuka1, Adrijana D’Silva1, Brant Pohorelic1, 
Haocheng Li2, D. G. Bebb1 1Translational Lab, Tom Baker Cancer Centre, Calgary/AB/
Canada, 2Oncology, University of Calgary, Calgary/AB/Canada
Background: Lung cancer is the leading cause of cancer deaths worldwide. Currently, 
tumor resection, radiation, and chemotherapy are the standard treatments for NSCLC. 
As with most cancers, targeted therapies are being researched and developed in an 
attempt to mitigate or avoid adverse side effects. T-type calcium channels, low-voltage 
gated transmembrane proteins, have recently been pathologically implicated in ovarian, 
breast and esophageal carcinomas. Our in vitro studies have indicated the presence of 
t-type calcium channels in NSCLC cell lines. Furthermore, IHC staining of 193 tumors 
from Albertan NSCLC patients have shown t-type calcium channel expression within 
the tumors and a significant correlation of this expression to poorer overall survival. 
Finally, specific t-type calcium channel inhibitors have already been approved for use 
with other diseases and show promise in depressing proliferation of various carcinoma 
cell lines. Methods: All Stage I-III NSCLC patients diagnosed between 2003 and 2006 
at the Tom Baker Cancer Centre were included in the Glans-Look Lung Cancer Database. 
Demographic details and clinical variables were collected retrospectively, with overall 
survival continually being updated every 3-4 months. Tissue micorarrays were generated 
from formalin embedded tumors for the included Stage I-III NSCLC patients. 5µm thick 
slices were stained for pan-cytokeratin to identify tumor cells and for t-type calcium 
channels using anti-cav3.1 antibodies. Tumor samples were labeled positive or negative 
for t-type calcium channel expression and clinical and demographic data was statistically 
analyzed with relation to expression.
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In particular, the patients with solid or micropapillary predominant growth pattern 
show a worse prognosis than other predominant growth patterns. However there are 
a few reports which have examined second and third dominant subtypes aside from 
predominant subtypes and the meaning is unclear. We aimed to investigate a clinical 
impact of these subtypes. Methods: We reclassified 531 ADCs according to the new 
ADC classification. The percentage of each histopathological subtype was determined 
in 5% increments. The relationship between these results and clinicopathological 
data including outcome was investigated statistically. Results: The histopathological 
assessment according to the IASLC/ATS/ERS classification presented that 8.1% (n = 43) 
of the cases were adenocarcinoma in situ (AIS) ; 8.7% (n = 46) were minimally invasive 
adenocarcinoma (MIA) ; 17.9% (n = 95) were lepidic predominant ; 20.0% (n = 106) 
were acinar predominant ; 29.6% (n = 157) were papillary predominant ; 10.4% (n = 55) 
were solid predominant ; 2.1% (n=11) were micropapillary (MP) predominant, and 3.4% 
(n=18) were invasive mucinous adenocarcinoma (IMA). In univariate analysis, the patients 
with solid predominant and MP predominant presented a worse disease-free survival 
(DFS)(p<0.01) and overall survival (p<0.01) than the patients with other predominant 
subtypes. Next, we examined the second dominant and less than the third dominant 
subtypes of lepidic, acinar, papillary predominant aside from solid and MP predominant, 
AIS, MIA and IMA. Sixty-six patients had solid or MP predominant, 27 patients had solid 
or MP second dominant, 37 patients had less than third solid or MP dominant and 294 
patients had neither solid nor MP subtypes. The patients with solid or MP predominant 
presented a worse DFS than those with neither solid nor MP subtypes (Hazards ratio 
(HR): 3.34, 95% Confidential interval (CI): 2.32-4.82, p<0.001). The patients with solid 
or MP second dominant also presented a worse DFS than those with neither solid nor 
MP subtypes (HR: 2.16, 95%CI:1.20-3.89, p=0.01). The patients with less than third 
solid or MP dominant also presented a worse DFS than those with neither solid nor MP 
subtypes (HR: 1.71, 95%CI:1.02-2.85, p=0.041). Conclusion: The patients with solid 
or MP subtypes had a worse prognosis even if their subtypes were not predominant. 
Therefore we need to take care of solid or MP subtypes at the time of diagnosis. 
Keywords: Adenocarcinoma, subtypes, Prognosis
PUB057 COX-2 Mediate Acquired Gefitinib Resistance in Non-Small Lung 
Cancer Cells via MAPK-Dependent Pathway Qin F. Deng1, Yin M. Zhao2, Bo Su2, 
Jian F. Xu1, Cai C. Zhou1 1Department of Oncology, Shanghai Pulmonary Hospital, Tongji 
University, Shanghai/China, 2Central Laboratory, Shanghai Pulmonary Hospital, Tongji 
University, Shanghai/China
Background: Epidermal Growth Factor Receptor (EGFR) and Cyclooxygenase-2(COX-2) 
contribute to the development and progression in NSCLC. Overexpression of COX-2 
could induce non-EGFR dependent activation of extracellular signal regulated kinase.
Our previous studies had shown that simultaneous blockage of EGFR and COX-2 may 
restore acquired gefitinib-resistant cells’ sensitivity to gefitinib. In this study, we explored 
the role of COX-2 and relevant signaling pathway in acquired gefitinib resistance in 
NSCLC. Methods: Gefitinib-resistant PC9/G cell lines was induced by exposure of PC9 
cell lines to MNNG and gefitinib and maintained in the mediua containing 0.05 umol/L 
of gefitinib. A combination of EGFR tyrosine kinase inhibitor (TKI) gefitinib and a COX-2 
inhibitor celecoxib were studied for theirs effects on the cell proliferation, cell cycle 
and apoptosis in two cell lines by MTT assay and flow cytometry analysis. Western 
Blot was used to detect expression of COX-2,NF-κB,EGFR, phospho-EGFR, Akt and 
phospho-Akt, Erk, phosphor-Erk. Results: Resistant index of PC9/G cells to gefitinib was 
about 147- to 198-fold higher than PC9 cells, and it was accompanied by significant 
increase of COX-2 expression in PC9/G cells. Inhibition of COX-2 with celecoxib in 
PC9/G resulted in dramatic inhibition of proliferation and promotion of apoptosis in 
response to gefitinib. PC9/G cells’ sensitivity to gefitinib is restored. Western blotting 
showed decreased expression of p-EGFR and COX-2 with both gefitinib and celecoxib 
treatments, but most pronouncedly in the combined group (P<0.05) in PC9/G cells. 
Furthermore, the combination as compared with effect of single agents showed strong 
reductions of NF-κB,p-ERK and PGE2 of PC9/G cell line. Conclusion: These findings 
suggest that COX-2 may be involved in the resistance of NSCLC to EGFR TKI. COX-2 
signaling by ERK pathway may be a mechanism of acquired gefitinib resistance and 
may serve as an alternative therapeutic target for NSCLC unresponsive to EGFR TKIs. 
Keywords: lung cancer;target therapy;drug resistance;COX-2
PUB058 CXC195 Induce Apoptosis and Endoplasmic Reticulum Stress in 
Human Non-Small Cell Lung Cancer Cells via IRE1α-Dependent Pathway 
Jiexia Zhang1, Ying Liang2, Yongbin Lin3, Yuanbin Liu1, Weiqiang Yin1, You You1 1State 
Key Laboratory of Respiratory Disease, Department of Medicine, Guangzhou Institute of 
Respiratory Disease, Guangzhou/China, 2Medical Oncology, Sun Yat-Sen University Cancer 
Center, Guangzhou/China, 3Thoracic Surgery, Sun Yat-Sen University Cancer Center, 
Guangzhou/China
Background: This study was to investigate the anti-cancer effect of CXC195 
against human non-small cell lung cancer (NSCLC) A549 cells and the underlying 
mechanisms. Methods: The effect of CXC195 on cell viability was assessed in A549 
cells at various concentrations and time points by measuring MTT production. Annexin 
V/PI straining was used to investigate whether apoptosis can be induced by CXC195. 
We examined the expressions of ER stress-associated proteins by RT-PCR. Cell lysates 
were immunoprecipitated with anti-IRE1α antibody. We transfected with IRE1α siRNA 
following treatment with CXC195. Results: First CXC195 inhibited the proliferation 
and induced cell cycle arrest and apoptosis of A549 cells. Second,Caspase3, 8, 
9 and PARP-1 activation, and Bax/Bcl-2 ratio analyses demonstrated that the anti-
cancer effect of CXC195 in A549 cells was mediated by promoting caspase- and 
mitochondria-dependent apoptosis. Furthermore, CXC195 induced ER stress in A549 
cells as evidenced by elevated levels of GRP78, GRP94, CHOP, IRE1α, TRAF2, p-ASK1 
2012). The aim of this study is to determine the epidemiological characteristics of 
primary lung cancer in Morocco. Methods: This is a descriptive retrospective study 
of all patients treated for primary lung cancer at Al Azhar Oncology Center in Rabat 
between 1994 and 2004. Results: During the period of study, 299 cases of primary 
lung cancer were diagnosed; 265 (88.6%) in men and 34 (11.4%) in women, giving a 
male-female ratio of 7.8 and representing 4.2% of all new cases of cancer reported 
during this period. The average age at diagnosis was 58.6±12.8 years (range 20-90 
years). Lung cancer is strongly related to age with only 5.4% of cases diagnosed in 
persons younger than 40 years, 82.5% in those aged 40-74 years and 12.1% in those 
aged 75 years and over. Among all detected cases, 89 (29.8%) died from lung cancer 
during the study period, accounting for 7.5% of all cancer deaths. Conclusion: The 
most recent estimates of lung cancer incidence and mortality in the world reveal sharp 
differences between developed and developing countries possibly related to missed 
opportunities for early diagnosis and incomplete reporting of lung cancer in Africa. 
Keywords: lung cancer, epidemiology, Morocco
PUB054 Clinically Relevant Gene Sequencing in Lung Cancer 
Patricia L. Thompson, Terri Redmond, Christopher Parks, Rabih Bechara Thoracic 
Oncology, Cancer Treatment Centers of America, Newnan/United States of America
Background: Individualized cancer treatment is the ultimate goal of clinicians and their 
patients. We report the results of a commercially available next-generation sequencing 
assay in advanced lung cancer. Methods: We retrospectively analyzed all the reports 
of biopsies from advanced lung cancer which were sent for testing using a commercial 
next-generation sequencing platform from a network of five tertiary referral centers 
during the year 2013. Results: 258 unique reports belonging to 258 patients with a 
diagnosis of advanced lung cancer were analyzed. Of these, 182 (70.54%) formalin 
fixed paraffin embedded tissue were sent for genomic testing with 182 yielding reports. 
177 reports had at least 1 genomic alteration, 3 had no alterations and 2 failed test 
results. There were a total of 23 genomic alterations detected, 21 in Adenocarcinoma, 
14 in Squamous cell, 6 in Small cell , 2 in large cell and 2 in Adenosquamous. Overall 
median age of patients was 57 years (range 28-78) having received a median of 
two prior lines of chemotherapy. Non-Small cell lung cancer (NSCLC) was present 
in all cases except 11 (6.04%) which were small cell lung cancer. Of the NSCLC, the 
reports were subdivided into Adenocarcinoma 134 (73.62%), Squamous cell 21 
(11.54%), Large cell 8 (4.40%), Adenosquamous 3 (1.65%) and Others (Lung Adenoid 
Cystic Carcinoma 2 (1.10%), Lung Sarcomatoid Carcinoma 2 (1.10%), Lung Typical 
Carcinoid 1 (0.55%)) KRAS was most commonly mutated in Adenocarcinoma 51/134 
(38.06%), CDKN2A in Squamous Cell 8/21 (40%), RB1 in Small Cell 5/11 (45.45%), 
Tp53 in Large Cell 2/4 (50%) and Adenosquamous 3/3 (100%). Of 177 reports, about 
one third 56 (31.64%) had at least 1 FDA approved treatment for lung cancer, two 
thirds 132 (74.58%) had at least 1 FDA approved treatment from another tumor type. 
143 (80.79%) reports had at least 1 “actionable result” (FDA approved treatment to 
patient’s or another tumor type) and 168 reports (93.78%) had at least one clinical 
trial for a targeted genomic alteration (in clinicaltrials.gov) in addition to FDA approved 
treatments in patients patients’ cancer or another malignancy. Conclusion: Molecular 
profile based therapy represents a milestone in the goal to develop personalized 
cancer therapies. We propose that future trials should address the molecular profile 
of each individual patient and treat each patient based on their molecular fingerprint. 
Keywords: gene sequencing lung cancer
PUB055 Clinicopathological Features of Resected Peripheral Squamous Cell 
Carcinoma of the Lung and Relation to Long Term Survival Qianjun Zhou 
Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, Shanghai/China
Background: Incidence of peripheral squamouscell carcinomas (p-SqCCs) of 
the lung has increased over decades, however, clinicopathological prognostic 
factors have not been well studied. Methods: We evaluated clinicopathological 
features in 251 patientswith resected peripheral lung SqCCs (which located in or more 
peripheral to the fourth branching bronchus), measuring ≤70mm in size, and analyzed the 
relation to the overall survival (OS) and recurrence-free survival (RFS) according to the 
primary location. Results: Multivariate analysis in all stages of patientsshowed that high 
CEA and CK19 level, vascular invasion, nodal metastasis were significant unfavorable 
prognostic factors. Among T1 tumor patients (≤30mm in diameter), high serum CEA 
level, vascular invasion and nodal metastasis were also strongly correlated with poor 
prognosisindependently. Among T2 tumor patients (≤70mm in diameter), high serum CK19 
level, vascular invasion,nodalmetastasis, N2 percentage were also strongly correlated with 
poor prognosis. Conclusion: High CEA and CK19 level, vascular invasion, nodal metastasis 
were significant unfavorable prognostic factors for completely resected p-SqCCs. 
Keywords: Peripheral squamous cell carcinoma, NSCLC,Vascular invasion, Prognostic 
factor
PUB056 Clinical Impact of Solid or Micropapillary Subtypes in Lung 
Adenocarcinoma Naoki Yanagawa1, Satoshi Shiono2, Masami Abiko2, Masato 
Katahira2, Mitsumasa Osakabe1, Shin-Ya Ogata1, Toru Sato2, Gen Tamura1 
1Diagnostic Pathology, Yamagata Prefectural Central Hospital, Yamagata/Japan, 2Thoracic 
Surgery, Yamagata Prefectural Central Hospital, Yamagata/Japan
Background: Lung adenocarcinoma (ADC) presents various histologic images. 
Predominant growth patterns according to new ADC classification proposed by the 
International Association for the Study of Lung Cancer, American Thoracic Society, and 
European Respiratory Society (IASLC/ATS/ERS) are correlated with patients’ outcome. 
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bioinformatics studies discovered that the expression of slc10a2 was increased in high-
grade hypertriglyceridemia patients, but the detailed mechanism still not clear. The 
purpose of this study is to explore the mechanism which slc10a2 may involve in this 
process. Methods: Bexarotene-mediated growth response and pathway activation were 
examined in human NSCLC A549 cell lines. The effect of Bexarotene combined with 
SLC10a2 over expression or down-regulation on cell proliferation was detected by cck-8 
assay, the potential of cell invasion was employed by transwell invasion assay and the 
induction of apoptosis was tested using the AnnexinV-PI reagent assay. Apoptosis related 
gene and anti-oncogenes wre also conducted by Quantitative-PCR and PPARy pathway 
associated genes was analyzed by using a western blot analysis. Results: We found 
that the proliferation and migration were inhibited and the apoptosis of A549 cells was 
accelerated by bexarotene. In addition, over expressed slc10a2 in A549 cells can further 
suppress the proliferation and migration, and promote apoptosis under the treatment 
of bexarotene. Moreover, the expression of caspase 7, PTEN, P21, P53, LKB1, TSC2 
were increased and the expression of Bcl-2, cyclin D1, c-FLIP were declined in A549 cells 
and slc10a2 over expressed A549 cells with the treatment of bexarotene. The opposite 
results were obtained after slc10a2 gene was silenced in A549 cells treated with 
bexarotene. The further studies revealed the increased expression of slc10a2 activated 
the expression of PPARγ, then up-regulated PTEN expression and down-regulated mTOR 
expression. Conclusion: These results suggest that bexarotene inhibits the viability of 
lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway.
PUB062 Triggered Cancer Therapeutics: Synthetic Polymer Metal Complex 
Conjugates Ilayaperumal Pradeep, Sankaralingam Arunachalam, Balagurusamy 
Balajothi School of Chemistry, Bharathidasan University, Trichy/India
Background: Recently Studies on the polymer-metal complexes have received 
increased interest in various branches of chemistry. At the same time, significant 
developments have also occurred in recent years in the field of biopolymers and 
biomaterials. Many reports are available on pharmacologically active polymers (polymer 
drugs) which by themselves may act as drugs or alternatively may act as carriers for 
normal pharmaceutical agents. Applications for polyetheleneimine (PEI) have emerged in 
biology and medicine. The branched form of PEI has yielded significantly greater success 
in terms of cell transfection and a possible alternative to viral and liposomal routes of 
gene delivery. Metal complexes are presently an object of great attention in the field of 
medicinal chemistry, especially many copper and cobalt have been reported as promising 
cytotoxic agents on the basis of invitro anti-proliferative assays and their mechanisms of 
action. Gene carriers fabricated by conjugation of branched polyethyleneimine (BPEI) 25 
kDa, molecular weight of BPEI and consequently improved DNA binding, condensation 
and transfection efficiency. These investigations have resulted in the synthesis of many 
new polymer metal complexes. In this work a new class of water soluble polymer metal 
conjugates were prepared, characterized and anticancer properties were tested with 
A549 lung cancer cell lines. Methods: MTT assay To find out the synthesized PMCCs 
quality of being cytotoxic to A549 cells we performed dimethyl thiazolyltetrazolium 
bromide (MTT) assay. Apoptosis study The influence of PMCCs to induce apoptosis 
in lung cancer cells were confirmed using an acridine orange (AO) and ethidium 
bromide (EB) (1 mg/ml for both AO and EB in phosphate-buffered saline) staining 
method. Materials Branched polyethyleneimine (BPEI) 25 KDa, Calf thymus DNA (Sigma 
Aldrich), CoCl2 anhydrous (Acros.), CuCl2 .2H2O (Merck), 2,2’–bipyridyl (SpectroChem), 
1,10–phenanthroline (Spectrochem), NaCl (Loba chemie) and Buffer capsules (Merck) 
pH ~ 7.1 were used as received.
and p-JNK, and enhanced formation of an IRE1α-TRAF2-ASK1 complex. Knockdown of 
IRE1α by siRNA suppressed activation of IRE1α, TRAF2, p-ASK1 and p-JNK in CXC195 
treated A549 cells. In addition, the effects of CXC195 on the formation of an IRE1α-
TRAF2-ASK1 complex, caspase- and mitochondria-dependent apoptosis were also 
reversed by IRE1α siRNA in A549 cells. Conclusion: We showed that CXC195 induced 
apoptosis of A549 cells were through IRE1α-TRAF2-ASK1 complex-mediated ER stress, 
JNK activation, and mitochondrial dysfunction. These insights on this novel compound 
CXC195 may provide a novel anti-cancer candidate for the treatment of NSCLC. 
Keywords: apoptosis, IRE1α, non-small cell lung cancer, CXC195
PUB059 Macrophages Promote Tumor Transformation of Human Bronchial 
Epithelial Cells via NF-κB and STAT3 Signaling in a Bionic Airway Chip Culture 
Qi Wang, Encheng Li, Zhiyun Xu, Hui Zhao Respiratory Medicine, The Second Affiliated 
Hospital, Dalian Medical University, Dalian/China
Background: Numerous epidemiological studies have indicated that chronic 
inflammation may play a critical role in lung tumorigenesis. However, the key molecules 
and signaling pathways that are involved in inflammation-mediated lung tumorigenesis 
remain to be fully elucidated. The chronic inflammatory microenvironment containing 
inflammatory cells, cytokines, and chemokines can promote malignant transformation of 
bronchial epithelial cells. Among these inflammatory cells in the lung, macrophages are 
the most abundant and the key components that link inflammation and cancer. To date, 
most studies have focused mainly on the role of macrophages in tumor progression 
based on an established tumor model with or without metastasis, but macrophages are 
rarely involved in tumor initiation. Methods: The role of macrophages and their related 
molecular mechanisms in lung tumorigenesis were assessed using a BaP-induced 
tumor transformation model with a bionic airway chip in vitro and animal models. Cell 
morphology, proliferation, anchorage-independent growth, tumor formation in nude 
mice, and molecular signaling pathways were also analyzed. Results: The bionic 
airway chip culture data showed that macrophages promoted BaP-induced malignant 
transformation of human bronchial epithelial cells, which was mediated by nuclear 
factor (NF) -κB and STAT3 pathways to induce cell proliferation, colony formation in 
chip culture and tumorigenicity in nude mice. However, blockage of interleukin (IL) -6 
or tumor necrosis factor (TNF) -α signaling or inhibition of NF-κB, STAT3, or cyclinD1 
expression abrogated the effect of macrophages on malignant transformation of 
bronchial epithelial cells in the bionic airway chip culture. In vivo, macrophages promoted 
lung tumorigenesis of carcinogen-induced animal model. Similarly, blockage of NF-
κB, STAT3, or cyclinD1 using siRNA transfection, decreased the carcinogen-induced 
tumorigenesis in rats. Conclusion: Macrophages were critical in promoting lung 
tumorigenesis and that the macrophage-initialed TNF-α/NF-κB/cyclinD1 and IL-6/
STAT3/cyclinD1 pathways were primarily responsible for promoting lung tumorigenesis. 
Keywords: macrophages, NF-κB, STAT3, malignant transformation
PUB060 Clinical Characteristics of T790M in Pre and Post Treatment with 
EGFR TKIs Ee Ke, Qiuyi Zhang, Qing Zhou, Yilong Wu Guangdong Lung Cancer Institute; 
Guangdong General Hospital(Ggh) & Guangdong Academy of Medical Sciences, Guangzhou/
China
Background: T790M mutation was first discovered in patients who acquired resistance 
to gefitinib or erlotinib. It has then been shown to be a “second-site mutation” in 
approximately 50% of EGFR-mutant lung cancers that have developed acquired resistance 
to EGFR-TKI. However, in some patients, the T790M mutation was also detected as a 
primary event before drug exposure, at a frequency that is highly dependent on the 
technique used. Methods: 6554 DNA samples from lung cancer patients in Guangdong 
General Hospital during 2005-2014 was retrospectively collected for both EGFR sensitive 
mutation (exon 19 deletion and L858R mutation) and T790M mutation analysis, by either 
direct DNA sequencing or amplification refractory mutation system (ARMS). Results: Of 
6046 patients whose tumor samples were collected before EGFR-TKI exposure, the 
frequency of de novo T790M mutation was as low as 0.5%. Gender (p=0.026) and 
smoking status (p=0.020) correlated significantly with T790M mutation frequency, 
whereas age, disease stage and histology type were not. The T790M mutation frequency 
was higher in female non-smoking patients compared with male smoking patients. Of 
508 patients who had a post-TKI biopsy, the incidence of T790M mutation was 22.5%. 
And ARMS was shown to be more sensitive than direct DNA sequencing (27.8% vs 19.6%, 
p=0.034). In mutation-positive subgroup, the prevalence of concomitantT790M was 1.4% 
in TKI-naïve samples and 39.9% in TKI-treated samples. No difference between exon 19 
deletions and L858R mutations existed in pre-TKI samples (1.1% vs 1.6%, p=0.438), 
whereas a higher frequency of T790M mutation was found in exon 19 deletions in post-
TKI samples (40.1% vs 28.3%, p=0.034). Conclusion: Tumors with a preexisting EGFR 
T790M mutation are extremely rare when tested by the traditional techniques. The 
observed mutation frequency suggests that the majority of T790M mutation emerge 
during EGFR-TKI exposure and it might occur more frequently in exon 19 deletions. 
Keywords: T790M mutation, lung cancer, epidemiology, Epidermal growth factor 
receptor-tyrosine kinase inhibitors
PUB061 Bexarotene Inhibits the Viability of A549 Cells via slc10a2/PPARy/
PTEN/mTOR Signaling Pathway Xinghao Ai, Shun Lu Shanghai Lung Tumor Center, 
Shanghai Chest Hospital, Shanghai/China
Background: Thirty to forty percent of non-small cell lung cancer (NSCLC) patients 
developed higher hypertriglyceridemia in the process of treatment with bexarotene, 
and the high-grade hypertriglyceridemia patients had significantly longer survival. The 
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PUB064 Analysis of the Immune Contexture in Tumor and Tumor-Adjacent 
Stroma in Resected NSCLC Marta Usó1, Eloisa Jantus-Lewintre2, Rafael Sirera3, 
Sandra Gallach4, Silvia Calabuig-Fariñas5, Ricardo Guijarro6, Jerónimo Forteza7, Carlos 
Camps8 1Molecular Oncology Laboratory/Department of Medicine, Fundación Investigación 
Hospital General Universitario/Uv, Valencia/Spain, 2Molecular Oncology Laboratory/
Department of Biotechnology, Fundación Investigación Hospital General Universitario/Upv, 
Valencia/Spain, 3Department of Biotechnology, Upv, Valencia/Spain, 4Molecular Oncology, 
Fihguv, Valencia/Spain, 5Molecular Oncology Laboratory/Department of Pathology, 
Fundación Investigación Hospital General Universitario/Uv, Valencia/Spain, 6Department 
of Thoracic Surgery/Department of Surgery, Consorcio Hospital General Universitario/Uv, 
Valencia/Spain, 7Instituto Valenciano de Patología, Valencia/Spain, 8Department of Medicine/
Department of Medical Oncology, Uv/Consorcio Hospital General Universitario, Valencia/
Spain
Background: The analysis of immunologic features of tumor microenvironment is 
leading to the development of new immunotherpies and the identification of biomarkers. 
Therefore, it would be interesting to better understand the key elements involved 
in shaping the immune microenvironment in solid tumors. In this study, we have 
investigated the immunologic markers, especially those related to immunoregulation in 
resected NSCLC. Methods: In this retrospective study, FFPE samples from 122 early-
stage NSCLC patients of primary tumor tissue were used. Laser capture microdissection 
was carried out in order to separately obtain tumor and stroma areas. Thirty-eight 
genes relevant to tumor immune response and immunoregulation were assessed by 
relative gene expression analysis by RTqPCR using hydrolysis probes. Furthermore, 
the presence of CD4+, CD8+ and FOXP3+ lymphocytes was also assessed in 84 of 
these FFPE samples by immunohistochemistry. All statistical analysis were considered 
significant at p< 0.05. Results: Survival analysis carried out with cluster groups obtained 
from unsupervised hierarchical clustering analysis based on gene expression data 
showed that patients in stromal Cluster I had a worse PFS than in Cluster II (17.4 vs. 
44.3 months, p = 0.006). With regard to the tumoral clustering, patients in Cluster II 
had a worse OS than patients in Cluster I (34.4 vs. 70.4 months, p = 0.005) as well 
as a shorter PFS (19.1 vs. 32.5 months, p = 0.010). Those clusters associated with 
better survival presented higher levels of gene expression in general. Furthermore, the 
presence of CD8+ cells in the tumor compartment was significantly associated with 
better OS (73.9 vs 40.4 months, p=0.021) and PFS (56.8 vs 23 months, p=0.026). 
We also investigated whether there were significant differences in gene expression 
patterns according to CD4+, CD8+, and FOXP3+ cell infiltration. Interestingly, tumors 
with higher levels of CD8+ cell infiltration expressed significantly higher levels of genes 
related to immunosuppressive factors (p = 0.008), chemokines and their receptors (p = 
0.017), MDSCs (p = 0.008) and TAMs, and other APCs (p = 0.006). Moreover, significant 
positive correlations were observed between higher levels of CD8+ cell infiltration and 
the expression of certain individual genes such as IDO1 (p < 0.001), CCL5 (p = 0.005), 
CD209 (p = 0.031), CD86 (p < 0.001), and IL23A (p = 0.008), whereas IL8 expression 
was inversely correlated (p = 0.015). Conclusion: Our results indicate the existence of 
two possible immune-scenarios in NSCLCs. One major subset presents a T cell-inflamed 
 Scheme 
1. Schematic representation for PMCC 1-4 preparation. Preparation of PMCC Each 
PMCC with different amount of cobalt(III) and copper(II) chelates content in the polymer 
was synthesized by ligand substitution method in which labile chloride ligand in the 
[Co(bpy/phen)2Cl2]Cl and [Cu(bpy/phen)2Cl]Cl was replaced by the amine group of the 
BPEI. Results: The IC50 of four PMCCs good compared to other clinical drugs and 
PMCC 4 is high when compared to other PMCC 1-3.Conclusion: The in vitro cytotoxicity 
study demonstrates that the PMCC 1-4 have good anticancer activity against A159 lung 
cancer cell lines. So these PMCCs are alternative for better anti-cancer drugs and 
combined drug therapy. Keywords: Polymer metal complex conjugates
PUB063 The Role of Vascular Endothelial Growth Factor in Pathogenesis 
of the Non-Small Cell Lung Cancer Anna Shchayuk1, Michael Shepetko2, Elena 
Mikhalenko1, Natalia Chebotaryova1, Evelina Krupnova1 1Institute of Genetics and Cytology 
of the National Academy of Sciences of Belarus, Minsk/Belarus, 2Belarusian State Medical 
University, Minsk/Belarus
Background: Angiogenesis is an important process in pathogenesis of any malignancies, 
including non-small cell lung cancer (NSCLC). The vascular endothelial growth factor 
VEGF-A plays the central role in angiogenesis. The aim of the present study is to 
evaluate possible associations of functional VEGF -2578C>A, -634G>C, and +936C>T 
polymorphisms with the risk for occurrence and progression of NSCLC in patients living 
in the territory of the Republic of Belarus. These polymorphisms are located in key 
regulatory elements of gene VEGF: -2578C>A in promoter region, -634G>C in the 5 ‘ and 
+ 936C> T in the 3’-UTR of the gene elements that influences the efficiency of protein 
translation and the expression of VEGF in tumor tissue. Methods: In all 202 patients with 
NSCLC were included in the study. The control group consisted of 336 individuals without 
an oncopathology who matched to the patients in age-, gender- and comorbidity. Results: 
Comparative analysis of genotype distribution of three gene VEGF polymorphisms with 
the tumor size has revealed no significant associations between the studied polymorphic 
allelic variants and regional and/or distant metastatic spreading. No association were 
found between polymorphic variants in the position -634G>C and survival the patients 
with NSCLC. In the carriers of -2578СС genotype, a greater degree of tumor spreading 
(Т2-Т4) occured significantly more often (р=0,002) than the smaller extent of primary 
tumor (Т1), while small non-invasive cancer (Т1) occurs more often in the carriers of 
–2578СА (р=0,021). The carriers of –2578CA genotype were significantly more often 
observed in the “follow-up” group. The carriers of heterozygous genotype +936CT 
gene VEGF were significantly more often (p=0,012) included in the observation group. 
Conclusion: The results of study demonstrate that VEGF –2578A/C and +936C/T 
polymorphisms are among the factors determining the individual peculiarities of NSCLC 
course in this population and can be used for clarifying the prognosis of the disease. 
Keywords: vascular endothelial growth factor (VEGF), polymorphism, non-small cell lung 
cancer
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of Zingerone (ZO) a dietary compound was investigated for its ability to protect against 
radiation induced cytotoxicity and genotoxicity in Chinese hamster lung fibroblast (V79) 
cells growing in vitro. Methods: The radiation antagonistic potential of ZO was assessed 
by MTT, clonogenic, micronucleus and apoptotic assays. Results: Treatment of V79 cells 
with ZO (10 µg/ml) prior exposure to 10 Gy gamma radiation resulted elevation in the 
cell survival as evaluated by MTT assay. Similarly, there was a significant increase in the 
surviving fraction observed with 10 µg/ml of ZO treatment one hour prior to graded doses 
of gamma radiation. The genotoxic effect of radiation increased in a dose dependent 
manner indicated by increased in micronuclei frequency with increasing radiation dose. ZO 
(10 µg/ml) treatment significantly reduced the radiation induced micronuclei formation. 
Further, treatment with ZO (10 µg/ml) before irradiation significantly decreased the 
percentage of apoptotic cells (sub-G1 population) analyzed by flow cytometric method and 
DNA ladder assay. To understand the mechanism of action of ZO, separate experiments 
were conducted to evaluate the various free radical scavenging generated in vitro. ZO 
was found to inhibit the generation of free radicals in a dose dependent manner up to a 
dose of 100 g/ml for majority of the radicals and plateaued thereafter. Conclusion: Our 
study demonstrates the antagonistic effect of ZO against radiation-induced cytotoxicity 
and genotoxicity by elevating the antioxidant status and reducing the membrane lipid 
peroxidation and therefore ZO may have its application as a radioprotective agent. 
Keywords: lung fibroblast, radiation, DNA damage, cytotoxicity
PUB068 EGFR Gene Mutation in Advanced Non-Small Cell Lung Cancer - A 
Case Tahir Mehmood, Muhammad Irfan, Asma Rashid Radiation Oncology, Shaukat 
Khanum Memorial Cancer Hospital and Research Centre, Lahore/Pakistan
Background: Molecular targeted therapy based on TKIs, directed at the Epidural growth 
factor receptor (EGFR) is one of the recent option for the management of advanced 
Non-Small Cell Lung Cancer (NSCLCs). EGFR gene mutations, exon 19 deletions (LREA 
deletions) and exon 21 (L858R) are most common and good predictions of response 
to EGFR-TKI treatment. EGFR gene mutations are found in approximately 10% of 
Caucasian patients and up to 50% of Asian populations. Recent studies have endorsed 
these incidences in European and Asian populations. The frequency of EGFR mutation 
is higher in non-smokers and in women. To objective of this study was to determine the 
frequency of EGFR gene mutations in non–small-cell lung cancer patient presenting at 
our institute. Methods: Between September 2011 to September 2013, we sent EGFR 
mutation testing for 39 patients with proven histology of TTF-1 positive adenocarcinoma 
lung. EGFR gene mutations in exons 18, 19, 20 and 21 were carried out by National 
University Hospital Singapore and at Shaukat Khanum Memorial Cancer Hospital 
Lahore, Pakistan. Results: 72% of the patients were males and 28% were females. 
49% were smokers, 41% were non-smokers and this information was missing in 10% 
of the patients. 18.5% of the patients were found to have EGFR gene mutation positive; 
28.5% on exon 18, 28.5% on exon 19, 14.5% on exon 20 and 28.5% on exon 21. Among 
patients having EGFR gene mutation positive, 57% were smokers while 43% were non-
smokers. Conclusion: The frequency of EGFR mutation in our institution was 18.5% 
and all these patients were male, with almost half of the patients being smokers. This 
trend is not in accordance with published literature and merits similar study with a larger 
number of patients to find out the real trend of EGFR gene mutation in our population. 
Keywords: EGFR, NSCLC
PUB069 Exploration of ALK Fused Gene Expression in Non-Small Cell Lung 
Cancer Patients by Immunohistochemistry Jie L. Cao Pulmonary Medicine, Anhui 
Provincal Hospital, Hefei Anhui Province/China
Background: With RT-PCR as a reference , our aim is to explore the accuracy of ALK 
fused gene expression by immunohistochemistry in NSCLC patients, and to establish an 
economical feasible method for the screening of ALK positive NSCLCs. We also investigate 
the clinical and pathological features of ALK-positive NSCLC patients. Methods: By using 
rabbit monoclonal D5F3 antibody, ALK IHC was performed on 234 NSCLC patients. 
ALK positive cases were confirmed by RT-PCR. Results: The positive incidence of ALK 
by IHC in 234 NSCLC specimens was 8.97% (21/234), the positive rate of ALK fused 
gene verificated by RT-PCR was 5.98% (14/234). There is significant difference with 
histological type, age, stage-related (P <0.05); but no significant difference with gender, 
smoking history, tumor differentiation. Of 21 cases of ALK-positive NSCLC patients,The 
consistency of IHC and RT-PCR increased with the increasing of IHC-positive level. The 
consistency of IHC and RT-PCR was 0 when IHC wan 1+ ,however, when IHC was 3 + or 
immunohistochemical score was > 120, the consistency rate was 100%. Conclusion: 
Although immunohistochemical expression of ALK fused gene may have a certain false 
positive, IHC 3+ or immunohistochemical score> 120 show very high value for ALK fused 
gene RT-PCR followed by ALK immunohistochemistry in lung cancer is a economical and 
feasible method for the valuation of ALK fused gene.
PUB070 Acquired Genetic Changes Identified in Lung Adenocarcinoma with 
ALK Translocation Sana Yokoi1, Soutaro Kanematsu2, Hitomi Kondo2, Hideki Kimura3, 
Toshihiko Iizasa4 1Cancer Genome Center, Chiba Cancer Center Research Institute, Chiba/
Japan, 2Genetic Diagnostics, Chiba Cancer Center, Chiba/Japan, 3Respiratoly Surgery, 
Saiseikai Narashino Hospital, Narashino/Japan, 4Thoracic Surgery, Chiba Cancer Cener, 
Chiba/Japan
Background: Anaplastic lymphoma kinase (ALK) is the oncogenic kinase activated by 
chromosomal translocation in pulmonary adenocarcinoma. Although ALK inhibitor was 
effective, the recurrence was observed in the patient without ALK mutation. Methods: To 
explore the novel therapeutic targets of the ALK-positive lung cancer patients, we 
phenotype consisting of infiltrating T cells, which reflects innate immune cell activation, 
and in which immunoregulation processes are activated in order to resist immune attack. 
In this case patients had better outcomes. The other major phenotype lacks this T-cell 
inflamed phenotype and resists immune attack through immune system exclusion or 
ignorance. These results provide new insight into the tumor immunity field in NSCLC, 
and could be useful in the future development of prognostic and therapeutic tools. 
Keywords: NSCLC, immune ckeckpoint, biomarker
PUB065 Angiogenic Factors and Angiogenesis Inhibitors in Malignant Pleural 
Effusion Associated with Patient Survival in Lung Cancer Yu Zhang, Wei Hu, Guo-
Jun Lu First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing/China
Background: Angiogenesis is important in malignant pleural effusion (MPE) formation 
and it is regulated by a number of pro- and anti-angiogenic cytokines.This study aimed 
to evaluate the prognostic value of angiogenic factors vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF), and angiogenesis inhibitors 
endostatin, pigment epithelium-derived factor (PEDF), in lung cancer patients with 
MPE. Methods: Using enzyme-linked immunoadsorbent assay, the concentrations of 
VEGF, bFGF,endostatin and PEDF were measured in MPE from a total of 70 lung cancer 
patients with MPE. Results: There were statistically signifiant correlations between VEGF 
and endostatin levels (r=0.287, p=0.019),and VEGF and bFGF levels in MPE (r=0.33, 
p=0.012).The levels of VEGF and PEDF, bFGF and endostatin,PEDF and endostatin were 
not correlated.By univariate and multivariate analysis, pleural VEGF and endostatin levels 
were independent prognostic factors in lung cancer patients with MPE. Conclusion: There 
may be some homeostatic interrelationship between pro- and anti-angiogenic 
substances. Our results suggest that VEGF and endostatin may be potential prognostic 
parameters for lung cancer patients with MPE. We need more in-depth studies to explore 
whether measurement of these pro- and anti-angiogenic cytokines can guide treatment. 
Keywords: malignant pleural effusion, Prognosis, vascular endothelial growth factor, 
endostatin
PUB066 Gene E: A New Suicide Gene Therapy for Non-Small Cell Lung 
Cancer Ana R. Rama, Rosa Hernandez, Gloria Perazzoli, Jaime Oliver, Laura Cabeza, 
Cristina Jiménez-Luna, Maria Carmen Leiva, Julia Jiménez, Jose C. Prados Institute of 
Biopathology and Regenerative Medicine (Ibimer), Granada/Spain
Background: The potential use of combined gene therapy is under intensive study to 
improve the effectiveness of these cytotoxic agents and reduce their adverse effects. In 
this context, the association of the cytotoxic drugs with killer genes could enhance their 
antiproliferative effect. The gene E from ΦX174 encodes for a membrane protein with a 
toxic domain which causes cell lysis. To improve the antitumoral effect of some classical 
citotoxic agents we investigated a combined suicide gene therapy on A-549 cells (lung 
cancer). Methods: The gene E was cloned into the plasmid pcDNA3.1 (pcDNA3.1-E) and 
the lung carcinoma cell line A-549 were grown in monolayer. Experiments were performed 
in two groups: - Gene E alone: A-549 transfected (pcDNA3.1-E). - Combined gene 
therapy: A-549 transfected and non-transfected cells were exposed to Paclitaxel (Pac), 
Carboplatin (Car) and Gemcitabine (Gem), all of them to 100, 50 and 1 µM concentration. 
We evaluated the effect of gene E and its combination with the cytotoxic drugs by several 
techniques. Results: Our results showed that the E expression in A-549 cells carried to 
ultrastructural changes, including dilated mitochondria. These findings were corroborated 
with a significant decrease in mitochondrial transmembrane potential (p<0.05). On the 
other hand, assays with combined therapy showed that effect of the drugs at all different 
concentration was enhanced by gene E expression. Pac induces the greater inhibition 
of the proliferation, showing at the average concentration and transfecting 3 times 85% 
of growth inhibition, just as the therapy only with Pac to the maximum concentration. 
Parental and cancer cells treated with combined therapy or with citotoxic or gene E 
separately were analysed by FACscan after anexin-PI staining. The results indicated 
the ability of gene E to stimulate apoptosis in A-549 treated with their respective 
drugs. Conclusion: In conclusion, gene E has a killer effect in A-549 lung cancer cells 
which enhances growth inhibition cell when used with citotoxic drugs. That suggests a 
possibility to reduce the dose of cytotoxic agents applied in the tumours. These results 
indicate that this combined therapy may be of potential therapeutic value in lung cancer 
Keywords: gene E, suicide gene therapy, lung cancer, chemotehrapy
PUB067 Protection of Radiation-Induced Cytotoxicity and DNA Damage in 
Chinese Hamster Lung Fibroblast Cells by Dietary Compound Zingerone 
Nageshwar Rao1, Satish R. B2 1Microbiology, Mamata Medical College, Khammam/
India, 2Radiation Biology, Manipal Life Science Center, Manipal/India
Background: Radiotherapy is commonly used to treat several neoplastic diseases. 
During irradiation of tumors the deleterious effects of radiation are also felt by the normal 
tissue surrounding the neoplastic lesions. This limits the dose of radiation to cancer; as 
a result the effective treatment of tumor may not be affected. Therefore, any agent with 
its radioprotective effect on normal tissue toxicity will be clinically useful. The present 
study will be of great importance, as we do not have an ideal radioprotective agent for 
its application in Radiotherapy. If Zingerone (ZO) renders radiation protection as that of 
the standard drug Amifostine (WR 2721), it may have its potential for clinical application. 
Besides, the anticlastogenic and free radical scavenging potential of the Zingerone 
may have varied applications not only for radiation protection but also in the areas of 
chemoprotection and against any other free radical mediated pathological conditions. 
The results of the proposed study may give one such a potential candidate drug which 
may be useful as radioprotector with further investigation. The radioprotective effect 
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the perceptions of out-of-school youths about the carcinogenic effects of smokeless 
tobacco products. Methods: Participants were recruited among one hundred and 
thirty two youths in Ibadan who had been out of school for at least one year. All the 
participants were males. Ten focus group discussion sessions were then conducted 
for willing participants who said they had used or come into contact with a smokeless 
tobacco product before. The discussions were audio-taped, transcribed and coded using 
the NUDIST software. Inter-observer variability was 82%. Results: The responses could 
be classified under four major themes were identified: (1) Smokeless tobacco products 
are used by females or by males (2) Smokeless tobacco products are not necessarily 
safer (3) Smokeless tobacco products are less carcinogenic and (4) Smokeless 
tobacco can be used by “social smokers” and should be easy to quit. Comments include 
“Smokeless tobacco products will not cause cancer because it will not get into the 
lungs”. Conclusion: Perceptions about the carcinogenic effects of these products and 
the purported ease of cessation of their users suggest a need to design and test true 
knowledge and attitude patterns among Nigerian tobacco users. There is also a need 
to further explore perception of smokeless tobacco products in the larger population. 
Keywords: smokeless, tobacco, carcinogenic
PUB074 20-Years of Lung Cancer Incidence and Baseline Survival Rates in 
the Gambia, West Africa Ebrima Bah1, Maria P. Carrieri2, Omar Sam3, Swaminathan 
Rajaraman4 1Directorate of Public Health Research, Ministry of Health & Social Welfare, 
Serekunda/Gambia, 2Ird, Université Aix Marseille, Marseille/France, 3World Health 
Organisation, Bobodulaso/Burkina Faso, 4Cancer Institute (Wia), Chennai/India
Background: The monitoring of lung cancer occurrence provides fundamental 
information for tracking and stopping the tobacco epidemic globally, regionally and 
nationally. Information on lung cancer incidence and survival from the disease which is 
an important piece in such endeavors is very scarce in sub-Saharan Africa. This is mainly 
due to the fact that less than 10% of this vast continent is covered by population-based 
cancer registries (PBCR). PBCR can assist in monitoring the tobacco epidemic and the 
evaluation of interventions against it by providing information on lung cancer occurrence. 
There is no dispute among researchers that tobacco use, especially, via smoking, causes 
lung cancer. In The Gambia, legislature against tobacco use have been introduced a 
couple of years ago as part of the country’s implementation of her ratification of the 
World Health Organization’s (WHO) Framework Convention on Tobacco Control (FCTC). A 
PBCR was already established to study the incidence of all cancers including lung cancer 
since 1986. This made it possible for us to utilize the data collected over a period of 
20-years via the PBCR to:
• assess for the first time, the evolution of the incidence rates and baseline information 
on survival rates of lung cancer diagnosis in The Gambia
• demonstrate the role of the PBCR in cancer control, specifically in monitoring the 
tobacco epidemic in sub-Saharan Africa.
Methods: Age-Standardized Incidence Rates (ASR (W)) of lung cancer diagnosed and 
registered in the population of The Gambia during the period 1990 - to - 2009 were 
estimated by gender. To enhance the analysis and interpretation of our findings, 
we divided the registration period into four 5-year intervals and estimated incidence 
rates for each interval. The (ASR) (W)) was standardized to the world standard 
population commonly used by PBCR to aid the comparison of incidence rates between 
populations. Using data collected from 1993 – to – 1997 and with patients followed-up to 
31st December, 1999, baseline 5-year Relative Survival Rates were analyzed for males. 
In The Gambia cancer registration is more active than passive and patient follow-up to 
assist population-based survival analysis is predominantly active and based on home-
visits by trained health workers. Results: Lung cancer is the third commonest cancer 
in males accounting for 5% (158 cases, ASR (W)) = 2.45 per 100, 000 person-years) of 
all male cancers. The 5-year relative survival in males was estimated to be 29%. The 
disease is uncommon among female Gambians. Over the 20-year period, only 29 cases 
of lung cancer were observed among female Gambians, which translates to ASR (W)) = 
0.4 per 100,000 person-years. Conclusion: Further study of this population via regular 
analysis of the PBCR database and the conduct of epidemiological studies to adequately 
document the tobacco epidemic is necessary. Such information is fundamental to 
stopping the tobacco epidemic nationally and elsewhere in sub-Saharan Africa were such 
information is non-existent.The monitoring of lung cancer occurrence through PBCR is 
a key public health pre-requisite for rational planning and implementation of targeted 
interventions for health protection, health improvement and health promotion in Africa. 
Keywords: survival, Incidence, Gambia, Cancer
PUB075 Plain Packaging of Tobacco Products: Dressing Down the Tobacco 
Industry Karuvaki Mohanty Legal, Hriday, New Delhi/India
Background: Plain packaging of tobacco products results in reduction of brand imagery 
which would diminish the attractiveness of tobacco products, promote cessation-related 
behaviours among some smokers, and reduce initiation. However, the multinational 
tobacco companies have misinterpreted the relevant legal issues related to plain 
packaging and have exaggerated the restraints that the investment and international 
trade agreements can impose on the autonomy of the countries and the respective 
governments to ensure protection of public health.[1] The tobacco industry has a history of 
using international trade agreements to force open new markets in low and middle income 
countries, greatly increasing tobacco use and the consequent death/disease it causes. 
These companies argue that against tobacco control laws like mandatory plain packaging 
breach international laws. necessary that the key decision makers and the governments 
of nations are completely aware of the tobacco industry tactics and use flexibilities 
provided under WTO agreements to the advantage of public health policies for the greater 
analyzed genome wide copy number aberrations in 12 ALK-positive lung tumors by using 
array-comparative genomic hybridization. For the loci with copy number loss, the mRNA 
expression of the gene on the loci were analyed. Moreover the methylation status of the 
promoter region of the gene was evaluated by pyrosequencing. Results: The 111 loci 
showed copy number losses. The down-regulated gene was demonstrated in these loci 
with hyper methylation in tumor tissues compared with their non-tumorous counterparts. 
In pulmonary adenocarcinoma, the tumors with ALK showed lower expression than those 
without ALK. The patients with lower expression of the gene showed poor prognosis 
in lung adenocarcinoma. Conclusion: These results demonstrated that acquired 
genetic changes in ALK-positive cancer may relate to be a secondary pathway of ALK. 
Keywords: ALK, translocation, copy number, methylation
PUB071 A Lung Cancer Bayesian Network Facilitated Identification of Key 
Regulators of Epithelial to Mesenchymal Transition (EMT) Seungyeul Yoo1, 
Li Wang1, Sachiko Takikawa1, Mark J. Schliekelman2, Samir M. Hanash3, Charles A. 
Powell1, Jun Zhu4 1Icahn School of Medicine at Mount Sinai, New York/United States 
of America, 2Fred Hutchinson Cancer Research Center, Seattle/AL/United States of 
America, 3The University of Texas MD Anderson Cancer Center, Houston/TX/United States of 
America, 4Icahn School of Medicine at Mount Sinai, New York/NY/United States of America
Background: Epithelial to mesenchymal transition (EMT) is a key process associated 
with tumor progression and metastasis. The EMT process is complex and regulated at 
multiple levels. Multiple in vitro and in vivo omics signatures based on mRNA, microRNA, 
DNA methylation and proteomic profiles have been generated for portraiting EMT process 
in non-small cell lung cancers (NSCLCs). Currently, there is no drug targeting metastasis. 
We aim to identify key regulators of EMT for therapeutic development. However, given 
these diverse omics signatures it is still not clear which genes are key regulators of 
EMT. Methods: Network approaches have been commonly used to integrative analyze 
diverse omics signatures. There are multiple types of networks that can be used for 
network analysis. We selected two representative networks, a protein-protein interaction 
(PPI) network from Human Protein Reference Database (HPRD), which represents general 
non-context specific regulations, and a Bayesian molecular causal network constructed 
from large scale molecular profiling of NSCLCs, which represents context specific 
regulations. We compared the two networks in term of their abilities for bridging multiple 
lung cancer related molecular signatures in public databases. The lung cancer Bayesian 
network performed much better than the PPI network from the HPRD in both sensitivity 
and specificity. Results: Using the Bayesian network constructed from NSCLC profiling 
data for representing lung cancer network we applied network analysis to multiple omics 
signatures related to EMT that we generated. The EMT related subnetwork identified 
was significantly enriched for genes involved in cytoskeleton modeling. We further 
inferred TPX2, BIRC5, EMP3, and PMSD9 as putative key regulators of the EMT subnetwork 
and experimentally validated their contribution to EMT by in vitro migration and invasion 
assays. Conclusion: Our network analysis of multi-omics EMT signatures identified multiple 
key regulators of EMT that can be targeted for against lung cancer metastasis and invasion. 
Keywords: Network analysis, Bayesian Network, EMT
PUB072 Correlates of Tobacco Cessation Counseling across Health 
Professional Groups - Findings from India Rajmohan Panda, Divya Persai Public 
Health Foundation of India, New Delhi/India
Background: Tobacco cessation counseling by health professionals is an effective 
approach to increase cessation rates among tobacco users. The present study aimed 
to compare cessation counseling practices across the four health professional groups 
including physicians, nurses-midwives, lab technicians and pharmacists. We also identify 
the correlates of tobacco cessation counseling associated with each group. Methods: The 
study was a cross-sectional study conducted among 1483 health professionals 
(Physicians-345; Nurses-midwives-800; lab technicians and pharmacists-338) working 
in primary health care in 12 districts of Andhra Pradesh and Gujarat in India from June 
to August 2013. The health facilities were chosen using systematic random sampling. 
We used multiple regression analysis to identify independent correlates of counseling 
score within each health professional group. Results: Findings indicate that three factors 
emerged consistently across most groups as positively associated with counseling, 
including the belief that counseling is the role of health professionals, knowledge of tobacco 
cessation techniques and training in tobacco cessation. Physicians who have sufficient 
knowledge on tobacco cessation techniques (OR-5.7; CI:1.6-20.1) and received training 
in tobacco cessation (OR-3.5;CI:1-11.8) were more likely to provide counseling services 
as compared to nurses and midwives (OR-2.2 CI-0.7-6.5).Conclusion: The correlates of 
cessation counseling differ across health professional groups. Interventions that address 
knowledge of health professionals on tobacco cessation techniques and training in 
tobacco cessation may result in improved cessation counseling practices among health 
professionals. An intensive intervention needs to be designed for nurses-midwives, lab 
technicians and pharmacists to enhance their counseling practices in tobacco cessation. 
Keywords: Tobacco cessation, Health Professionals, India
PUB073 Perceptions of Carcinogenic Effects of Smokeless Tobacco Products 
among Out-Of-School Youths in Lagos, Nigeria Olanrewaju O. Onigbogi1, Omobola 
Ojo2 1Community Health, University of Lagos, Team/Nigeria, 2Comm Health, Lagos Univ 
Teaching Hosp, Lagos/Nigeria
Background: There have been speculations about introduction of smokeless tobacco 
products to the African markets in the near future. There are already indications that this 
marketing strategy may be adopted soon in Nigeria. This study was designed to elicit 
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was recorded and the questionnaires were statistically analyzed. Results: Prevalence 
of consumption of tobacco products was very high (57%). Most of them started using 
tobacco products in age less than 18 years (70%) and associated factors for tobacco 
use are due to friends and their influence (78%). Awareness level was (48%) but still 
uses tobacco products because of its addiction (73%). In their opinion, increase in tax 
may reduce it consumption and the majority (70%) think that tobacco must be banned. 
42% used tobacco as second hand exposure in job places and only 14% from all males 
enrolled, were smoking in public places. Conclusion: Outreach programmes from 
hospitals can educate the community about the dangers of tobacco and the signs of 
tobacco-related cancer. These programmes can attract tobacco users (smokers and 
smokeless) to its cessation. Anti-tobacco education must be imparted through schools, 
hospital outreach programmes, existing government health programmes such as 
maternal and child health programmes and routine home visits, using suitable materials 
Keywords: Tobacoo, smoking, prevalence, second hand smoke.
PUB078 Tobacco Use, Awareness and Cessation Among Malayali Tribes, 
Yelagiri Hills, Tamil Nadu, India Delfin Lovelina Francis1, Clement Joy Kingsly 
Francis2 1Public Health Dentistry, Tagore Dental College and Hospital, Chennai/
India, 2Finance and Economy, Nestle India Private Limited, Gurgaon/India
Background: Health is a state of complete wellbeing free from any discomfort and 
pain. Despite remarkable world-wide progress in the field of diagnostic, curative and 
preventive medicine, still there are large populations of people living in isolation in natural 
and unpolluted surroundings far away from civilisation, maintaining their traditional 
values, customs, beliefs and myths. India has the second largest tribal population of the 
world next to the African countries. About half of the world’s autochthonous people live in 
India, thus making India home to many tribes which have an interesting and varied history 
of origins, customs and social practices. The primitive tribal communities (comprising 
635 tribal communities) have been identified by the Government of India on the basis 
of their pre agricultural level of technology, extremely low level of literacy and small, 
stagnant or diminishing population. The present study was conducted to assess the 
tobacco use, awarness and its effect on health among Malayali tribes, Yelagiri Hills, Tamil 
nadu, India. Methods: The inhabitants of the 14 villages of the Yelagiri hills, who have 
completed 18years and residing for more than 15years present on the day of examination 
and who were willing to participate in the study were included. Ethical clearance from the 
Institution Review Board, permission from the Village panchayat leader and informed 
consent from individual subjects were obtained. Participants were selected using cluster 
random sampling method. Data was collected from a cross-sectional survey, using a 
Survey Proforma, clinical examination and a pre-tested questionnaire which included 
Demographic data, tobacco habits. An intra-oral examination was carried out by a 
single examiner to assess the Oral Health Status using WHO Oral Health Surveys – Basic 
Methods Proforma (1997). The data recorded were transferred and tabulated. SPSS 
version15 was used for statistical analysis. The alpha error (Type I error) was assumed 
to be 0.05. 95% confidence limit was set for the above analysis. Chi-square test for 
quantitative and Mann-Whitney U test for qualitative data were used for compare the 
prevalence of oral diseases between males and females. Results: Results showed that 
among 660 study population, 381(57.7%) had no formal education. Among the study 
population 75%) had the habit of alcohol consumption. Of those who had the habit of 
smoking, 26% smoked beedi, 10.9% smoked cigarette, 65% chewed raw tobacco, 18% 
chewed Hans and 28% had a combination of smoking and smokeless tobacco usage. The 
reason for practicing these habits were as a measure to combat the cold, relieving stress 
and body pain after work, and the lack of awareness of the hazards of the materials used. 
Prevalence of oral mucosal lesions in the study population was due to tobacco usage 
and alcohol consumption and lack of awareness regarding the deleterious effects of the 
products used. Conclusion: From the results of this study it may be concluded that the 
Malayali tribes were characterized by a lack of awareness about oral health, deep rooted 
dental beliefs, high prevalence of tobacco use and limited access to health services. 
Keywords: Malayali tribes, Tobacco usage, oral health status, WHO oral health proforma, 
Beliefs.
PUB079 Will Any Future Increase in Cigarette Price Reduce Smoking in Saudi 
Arabia? Sara I. Altraif, Omar Almohrej, Hani Tamim, Hana Fakhoury King Saud Bin 
Abdulaziz University for Health Sciences, Riyadh/Saudi Arabia
Background: In Saudi Arabia, no studies have been conducted on the correlation 
between any possible cigarette’s price increase and its effects on cigarette 
consumption. Methods: A cross-sectional study was conducted in April and May 
2013. The subjects included were 2057 Saudis of both genders aged 11-70 years. We 
developed an Arabic questionnaire with information on demographic and socioeconomic 
factors, smoking history, and personal opinion on the effect of price increase on 
cigarette consumption. The questionnaire was distributed in public places such as malls 
and posted on famous Saudi athlete media’s twitter accounts. Results: Among the 
2057 included responses, 802 (39%) were current smokers. The smokers’ population 
constituted of 746 (92%) males, of which 546 (68%) had a monthly income equal or 
greater to 3,000 Saudi Riyal (800 US dollars), and 446 (55%) were aged between 21 
and 30 years. Multivariate analyses of the risk factors for smoking showed that male 
gender and older age were associated with greater risk. Despite the current low prices 
of 10 Saudi Riyal (2.67 US dollars), 454 smokers (56%) thought that cigarette prices 
are expensive. When asked about the price of cigarettes that will lead to smoking 
cessation, 443 smokers (55%) expected that a price of 31 Saudi Riyal (8.27 US dollars) 
and more per pack would make them quit. Conclusion: Increasing the price of popular 
cigarettes pack from 10 Saudi Riyal (2.67 US dollars) to 31 Saudi Riyal (8.27 US 
dollars) is likely to lead to smoking cessation in approximately 39% of Saudi smokers. 
Keywords: price increase, cessation, cigarette, saudi arabia
purpose of promoting and protecting public health.[2] Positive Measures of advocacy for 
plain packaging has also started in India taking clue from Australia which has adopted 
plain packaging. To bring plain packaging to India, a Bill, Cigarettes and other Tobacco 
Products (Prohibition of Advertisement and Regulation of Trade and Commerce, Production, 
Supply and Distribution) Amendment Bill, 2014 has been introduced in the Parliament by 
Member of Parliament Mr Baijayant J Panda seeking amendment in the Cigarettes and 
Other Products Act, 2003.  [1] Davison Mark, Liberman Jonathan, Andrew Mitchell, 
Responding to the tobacco industry’s claims that plain packaging breaches international 
trade and investment law, [Internet] 2014 [cited 2014, Nov 19]. Available from: http://
www.mccabecentre.org/blog-main-page/respondingtothetobaccoindustrysclaims.
html [2] Id. Methods: A theoretical research approach has been undertaken including 
perusal of published research articles, academic journals, opinion of judiciary and 
other primary, secondary data regarding the relevance of plain packaging has been 
analysed. Results: The opposition against plain packaging by the tobacco industry 
shows the real image of the multinational companies and their intention to market harmful 
tobacco products through coloured, attractive packaging. The industry is only concerned 
about the marketing and sale of their products and is least concerned about the harm 
that such products cause to the consumers using them. The international treaties like 
WHO Framework Convention on Tobacco Control, Doha Declaration related to tobacco 
control, the Punta del Este Declaration, the TRIPS agreement provide for the 
parties to take steps to protect public health and this justifies the incorporation of 
plain packaging as an anti-tobacco measure. Right to free trade comes with certain 
reasonable restrictions which include taking measures to restrict marketing strategies 
of products harmful to health. Moreover, plain packaging only places restrictions on the 
display of the brand logo and brand name, colour combination and does not completely 
disallow the sale of such products. Conclusion: Packing cigarettes and other tobacco 
products in plain single dull drab colours will make the products unattractive and reduce 
acceptability amongst youth thereby bringing down the youth initiation of tobacco. 
Keywords: Unattractive tobacco products, Plain Packaging tobacco use public health
PUB076 Missed Opportunities for Brief Intervention in Tobacco Cessation in 
Primary Care in India Rajmohan Panda, Divya Persai Public Health Foundation of India, 
New Delhi/India
Background: Tobacco use is ranked as the one of the major preventable risk factors 
for mortality and morbidity in India. Tobacco cessation can substantially reduce 
tobacco-related morbidity and mortality. Brief intervention has been recommended 
as a best practice for tobacco cessation. The present study aims to investigate the 
brief intervention practices of Health Service Providers (HSPs) in tobacco cessation 
and the factors influencing screening practices of HSPs for tobacco usage in patients 
attending health facilities providing primary care. Methods: The study was a cross-
sectional study conducted among 1,549 patients aged more than 18 years visiting 
health facilities providing primary care in 12 districts of two high tobacco burden states 
i.e. Andhra Pradesh (AP) and Gujarat in 2012. The study was conducted in 200 health 
facilities providing primary care. The health facilities were chosen using systematic 
random sampling. The study participants were recruited through simple random 
sampling. Results: Only 136 (36%) of the patients reported to have been counseled. 
Less than one-third (447) of patients were screened for tobacco use during their visit 
to the health facility. ‘Number of quit attempts in the past 12 months’ was strongly 
associated with the outcome of being screened for tobacco use. Patients who had made 
‘1 to 5 quit attempts’ and ‘>5 quit attempts’ were associated with an OR of 1.54 (95% 
CI: 1.16 to 2.05) and 1.99 (95% CI: 1.03 to 3.85) respectively of being screened for 
tobacco use than those who had never attempted to quit tobacco. Conclusion: Our 
results show that opportunities for screening and providing tobacco use cessation 
advice were largely missed by the health service providers. There is an urgent need to 
incorporate tobacco cessation interventions as part of standard practice in primary care. 
Keywords: Tobacco cessation, Primary care, India
PUB077 A Survey on Tobacco Use in Chennai City Clement Joy Kingsly Francis1, 
Delfin Lovelina Francis2 1Finance and Economy, Nestle India Private Limited, Gurgaon/
India, 2Public Health Dentistry, Tagore Dental College and Hospital, Chennai/India
Background: India is the second largest consumer of tobacco products and third largest 
producer of tobacco in the world. Tobacco is a major, preventable cause of premature 
death and disease, currently leading to over five million deaths each year worldwide, 
which is expected to rise to over eight million deaths yearly by 2030. Vast majority of 
these deaths are projected to occur in developing countries. Nearly eight to nine lakh 
people die every year in India due to diseases related to tobacco use. Majority of the 
cardio vascular diseases, cancers and chronic lung diseases are directly attributed to 
tobacco consumption. Almost 40% of tuberculosis deaths in the country are associated 
with smoking. MMTR statistics revealed that 43% of all cancers among men and 17% of 
all cancers among women occurring in Chennai are related to tobacco use in some form. 
An efficient and systematic surveillance is essential for a comprehensive tobacco control 
effort to monitor the epidemic. Considering the burden of diseases caused by tobacco 
and the benefits we get by reversing the epidemic, effective interventions and evaluation 
strategies are need of the hour. Therefore, this study is aimed to evaluate tobacco 
usage in Chennai city covering both urban and rural population. Methods: The modified 
version of the GATS questionnaire developed by WHO was used for the survey. GATS 
is intended to assist countries to design, implement and evaluate tobacco control and 
prevention programme. The survey was conducted as follows 1) the selected households 
were visited to identify the adult family members in each household from the available 
adult respondents. 2) Each adult (15 years and above) was contacted over phone or in 
person to elicit the details of their tobacco use, exposure to second hand smoke, quit 
attempts, the impact of tobacco control and prevention initiatives, etc. Their response 
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smokers and 20.8% were smokers. There were more squamous cell carcinoma patients 
and small cell carcinoma patients in smoking group than non-smoking group(P＜0.01), 
but less adenocarcinoma patients in smoking group than non-smoking group(P＜0.05). 
Patients with different pathological types in squamous cell carcinomas of the highest rates 
of smoking (84.6%), followed by small cell lung cancer (67.3%). More atients in smoking 
group suffered from cough (P＜0.05)and hemoptysis(P＜0.01). The asymptomatic patients 
in non-smoking group were more than those in smoking group (P＜0.01). Conclusion: In 
male smoking patients with lung cancer, the proportion of squamous cell carcinoma 
is high, and the symptom of cough and hemoptysis is obvious. In male non-smoking 
patients with lung cancer, adenocarcinoma is common, and clinical manifestation 
is not obvious. Smoking is one of the important factors which lead to lung cancer. 
Keywords: lung cancer, smoking
PUB083 Role Models “A Tool for Effective Tobacco Control Campaign” 
Seye O. Omiyefa Programs, Youth Action on Tobacco Control and Health, Ibadan/Nigeria
Background: Each day, nearly 6,000 children under 18 years of age start smoking; 
of these, nearly 2,000 will become regular smokers. That is almost 800,000 
annually. Approximately one half of continuing cigarette smokers will die prematurely 
from tobacco use; this is mostly after several years or more of excess disease and 
disability. Methods: Experience has showed that adolescent and youths all over the 
world especially Nigeria are attracted to media of any form. Role Models will be used 
through the help of the media and the entertainment industries to give a tobacco 
control sensitization talk for two minutes each on a video that will be televise. This 
video will also be uploaded on “Facebook”, Twitter, Whatsapp and “YouTube” for a 
wider viewing of this campaign; these role models are mentors to many other youths 
in Africa. Results: These methods will creatively increase the awareness level of young 
people in Nigeria and Africa on the harmful effect of tobacco smoking and promote 
the campaign against tobacco smoking. The methods will also reduce the rate of youth 
smoking in Nigeria and Africa, as some of these role models are also models to many 
youths in other African countries. Conclusion: Evidence has showed that some of these 
role models are used as a campaign tool by the tobacco industry in Nigeria and other 
countries. It is therefore systemic and appropriate to use the same method to reduce 
the current upsurge in youth smoking and cancer related disease in Nigeria and Africa 
Keywords: Role Model, Tobacco Control, Youth
PUB084 Knowledge, Attitudes, and Smoking Behaviours Among Dental and 
Medical Students in Chennai, Tamil Nadu, India Delfin Lovelina Francis1, Clement 
Joy Kingsly Francis2 1Public Health Dentistry, Tagore Dental College and Hospital, Chennai/
India, 2Finance and Economy, Nestle India Private Limited, Gurgaon/India
Background: Tobacco use continues to be the leading cause of preventable disease 
and it is responsible for more than 5 million deaths each year worldwide. Despite this, 
there are still 650 million smokers in the world. The prevalence of smoking among 
adults accounts for approximately 25% deaths annually. Undoubtedly, there has been a 
gradual reduction in smoking prevalence in the last years in the western countries, but 
smoking remains the main cause of mortality and morbidity in the developing nations. 
Healthcare professionals have an important role to play both as advisers influencing 
smoking cessation and as role models. However, many of them continue to smoke. 
Several studies have demonstrated the efficacy of smoking cessation programs and 
the importance of physician’s advice to their patients. The aims of the present study are 
as follows: (i) to evaluate smoking prevalence, knowledge and attitudes, and tobacco 
cessation training (ii) to examine the difference between smokers and nonsmokers; (iii) to 
estimate the extent of teaching about tobacco and smoking cessation techniques (iv) to 
recommend the integration of tobacco-related education in the curriculum. Methods: A 
structured questionnaire consisting of 14 questions related to tobacco/smoking habits, 
cessation training and role of health professionals in tobacco control were asked to 
the study population and their response was recorded. Random sampling method was 
used and data was collected from a cross-sectional survey. The survey was conducted 
between January and February 2015. Statistical analysis was done using SPSS version 
17 and Logistic regression model was used to identify possible associations with 
tobacco smoking status. The level of significance was. Results: A total of 259 answered 
the questionnaire of which 29% declared to be smokers. About 53% of the males have 
smoked at least once in their life and the age of cigarette initiation was 16-17 years 
for 28% of the sample.76% considered health professionals as behavioural models 
for patients, and 96% affirmed that health professionals have a role in giving advice 
or information about smoking cessation. Although 87% heard about smoking related 
issues during undergraduate courses, only 17% received specific smoking cessation 
training during specialization. 93% of the sample agreed that health professionals 
should receive specific training on smoking cessation according to while 6% were of 
the opposite opinion. Conclusion: All healthcare professionals play an important role 
in the process of smoking cessation both as advisers and behavioural models for the 
general population. The present study highlights the importance of focusing attention 
on smoking cessation training, given the high prevalence of smokers among physicians 
specializing in medicine and dentistry, their key role both as advisers and behavioural 
models, and the limited tobacco training offered in the curriculum. In the field of public 
health, tobacco screening, and intervention is one of the most effective clinical preventive 
services. Planning and implementing smoking cessation training and cessation 
tailored to these young health professionals is therefore strongly recommended. 
Keywords: Medical Students, smokers, non-smokers, tobacco cessation
PUB080 Environmental Tobacco Smoke as a Risk Factor to Increasing 
Respiratory Childhood Infection and Pneumonia in South-West Region Nigeria 
Seye O. Omiyefa Programs, Youth Action on Tobacco Control and Health, Ibadan/Nigeria
Background: There is consistent evidence that children exposed to environmental 
tobacco smoke (ETS) have higher incidence of asthma, ear- and throat disease, 
worsening of asthma symptoms and lung symptoms as cough, wheezing and pneumonia. 
A child exposed to ETS has about 30% higher risk of absence from school due to illness. 
Evidence clearly implicates (ETS) as a cause of lung cancer, excess respiratory disease, 
and cardiovascular disease mortality in non-smokers. Few studies have looked at the 
interaction of tobacco use or ETS exposure with occupational and ambient air pollution 
(both indoor and outdoor) in contributing to chronic obstructive pulmonary disorders 
in developing countries, or the importance of ETS as a risk factor for the already high 
burden of childhood respiratory infections. Methods: A descriptive cross sectional 
study was carried out in 5 states (Ogun, Lagos, Akure, Oyo and Ekiti). A multistage 
cluster random sampling was employed to select 450 families in each state. Data was 
collected using structured questionnaires by trained interviewers. Results: About 2113 
records were available for analysis. There were 1298(60.7%) males and 815(38.1%) 
females aged 10 and below. A Majority, 807(38.0%) live with both parents, 213(10.0%) 
live with mother alone while 265(12.5%) live with relatives. The prevalence of children 
exposed to ETS in the southwest region Nigeria was 73.2%, the study further revealed 
that 28.5% of children in this region with respiratory childhood infection are exposed 
to environmental tobacco smoke and 18.4% pneumonia cases are attributed to ETS. 
However, (122, 14.7%) parents or relatives don’t see a problem with using tobacco 
products. It is also clearly stated that about 46.9% cases of respiratory childhood 
infection and pneumonia combined are caused by ETS in the south west region 
Nigeria. Conclusion: Since Environmental Tobacco Smoke has this much negative 
effects on children in the south west region Nigeria. Efforts should be tailored 
towards protecting children from ETS to reduce the rate of children exposed to ETS, 
thereby curbing or reducing respiratory childhood infection and pneumonia in Nigeria 
Keywords: ETS, Tobacco Control, Pneumonia
PUB081 Former Cigarette Smokers and the Risk of Lung Cancer Development 
Irina Pavlovska, Nikola Orovcanec, Biljana Taushanova, Beti Zafirova Department of 
Epidemiology, Institute of Epidemiology and Biostatistics, Skopje/Macedonia
Background: Cancer is a leading cause of death worldwide. There were 14,1 million 
new cancer cases, 8,2 million cancer deaths and 32,6 million people living with cancer 
(within 5 years of diagnosis) in 2012 worldwide. The leading kind of cancer in the world is 
the lung cancer (LC). This is the most frequent cancer localization in many countries. In 
the Republic of Macedonia LC is on the first place among the ten most common primary 
sites of cancer. The principal risk factor for LC is smoking, which is largely responsible 
for the development of the disease in men and women. Approximately 85% of LC can 
be directly attributed to smoking and secondhand smoke. The aim of this study was 
to determine the eventual causal associations between the habit of cigarette smoking 
and onset and distribution of lung cancer. Methods: This investigation was a case-
control study. It comprised 185 patients with LC (investigated group-IG) and matched 
controls with no malignant diseases (control group-CG). In the study were included 
only interviewees with pathohistologically confirmed LC. By calculating the odds-ratios, 
the risk factors that play a role in the disease onset, have been estimated. Statistical 
significance of the examined variables as risk factors has been defined with confidence 
intervals (CI). Results: According to the investigation results, among patients were 67% 
of current smokers (CS), 23,8% of former smokers (FS), and 9,2% of never smokers 
(NS), compared to 40,5% of CS, 28,7% of FS and 30,8% of NS among controls. The risk 
of LC development in FS is almost three-times (OR=2,78; 95% CI, 1,42-5,46), significantly 
greater compared to the NS (p<0,01). Up to the age of 20 years, 81,8% of the diseased 
persons started smoking, while in the CG that percent is 56.6%. FS who started smoking 
up to 20 years of age have 3,45 times significantly higher risk to become ill (95% CI, 
1,35-8,82), compared to those who started with this habit after the age of 20. The mean 
values of daily (IG-32,50±16,51; CG-26,62±15,04), and maximally (IG-43,18±19,20; 
CG-35,19±17,29), smoked cigarettes are higher in the diseased individuals. More than 
40 cigarettes/day were smoked by 25% of the FS with LC. More than a half of the FS 
(56,5%), practiced this habit ranging from 31-45 years. FS who smoked >40 years had 
5,35 times (95% CI, 2,11-13,57), significantly higher risk to become ill, compared to 
those which years of smoking is <40. Greatest percent of the FS stopped smoking 1-5 
years ago (59,1%), while in the CG this percent is 15,1%. FS who stopped smoking 1-10 
years ago had 3,56 times significantly greated risk to become ill (95% CI, 1,27-9,92), 
compared to those who abandoned this habit 11-20 years ago. Conclusion: Lung and 
other cancers caused by tobacco are often untreatable at the time of diagnosis. The 
key to reducing these cancers is to prevent initiation of smoking in young people, and 
to encourage smokers to quit. Quitting smoking substantially reduces cancer risk. 
Keywords: lung cancer, cigarette smoking, former smokers
PUB082 Study on Differences in Lung Cancer Between Male Smokers and 
Never-Smokers Feng S. Yun1, Zhang Yao2, Li C. Yuan1 1Thoracic Surgery, Second Part of 
the First Affiliated Hospital of Jilin University, Changchun/China, 2Thoracic Surgery, The First 
Affiliated Hospital of Jilin University, Changchun/China
Background: To investigate the effect of smoking on male patients with lung 
cancer. Methods: Clinical data of 1298 male patients with lung cancer who were diagnosed 
by histology or cytology were collected and retrospectively analyzed. Patients were 
divided into smoking group and non-smoking group. Results: 79.2% patients were never 
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plan and policies to the clinicians, policies makers to give priorities for the cancer 
prevention and control activities. Methods: The total 34,940 cases were included 
in this study to know the burden of cancer patients in seven major government and 
non-government hospitals of Nepal where cancer diagnosed and treated from 2003-
2009. This was descriptive type of study and all cases were collected from medical 
record section of seven collaborative institutions for data analysis. Results: In this 
study Female (53.3%) cases were diagnosed more than males (46.7%). Overall, the 
most common cancer sites in Males were lungs, stomach and leukemia but in Females 
Caner of cervix uteri , breast and lung . More cancer cases (67.7%) seen in Female 
but in Males found 52.5% in the broad age group 35 to 64 yrs. In young age leukemia 
and lymphoma were more common replaced by lung, oral and stomach cancer in 
middle age but in older lung, stomach and larynx cancer were found in males but in 
females breast cancer in young, cervix uteri cancer in middle and followed by lung 
cancer in older age. Conclusion: This type of study shows burden across a greater 
proportion of cancer from 7 major hospitals where cancer is diagnosed and treated, 
but the coverage may not represent the whole country. More than 50% cancer was 
diagnosed in BPKM national cancer hospital. Population based cancer registry program 
is not yet established so, it is difficult to reflect the burden of cancer in the country. 
Keywords: Incidence, Cancer Registry, Burden of cancer, Prevention and control policies
PUB089 Mathematics Diagnosis Model to Differentiate Multiple Primary Lung 
Cancers from Intra-Pulmonary Metastases Feng Li1, Wen-Zhao Zhong1, Fei-Yu Niu1, 
Chao Liu2, Zhi-Yong Chen1, Ning Zhao1, Jin -Ji Yang1, Yi-Long Wu1 1Guangdong General 
Hospital, Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, 
Guangzhou/China, 2Department of Pathology,Guangdong General Hospital, Guangdong 
Academy of Medical Sciences, Guangzhou/China
Background: It is important to differentiate multiple primary lung cancers(MPLC) 
from intra-pulmonary metastases(IPM) for the patients with multiple lung nodules. 
Currently, there are several criteria to distinguish MPLC from IPM but with conflict 
results. Methods: Five criteria including Martini and Melamed guideline, American 
College of Chest Physicians (ACCP) guideline, radiological evaluation, comprehensive 
histological assessment (CHA) and genetic profiles (EGFR, KRAS and ALK gene detection) 
were applied to evaluate the origin of tumor cells in paired lung specimens respectively. 
Finally, the multi-disciplinary consultation are considered as golden standard of the 
diagnosis, 65 cases of five definite independent results were enrolled as training set, 
while 9 cases of one method without definite results were enrolled as validation set. 
Based on Bayes discriminant analysis, we developed mathematics diagnosis model 
ultimately. Kaplan-Meier analysis was used to analyze the prognosis by mathematical 
diagnosis model. Results: Totally, 74 consecutive patients with multiple lung nodules 
confirmed with adenocarcinoma were enrolled in the study from 2457 surgical resected 
lung cancer between January 2007 and July 2014. Among 74 cases with multiple lung 
nodules, 63 cases were identified as MPLC and 11 cases as IPM by Martini and Melamed 
guideline; 39 cases were identified as MPLC and 29 cases as IPM by ACCP guideline, 
while 6 cases cannot be classified; 39 cases were identified as MPLC and 35 cases as 
IPM by radiological evaluation; 53 cases were identified as MPLC and 21 cases as IPM 
by CHA; 45 cases were identified as MPLC and 26 cases as IPM by gene detection, while 
3 cases cannot be identified because of triple negative results of gene detection, so 
the identification rate was 95.9% (71/74). The Bayes discriminant analysis method was 
applied to develop mathematics diagnosis model as following, Y=-83.11+34.998*G+
13.932*C+4.553*R+1.874*A -0.339*M(Abbreviation, G: genetic profile; C: CHA; R: 
radiological evaluation; A:ACCP guideline; M: Martini and Melamed guideline). The value 
and significance of five criteria are as following,“1” is for MPLC and “2” is for IPM. When 
Y>0, the diagnosis is intended for IPM, when Y≤0, the diagnosis is intended for MPLC. The 
retrospective and prospective accuracy rate of the model in 65 cases and 9 cases was 
96.9% and 88.9% respectively. Kaplan-Meier analysis was used to explore the prognosis 
by mathematical model, which show that the prognosis of MPLC patients are better than 
that of IPM patients(P = 0.006). Conclusion: The practical mathematical diagnosis model 
was developed to distinguish MPLC from IPM in the patients with multiple lung nodules of 
adenocarcinoma. The prognosis of MPLC patients are better than that of IPM patients. 
Keywords: multiple primary lung cancers, Prognosis, Mathematics diagnosis model, 
Intr-pulmonary metastases
PUB090 Lung Cancer in Niger: An Analysis of the National Cancer Registry 
Data Salamatou Mamoudou Garba1, Hinde Hami2, Harouna Mahamadou Zaki1, 
Abdelmajid Soulaymani2, Abdelrhani Mokhtari2, Hassan Nouhou1, Ali Quyou2 
1Laboratory of Pathological Anatomy and Cytology, Faculty of Health Sciences, Abdou 
Moumouni University, Niamey/Niger, 2Laboratory of Genetics and Biometry, Faculty of 
Science, Ibn Tofail University, Kenitra/Morocco
Background: Lung cancer is a major cause of morbidity and mortality worldwide, with 
an estimated 1.8 million new cases of lung cancer (13% of the total) and 1.6 million 
cancer deaths in 2012 (19.4% of the total) (GLOBOCAN 2012). The aim of this study is to 
estimate the incidence and determine the epidemiological characteristics of lung cancer 
in Niger. Methods: This is a descriptive retrospective study of lung cancer cases, reported 
between 1992 and 2009 to the Niger Cancer Registry. The sites of lung cancer include the 
following: trachea (C33.9), main bronchus (C34.0), upper lobe, lung (C34.1), lung, not otherwise 
specified (C34.9) and pleura, not otherwise specified (C38.4). Results: During the period 
1992-2009, there were 61 cases diagnosed with lung cancer in Niger, which was 0.87% 
of all new cases of cancer reported during the study period. More than 85% of the cases 
were men with a male-female ratio of 5.78. The incidence of lung cancer was 0.54 cases 
per 100 000 persons. The average age of the patients at diagnosis was 54.80±14.32 
years (range 20-85 years). According to the available data, 77% of the patients came 
from the Niamey region. The commonest histological type was carcinoma (11.4%). We 
PUB085 A Cross-Sectional Study on Tobacco Consumption Pattern Among 
Auto Rickshaw Drivers in Chennai City, Tamil Nadu, India Clement Joy Kingsly 
Francis1, Delfin Lovelina Francis2 1Finance and Economy, Nestle India Private Limited, 
Gurgaon/India, 2Public Health Dentistry, Tagore Dental College and Hospital, Chennai/India
Background: Tobacco use is a major preventable cause of premature death and 
diseases, currently leading to five million deaths worldwide which are expected to raise 
over eight million deaths worldwide by 2030. About 29% of adults use tobacco on a 
daily basis and an additional 5% use it occasionally. The habit has very high opportunity 
cost as it reduces the capacity to seek better nutrition, medical care and education. In 
line with the WHO Framework Convention on Tobacco Control (FCTC), the Cigarettes 
and Other Tobacco Products Act (COTPA) is a powerful Indian national law on tobacco 
control. The prevalence of tobacco use among adults (15 years and above) is 35% and 
the prevalence of overall tobacco use is 48% among males. This study is contemplated 
with an aim to assess the prevalence of tobacco consumption and the associated 
factors involved in its consumption, as this group of the population is under constant 
pressure and account for the workforce of the country. So through this study we could 
be able to know * The reasons of consumption. * Amount of consumption *Awareness 
of ill effect of tobacco consumption * Out of Pocket expenditure. Methods: A Cross 
sectional descriptive study was conducted among Auto Rickshaw Drivers in Chennai 
City. Auto drivers who were working for more than two years and present on the day 
of examination and who were willing to participate in the study were included. Cluster 
random sampling technique was used. 400 samples were selected from 40 auto 
stands of various parts of Chennai City. Data was collected using a Survey Proforma 
which comprised of a Questionnaire which can assess the frequency of consumption, 
age of initiation, the amount of consumption, mental stress, economic factors, any 
past history of disease and most importantly the awareness towards oral cancer. The 
data recorded was transferred and analysed using SPSS version 20. Age, tobacco 
consumption pattern, reasons of consumption, amount of consumption, harmful effects 
of tobacco are the variables. Chi- square test was used to test the significance between 
groups. Results: Prevalence among auto rickshaw drivers for consumption of tobacco 
products was very high (87%). Auto rickshaw drivers were mostly used tobacco in the 
form of Gutkha (72%) and bidi (40%) in comparison to other products. It also shows 
that they use cheap tobacco products. Most of the auto rickshaw drivers start using 
tobacco products in age less than 18 years (80%) and associated factors for tobacco 
use are due to friends and their influence (78%). Awareness level among auto rickshaw 
driver was high (70%) but still uses tobacco products because of its addiction (66%). In 
the opinion of auto rickshaw drivers increase in tax may reduce it consumption and the 
majority of drivers (70%) think that tobacco must be banned. Conclusion: Prevalence 
of tobacco use was very high. Mostly they use tobacco products to reduce stress, 
to be awake or to remove nervousness but a large number of participants also use 
them without any reason. They are in definite need of tobacco cessation activities. 
Keywords: Tobacco, Awareness, Prevalence, Addiction.
PUB086 Smoking Habits and Awareness about Anti-Smoking Acts among 
General Public in Gurgaon, Haryana, India Clement Joy Kingsly Francis1, Delfin 
Lovelina Francis2 1Finance and Economy, Nestle India Private Limited, Gurgaon/India, 2Public 
Health Dentistry, Tagore Dental College and Hospital, Chennai/India
Background: India is the world’s third largest tobacco-growing country. The Indian 
scenario as far as tobacco consumption is concerned is far worse because of the 
prevalence of the tobacco chewing habit which covers a wide spectrum of socioeconomic 
and ethnic groups and is spread over urbanized area as well as remote village. Tobacco 
use is alarming in terms of its current and projected future impact on global mortality. 
Recent shift in global tobacco consumption to developing countries indicate that an 
estimated 930 million of the world’s 1.1 billon in India alone. Despite the facts, that 
the harmful effects of tobacco chewing and smoking are widely known, many young 
people start smoking during adolescence, largely because they believe that smoking will 
boost their social acceptability and image. This study was contemplated with an aim to 
assess tobacco / smoking habits and awareness about anti-smoking act among general 
public in Gurgaon, Haryana, India. Methods: A structured questionnaire consisting of 
14 questions related to tobacco/smoking habits and awareness about anti-smoking act 
were asked to general public and their response was recorded. Random sampling method 
was used and data was collected from a cross-sectional survey. Anti-tobacco counselling 
was given on the spot and followed. Results: The study population consisted of total 430 
individuals , male 364 (84.65%) and females 66 (15.34%) . Then the questionnaires were 
asked and statistically analyzed. Around 286 (78.57%) from 364 male were indulged 
in some form of tobacco usage (smoker =32.86% , tobacco chewer = 16.78% , both 
=11.18 % , alcohol + tobacco user =21.67%). In the present study , most common cause 
of tobacco use was pleasure 40.5% , inducing factor were friends 53.1% followed by 
parents and siblings . 36.20% patients used tobacco as second hand exposure in job 
places. 54.8% were aware about the anti-smoking act in public places, so only 8.6% 
people from all males enrolled, were smoking in public places. Conclusion: Even 
though there exist Anti-smoking Law in the country, General public are unaware. 
Involvement of Healthcare proffessionals becomes mandatory to overcome this issue. 
Keywords: Tobacoo chewing , smoking , anti-smoking act , prevalence
PUB087 A Study on Seven Years Hospital Based Cancer Incidence in Nepal 
(2003 -2009) Kishore K. Pradhananga Cancer Prevention, Control and Research, BPK 
Memorial Cancer Hospital, Chitwan/Nepal
Background: The objective of the study gives overview to reliable information about 
Seven yrs cancer incidence in Nepal. It helps to make some prevention and control 
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standard technique for lung cancer screening, however, no clear evidence of benefi ts 
from lung cancer screening has been established in a high-risk population residing in an 
endemic area of TB. Methods: A prospective lung cancer screening using LDCT enrolled 
635 former or current heavy smokers (>30 pack-years) aged 50-70 years without a history 
of active TB within a recent year between July 2012 and January 2014 at Chulabhorn 
Hospital Cancer Centre in Thailand. Results: 635 subjects were enrolled. At baseline 
LDCT, 419 cases (66%) had lung nodule(s); half of them had 2-10 lung nodules, 41.7% had 
a single nodule, and 8.6% had lung nodules >10 nodules. Of these 419 cases, 63% had 
benign nodule(s) characteristic, 15.2% had nodule(s) with lesion suspected infl ammation 
or infection, 15.5% had nodule(s) with diameter 5·0–9·9 mm, and 5.7% had nodule(s) 
with diameter >10·0 mm. Nine cases(1.4%) were proven to have lung cancer (56% stage 
I, 22% stage II/III, 22% stage IV) within 12 months. Of these 9 participants 8 had nodule(s) 
with diameter >10·0 mm and the other had mediastinal lymphadenopathy from baseline 
LDCT. Most of them (66%) had 2-10 lung nodules that all were non-stage 4 lung cancers, 
while only 33% had single nodule including 2 cases of stage 4 lung cancers. Three cases 
were diagnosed active pulmonary TB within 12 months (one culture positive TB, one 
caseous granulomatous infl ammation and one chronic infl ammation on tissue pathology) 
and all were responded to antituberculosis drugs. Conclusion: Despite a high burden of 
TB in Thailand, LDCT screening in heavy smokers could yield a high rate of primary lung 
cancer in this population at risk. However, high prevalence of lung nodules is one of the 
major problems in diagnosis and staging lung cancer in endemic area of Tuberculosis. 
Keywords: lung cancer screening, low-dose computerized tomography (LDCT), 
Pulmonary Tuberculosis (TB), Endemic Area
PUB093 Relationships Between Circulating Tumor Cells and Platelets, D-Dimer 
and Fibrinogen in the Patients With Lung Cancer Chunhua Liu, Ping Gong, Jie Yang
Department of Radiotherapy, People’s Hospital of Xinjiang Uygur Autonomous Region, 
Urumqi/China
Background: To investigate the relationships between circulating tumor cells (CTCs) 
and platelets (PLT), D-dimer (D-D) and fi brinogen (FIB) in the patients with lung 
cancer. Methods: The clinicopathological fi les of 79 initially-treated patients with 
primary lung cancer were collected. The number of CTCs in peripheral blood and levels 
of D-D, PLT and FIB in plasma were respectively detected, and their relationships were 
analyzed. Results: The level of D-D was associated with the presence or absence of distant 
metastasis in patients with lung cancer (P=0.046), FIB with clinical staging (P=0.028) 
and presence or absence of distant metastasis (P=0.004) as well as PLT with the age 
(P=0.000), clinical staging (P=0.000) and presence or absence of distant metastasis 
(P=0.000). Among 79 patients with lung cancer, there were 45 ones with positive CTCs 
and 34 with negative CTCs. The levels of D-D, FIB and PLT in patients with positive CTCs 
were dramatically higher than those with negative CTCs (P<0.05). The positive detection 
rate of CTCs in the patients with distant metastasis was signifi cantly higher than those 
without distant metastasis (83% vs. 42%, P=0.000), and the levels of D-D, FIB and PLT 
were all higher than those without distant metastasis (P<0.05). Conclusion: CTCs 
can predict the metastasis of lung cancer early, and blood hypercoagulable 
state is likely to promote the occurrence of distant metastasis of lung cancer. 
Keywords: lung cancer; circulating tumor cells; D-dimer; fi brinogen, platelets
PUB094 Image Guided Biopsy of Thoracic Masses and Reduction of Risk 
of Pneumothorax: 25 Years Experience in a Remote Cancer Center Binoy 
K. Choudhury Department of Radiology and Imaging, Dr. B. Borooah Cancer Institute, 
Guwahati/India
Background: The purpose of our study was to determine the role, accuracy and reliability 
of image guidance of thoracic biopsy and to know the effi cacy of uses of different 
measures to reduce the risk of pneumothorax. Methods: Needle aspiration biopsies were 
performed in 1520 patients from February,1989 to December,2013 using Fluoroscopy, 
Ultrasound and Computed Tomography ( CT ) as Image guidance. Ultrasound guidance 
was used for peripheral lesions abutting the chest wall. Fluoroscopic and CT guidance 
were used for both peripheral and central lesions. After reviewing the patient, chest 
skiagram, CT Scan and coagulation profi le, a plan is formulated to the safest approach 
to the thoracic lesions. A needle was guided to the thoracic lesion with an appropriate 
Image technique and material was aspirated with 20 cc plastic syringe and smeared on 
slides. Several measures were applied to reduce the risk of pneumothorax. Immediately 
after the technique, puncture site was put on dependant position ( Roll-over technique ) to 
reduce the risk of pneumothorax. Other measures taken to reduce the pneumothorax risk 
included selection of appropriate image guidance, accurate and delicate performance of 
needle manipulation, extra pleural approach, widening of extrapleural parasternal and 
paravertebral space by saline injection, pathway through non-aerated lung, minimized 
the pathway of normal aerated lung, avoiding fi ssure & bullae, limited number of pleural 
puncture, small bore needle, up & down movements of needle tip were very slowly & 
carefully done in a small lesion. Needle biopsy was not performed in bronchoscopically 
accessible hilar or central lesions. All patients underwent chest radiography to detect a 
pneumothorax. Results: There were 1201 male and 319 female in the range of 12 to 91 
years. Fluoroscopy, US and CT as guidance were used in 170 ( 11.18%), 259 ( 17.04%) 
and 1091 ( 71.78%) cases respectively. The diameter of masses ranges from 1.2 cm 
to 12 cm. Procedure time was signifi cantly less under US guidance. 152 cases ( 10%) 
needed repeat biopsy and most of these were Fluoroscopic or CT guidance. Results 
obtained in 1292 cases ( 85%). Malignant cases were 982 (76%). Complications included 
haemoptysis ( six ) and pneumothorax in 35 ( 2.3%). There was no pneumothorax in 
US guided biopsy. Pneumothorax occurred in 10 cases following fl uoroscopic guidance 
and 25 cases in CT guided biopsy. Only three cases of pneumothorax required 
placement of a chest tube, rest were small and resolved spontaneously. Incidence 
of pneumothorax dropped signifi cantly after we started meticulous planning using 
registered 22 deaths, with a lethality rate of 36.06%. Conclusion: Despite the limitations 
of the available data, it is clear that there are several barriers to access to cancer control in 
developing countries. This includes prevention, early detection, diagnosis and treatment. 
Keywords: epidemiology, Niger, lung cancer
PUB091 Epidemiological, Clinical and Radiological Profi les of Lung Cancer 
Patients in a Tertiary Care Hospital of Pakistan Madiha Tawfi k, Nadeem Rizvi
Jpmc, Karachi/Pakistan
Background: Among the various cancers worldwide, lung cancer continues to be one 
of the leading causes of morbidity and mortality. According to WHO in 2012, 1.8million 
estimated new cases of lung cancer occurred globally with 58% belonging to less 
developed countries.We evaluated the common factors contributing to this fatal disease 
as it has been proven that 5 years and even 10 years survival rates close to 90% can be 
achieved by screening programs. Methods: A cross sectional study done in Pulmonology 
Department from December 2013 -2014. Total 125 lung cancer suspects, selected 
through consecutive sampling, were admitted through the Outpatient Department 
after counseling and written consent for invasive tests. Basic biodata, smoking 
history, biomass exposure, symptoms and signs related to lung cancer, laboratory and 
radiological fi ndings deduced via workup were entered in questionnaire. After assessing 
patients, CT guided or bronchoscopic biopsies were done and tissue samples sent for 
histopathology. Clinical records of 121 cases, confi rmed on histopathology as lung 
cancer, were compiled and evaluated. Frequency and percentage for qualitative variables 
including gender, smoking history,biomass exposure, signs and symptoms, Tuberculosis 
history, laboratory, radiological, bronchoscopic and histopathological fi ndings were 
calculated. Mean ± standard deviation for quantitative variables including age and pack 
years were calculated. Results: In all, 67.8% cases belonged to 41 to 60years age group, 
mostly males, ex smokers with 57.3% having more than 30 packyears smoking history. 
Non smokers were 26.4 % and among females diagnosed of lung cancer 70.8% were 
nonsmokers as seen below: 
There was history of biomass exposure in 46.3% cases and Tuberculosis in 28.9% 
cases. Most common symptom and sign was breathlessness and anemia respectively. 
Radiographically, 53.7% cases showed right lung involvement,predominantly upper lobe. 
Laboratory workup revealed anemia in 81%, thrombocytsois in 16.5%,hyponatremia 
in 25.6% and hypercalcemia in15.7% cases. CT guided biopsy was done in 68 cases 
and bronchoscopy in 53 cases. Among those who underwent bronchoscopy, right main 
bronchus and endobronchial involvement was mostly seen. Histopathology showed 
Squamous Cell Carcinoma in 48.8%, Adenocarcinoma in 28.1%, Small Cell Carcinoma 
in 20.7% and Large Cell Carcinoma in 2.5% cases. 54.2% females were diagnosed with 
Adenocarcinoma and 53.6% males with Squamous Cell Carcinoma.Those diagnosed 
with Adenocarcinoma were mostly non smokers (52.9%) while rest were predominantly 
smokers. Conclusion: Despite the advances made for lung cancer diagnosis, survival 
hasn’t improved much. By evaluating common profi les,we may be able to screen 
suspects and help diagnose lung cancer earlier especially in those who are non smokers. 
Keywords: Pakistan, lung cancer, Common Profi les, Screening
PUB092 Diffi culty of Low Dose Computerized Tomography (LDCT) as a 
Lung Cancer Screening Tool in an Endemic Area of Tuberculosis Natthaya 
Triphuridet, Sutida Singharuksa, Sirachat Vidhyarkorn, Naree Chuengkhlay, Supapun 
Luengingkasoot, Waraporn Krongthong Medicine, Chulabhorn Hospital, Bangkok/Thailand
Background: Pulmonary Tuberculosis (TB) and lung cancer are major health problems in 
developing countries. The radiographic fi ndings of TB can mimic lung cancer even after 
a complete anti-TB treatment. Low-dose computerized tomography (LDCT) is a current 
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PUB097 Plasma Epitome Profiles Are Specific for Early Stage Lung Cancer 
Laszlo Takacs Biosystems International Kft, Debrecen/Hungary
Background: Lung cancer (LC) mortality worldwide is at about 84%, the five-year 
survival rate improved unfortunately only by 4-5% since 1975. At the same time, 
survival rates of other types of cancers have significantly improved over the same 
period. Considering the frequency of LC (≈ 250 000 new cases just in the US/yr) we 
are faced with the most significant cancer lethality: more people die each year of LC 
than breast, prostate and colon cancers together. Early diagnosis at asymptomatic 
stages is key to increase the success of surgical and combined the treatment 
regimes, in order to increase survival rate. Methods: To better address proteome 
variability we generated large non redundant natural epitome specific mAb libraries 
(QuantiPlasmaTM). For epitome profiling we developed an easy to use capture 
inhibition assay and applied to the sensitive Evidence InvestigatorTM biochip platform 
manufactured by Randox Ltd. Results: We show apparent epitome profile differences 
of plasma proteins from COPD patients compared to matched LC. In a four center 
clinical trial of 1,200 subjects, we confirm that combined biomarker panels detect 
symptomatic and operable LC with sufficient sensitivity (>80%) and specificity (>90%) 
for early diagnosis Conclusion: As diagnostics, epitomic biomarker panels may 
contribute to LC survival in the future. The Randox Evidence InvestigatorTM biochip 
technology with Biosystems’ QuatiplasmaTM libraries is suitable for LC testing 
Keywords: NSCLC, Early Detection, copd, blood proteomics panel
PUB098 The CRP Combined with LDH Was an Independent Prognostic 
Factor for Limited Stage SCLC Fang Wang1, Jian Rong2, Heping Li3, Wenzhuo He4, 
Huiwen Weng3, Chang Jiang4, Sheng Ye3, Qiong Yang5, Liangping Xia4 1Department 
of Medical Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou/
China, 2Department of Extracorporeal Circulation, The First Affiliated Hospital of Sun Yat-Sen 
University, Guangzhou/China, 3Department of Oncology, The First Affiliated Hospital of Sun 
Yat-Sen University, Guangzhou/China, 4Collaborative Innovation Center for Cancer Medicine, 
Sun Yat-Sen University Cancer Center, Guangzhou/China, 5Department of Oncology, The 
Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou/China
Background: The prognostic value of inflammation related factors were rarely studied 
in patients with small cell lung cancer(SCLC), especially the limited-stage. The aim of this 
study is to screen the potential significant inflammatory factors in the subgroup patients. 
The prognostic value of inflammation related factors were rarely studied in patients 
with small cell lung cancer(SCLC), especially the limited-stage. The aim of this study 
is to screen the potential significant inflammatory factors in the subgroup patients. The 
prognostic value of inflammation related factors were rarely studied in patients with small 
cell lung cancer(SCLC), especially the limited-stage. The aim of this study is to screen 
the potential significant inflammatory factors in the subgroup patients. Methods: The 
data were collected retrospectively for 240 limited-stage small cell lung cancer patients 
who received the initial treatment in Sun Yat-sen University Cancer Center from October 
1st, 2006 to July 1st, 2013. Pretreatment modified Glasgow Prognostic Score (mGPS), 
C-reactive protein, Lactate dehydrogenase, neutrophil-to-lymphocyte ratio (NLR) and 
platelet-to-lymphocyte ratio were chosen as inflammation related prognostic factors 
of overall survival. Results: Median age was 59 years old. 209 patients (87.08%) 
were male. 94 patients (39.17%) were characterized by elevated CRP combined with 
LDH (scored: 1-2). The CRP combined with LDH, mGPS, stage, prophylactic cranial 
irradiation, response to the initial treatment, respectively, were significant factors for OS 
in univariate analyses. Among them, the overall survival was independently associated 
with CRP combined with LDH (OR: 1.346, 95%CI: 1.007-1.346) p=0.045), prophylactic 
cranial irradiation (OR: 1.571, CI: (1.096-2.253), p=0.014) and response to the initial 
treatment (OR: 1.749, CI: (1.295-2.363), p<0.001).
 
several measures as mentioned above in the methods. Conclusion: Image guided 
Needle aspiration biopsy is a safe, swift, easy and reliable method in tissue diagnosis 
of thoracic lesions. Morbidity is very low and accuracy is very high. Most important 
and common complication of the procedure is pneumothorax. Risk of pneumothorax 
can be significantly reduced by meticulous planning using several measures. Roll-
over technique plays an important role in reduction of incidence of pneumothorax. 
Keywords: Image-guided, FNAB, Thoracic masses, Pneumothorax
PUB095 Thoracic Malignancies in Cameroon. Twenty Years Experience 
Nkegoum Blaise1, Mboumtou Liliane2 1Pathology and Oncology, University Hospital 
Center, Yaoundé/Cameroon, 2Pathology and Oncology, University Hospital Center, Yaounde/
Cameroon
Background: Cameroon Is an underdevelopped country of 20 millions inhabitants 
located in Central Africa. It Is a blank area on the world cancer map as cancer registration 
Is scarce or inexistent. The University Hospital Center hold the oldest Pathology 
department in the country With four full Time pathologists.Only 10 percent of malignant 
tumours are confirmed by histology as other cancer patients are managed by traditional 
healers and marabouts. Methods: We recorded all cases of thoracic malignancies 
microscopically confirmed from the registries of Yaounde University Hospital from 
1995 to 2015 Results: 29 cases of thoracic malignancies were recorded for this 20 
years period. 21 Non Small Cell Lung Cancers, 7 lymphomas, one thymoma and one 
Small Cell lung cancer were observed. 90 percent of our patients had Previous history 
of tobacco smoking. Two patients With lymphomas were Hiv positive. All patients in 
this series present with advanced stage disease. None undergone curative teatment. 
Only the lymphomas cases and the thymoma undergone immunohistochemestry for 
typing as Rituxumab Is offered at low priize for our cancer patients. No other targeted 
treatment Is available in the country for lung cancera and we do not target ALk in our 
institution. Unfortunatelly, 18 patients With suspected thoracic malignancies on xrays 
or Scan refused or were unable to pay for biopsie and the diagnosis was not available 
for this study. Three patients were HIV positive in this series and superior vena cava 
syndrome followed By death was observed in four other cases. Conclusion: Thoracic 
malignancies are common findings and are underdiagnosed in Cameroonian settings.
Tobacco and HIV infection infections may be Ricks factors. Patients présent at late stage 
when no curative Treatment Cannot be offered. Lymphomas are not cured because no 
patient cannot buy new drugs. Most of our patients died With or without final diagnosis 
Keywords: Cameroon, New drugs, Thoracic malignancies, HIV and tobacco
PUB096 A Role of Diffusion-Weighted MRI in Prediction of Mediastinal Lymph 
Node Metastasis in Patients with NSCLC: Comparison to PET Results 
Erkan Yilmaz1, Uygar Teomete2, Atila Akkoclu3, Kemal C. Tertemiz3, Ahmet Onen4 
1Radiology, Sifa University, Izmir/Turkey, 2Radiology, Miami University, Miami/FL/United 
States of America, 3Respiratory Medicine, Dokuz Eylul University, Izmir/Turkey, 4Thoracic 
Surgery, Dokuz Eylul University, Izmir/Turkey
Background: To compare the diagnostic efficacies of diffusion-weighted magnetic 
resonance imaging (DWI) and fluorine 18 fluorodeoxyglucose (18F_FDG) positron 
emission tomography (PET) findings for the preoperative prediction of mediastinal nodal 
metastasis in patients with non–small cell lung cancer (NSCLC). Methods: The study 
included total 126 mediastinal lyph nodes of 57 patients (35 men and 22 women; mean 
age, 63.4 years) with NSCLC underwent both DWI (using a sigle-shot echo-planar sequence 
with diffusion factor of 0-600 s/mm² at 1.5 T) and PET examinations. A lymph node was 
considered as metastasis at DWI, when it showed apparent diffusion coefficent (ADC) 
value more than 0.95 s/mm², regardless of nodal size. In PET, a lymph node was regarded 
as positive for malignancy when it showed value of ≥3 in maximum standardized uptake 
value (SUV). Two observers evaluated prospectively and in consensus the mediastinal 
nodes by analyzing both DWI and PET images. Histopathologic results served as the 
reference standard. In terms of mediastinal lymf node metastasis, statistically significant 
differences between DWI and PET were determined with p<.05 obtained by using 
the McNemar test or as with a generalized estimating equation. Results: Mediastinal 
lymph nodes were positive for malignancy in 76 (60%) of 126 nodes and 25 (44%) of 
57 patients. According to the diagnosis of malignant nodes, the sensitivity, specificity, 
positive predictive value, negative predictive value, and accuracy of DWI were 81.5% 
(62 of 76 nodes), 82% (41 of 50), 87.3% (62 of 71), 74.5% (41 of 55) and 81.7% (103 
of 126) respectively; whereas those of PET were 86.8% (66 of 76), 74% (37 of 50), 
83.5% (66 of 79), 78.7% (37 of 47) and 83.3% (105 of 126). Specificity difference 
between two modalities was statistically significant (p<.05). There were 9 false-positive 
interpretations at DWI, compared with 13 false-positive on PET scans. There were 
10 false-negative interpretations on PET scans, while 14 false-negative assessments 
were done at DWI. Conclusion: DWI allows reliable differentiation between benign and 
malign mediastinal lymph nodes in patients with NSCLC. Although DWI shows better 
sensitivity, it has a similar accuracy for prediction of mediastinal lymph node metastasis 
compared to PET. Therefore DWI may have a potent alternative imaging method for the 
preoperative diagnosis of mediastinal lymph node metastasis in patients with NSCLC. 
Keywords: diffusion-weighted imaging, lymph node, mediastinal, magnetic resonance 
imaging
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infarcts) are carefully recorded. Neuropsychological screening measure of immediate 
and delayed verbal memory by using Hopkins Verbal Learning Test - Revised (HVLT - 
R), assessment of cognitive function using Mini-Mental Status Examination (MMSE) are 
applied before initiation of PCI and on follow up at 3 monthly interval. Results: Result of 
first 42 patients receiving PCI (LS- SCLC = 28, ES-SCLC = 14) with minimum duration of 
follow up of 18 months is being presented. There was no significant baseline difference 
in neuropsychological screening using HVLT. Brain metastasis, in spite of PCI was in 
none. Median survival was 9 months for ES and 14.5 months for LS-SCLC. 2/14 ES-SCLC 
and 18/28 LS-SCLC lived one year. Corresponding data for 18 months is 0/14 and 5/28 
respectively. MMSE deterioration was noted in 18/42 patients. Subset analysis of these 
18 patients revealed 3/18 were in the age group of 55 - 65 years (N= 24) and remaining 
15 were between 65 to 72 years (N = 18); P <0.0001. Interestingly all 3 of these below 
65 years patients and 13/15 of above 65 years patients were having long-standing 
hyperlipidimia and nearly half of them were Diabetic also. HVLT decline in immediate 
recall (16/42) was in 14/18 patients having MMSE deterioration and 13 out of these 16 
had delayed recall deterioration as well. Subset analysis of neurointellectual impairment 
(as evidenced by HVLT in 16 patients) revealed its presence among 14/20 patients having 
medical co- morbidities (Hyperlipidimia, Diabetes etc) and in only 2/ 22 without any (P 
<0.0001). Conclusion: 20Gy/ 5 fractions is an effective, safe, patient-compliant PCI 
protocol for well-selected patients aged below 65 years without medical comorbidities, 
specially those which have established role in causing cerebral microinfarcts. 
Keywords: Neurocognitive function, Hypofractionation, Small cell carcinoma, PCI
PUB101 Multiple Spinal Intradural -Intramedullary Involvement by Metastatic 
Small Cell Carcinoma Lung - An Unusual Presentation Anshu Gupta, Sachin Sinha 
Pathology, Institute of Human Behavior and Allied Sciences, Delhi/India
Background: Intramedullary metastases to the spinal cord is infrequent. Between 
5-10% of cancer patients develop spinal meastasis during the course of their diseases. 
Intramedullary tumors are rare, comprising 3.5% of spinal metastasis. Most metastatic 
spinal lesions (70%) are found at the thoracic level, 20% in lumbar region and 10% in the 
cervical region. We report a rare biopsy proven case of intramedullary spinal metastatic 
carcinoma with neuroendocrine differentiation , involving spine at multiple noncontiguous 
levels, which appeared as irregular small nodules on MRI. The primary tumor was most 
likely from occult primary in lung.Biopsy from the spinal lesion established the diagnosis 
of metastatic carcinoma with neuroendocrine differentiation. We highlighted herein 
the clinical presentation, radiological findings particularly MRI and role of biopsy in the 
diagnosis and treatment of intramedullary spinal metastasis. Methods: Intra-operative 
biopsy from nodular lesion in dorsolumbar spine was performed and sent to pathology 
department for frozen section examination. A provisional diagnosis of malignant small 
round cell tumor was made on frozen section by cryostat. Based on the provisional 
diagnosis, further excision biopsy done to relieve compression symptoms and sent for 
microscopic examination. The biopsy specimen showed multiple grayish brown soft 
tissue pieces that together measured 2.8x2.5x0.5 cms grossly. Cut surface was gray 
white with few hemorrhagic areas. Paraffin sections were prepared from tissue sent and 
stained with routine Haematoxylin and Eosin(H&E) stain, special stains such as reticiulin 
& vimentin and immunohistochemical stains for cytokeratin, synaptophysin,S-100 and 
chromogranin. Results: On microscopic examination, biopsy showed a cellular tumor 
in which cells were arranged in sheets, well defined clusters, trabeculae, around 
blood vessels forming pseudo-rosettes and scattered diffusely in highly vascularised 
fibrocollagenous stroma. Tumor cells were small, monomorphic round to oval to 
elongated with moderate atypia, stippled chromatin and inconspicous nucleolus. 
Cytoplasm was scanty and barely visible. Nuclear moulding was seen in occasional cells. 
Some of the cells were slightly larger and showed moderate amount of eosinophilic 
cytoplasm. Mitosis was infrequent. Reticulin stain showed reticular fibers around group 
of cells . On immunohistochemistry, tumor cells showed diffuse positivity for cytokeratin, 
synaptophysin and chromogranin . S-100 was focally positive. Vimentin positivity is seen in 
fibro connective stroma. Findings were that of metastatic carcinoma with neuroendocrine 
differentiation. Conclusion: Keeping in view the pathological findings, occult small cell 
carcinoma lung was considered the first possibility despite no supportive clinical and 
radiological evidence as chest X-ray and CT lung were normal. Thus, a thorough work 
up is advised in patient with spinal metastasis to evaluate primary site. This help to 
delineate the nature and the extent of the systemic disease. No treatment has been 
proven to increase the life expectancy of patients with lung cancer and spinal metastasis. 
Pain relief and maintenance of quality of life must be balanced against the patient life 
expectancy, presence of co-morbidities, immunological, nutritional and functional status. 
Keywords: Spinal cord, metastasis, carcinoma, neuroendocrine
PUB102 Randomized Phase II Study of Belotecan or Topotecan as Second-Line 
Chemotherapy after Platinum Based Chemotherapy for Small Cell Lung Cancer 
Shinkyo Yoon1, Dae Ho Lee2, Chang-Min Choi3, Jae Cheol Lee4, Jung-Shin Lee4, Sang We 
Kim5 1Oncology, Asan Medical Center, Seoul/Korea, 2Department of Oncology, University of 
Ulsan College of Medicine, Asan Medical Center, Seoul/Korea, 3Department of Pulmonary 
and Critical Care Medicine, Department of Oncology, Asan Medical Center, University of 
Ulsan College of Medicine, Seoul/Korea, 4Department of Oncology, Asan Medical Center, 
University of Ulsan College of Medicine, Seoul/Korea, 5Asian Medical Center, Seoul/Korea
Background: Topotecan has been accepted as second-line therapy for small cell 
lung cancer (SCLC), in addition, belotecan also reported with significant response 
rate. Based on these results, we designed prospective randomized phase II trial of 
belotecan as second-line treatment in patients with SCLC, who experienced disease 
progression within 6 months after first-line platinum containing chemotherapy or chemo-
radiotherapy. Methods: We randomly assigned patients to belotecan 0.5 mg/m2 (n=61) 
or topotecan 1.5 mg/m2 (n=55) for 5 days every 21 days, stratified by response to 
 
 
Conclusion: The CRP combined with LDH was demonstrated as the unique 
independent inflammation related prognostic factor of OS for limited-stage SCLC. 
Keywords: Limited-stage small cell lung cancer, C-reactive protein combined with 
Lactate dehydrogenase, modified-Glasgow prognostic score, Neutrophil-to-lymphocyte 
ratio
PUB099 Intensity-Modulated Radiotherapy in Treatment of Small Cell Lung 
Cancer Charu Singh, Shivani Gupta Department of Radiation Oncology, Sms Medical 
College and Hospital, Jaipur/India
Background: This study was done to analyze the feasibility of omitting clinical target 
volume (CTV) for limited small cell lung cancer treated with chemotherapy and intensity 
modulated radiotherapy. Methods: The study was done from June 2011 to January 
2015. 80 patients of small call lung cancer with limited disease were selected, from 
which 40 patients were irradiated with target volume without CTV, and 40 patients 
were irradiated with CTV. Both arms were irradiated to post chemotherapy tumor 
extent and elective nodal irradiation was omitted. Dose prescription was 95% PTV56-
63 Gy/28-35 F/5.6-7 weeks. Results: The arm without CTV had local relapse rate 
of 15% and arm with CTV had local relapse rate 17%. The distant metastases rates 
were 42.5% and 50% respectively. Grade 3-4 hematological toxicity and radiation 
esophagitis had no significant difference, but grade 3-4 radiation pneumonia was 
observed in only 7% in the arm without CTV, compared to 20% in the arm with CTV. 
The 1 year and 2- years’ survival rates of the arm without CTV and the arm with 
CTV were 81.0%, 65% and 90%, 60% respectively. The distant metastases were 
significantly related to overall survival. Conclusion: Target delineation omitting CTV 
in patients of small cell lung cancer with limited disease receiving IMRT is feasible. 
Keywords: small cell lung cancer, intensity modulated radiotherapy, clinical target 
volume
PUB100 Hypofractionated Prophylactic Cranial Irradiation – Analysis of 
Efficacy and Impact on Neuro-Intellectual Function Subrata Saha1, Aloke Ghosh 
Dastidar2, Partha Das Gupta3, Subrata Chattopadhyay4, Amitabha Manna5 
1Radiotherapy, Apollo Gleneagles Cancer Hospital, Kolkata/India, 2Radiotherapy, Ipgmer, 
Kolkata/India, 3Radiotherapy, R G Kar Medical College, Kolkata/India, 4North Bengal Medical 
College, Kolkata/India, 5Radiotherapy, Calcutta Medical College, Kolkata/India
Background: Prophylactic cranial irradiation plays a crucial role in prevention of brain 
metastasis from small cell lung cancer (SCLC) – be it limited stage (LS) or extensive 
one (ES) – who respond to initial therapy. To attain better quality-adjusted life expectancy 
and to avoid neurointellectual impairments (NIP), optimum dose and fractionation 
for PCI needs to be explored, with due consideration to coexisting medical co-
morbidities that might enhance the adverse events. Contrary to conventional 30 
Gy/10 fractions, short-course PCI is gaining popularity in recent time. Aim of this 
study is to find the safety and efficacy of PCI with 20 Gy/5 fractions and to analyze 
its impact on NIP with special focus on any possible influence of age and medical 
co-morbidities. Methods: This is an on-going single arm multicentric trial initiated in 
February 2011 where both LS- as well as ES-SCLC patients who responded to initial 
therapy and were not having any visceral metastasis are offered PCI for a dose of 20 
Gy in 5 fractions with CT-based planning. All patients received Platinum + Etoposide for 
6 cycles. LS-SCLC patients received, in addition, concomitant thoracic radiation after 2 
cycles of chemotherapy. To minimize neuro-psychological impairment, at least 2 weeks 
gap is given before PCI and after completion of all chemotherapy. All relevant medical 
comorbidities (Diabetes, Hyperlipidimia, previous history of CVA including lacunar 
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Afraid of treatment toxicity is the most reason to refusing anti-cancer treatment. 
Keywords: Small cell lung cancer(SCLC), initial care patterns, Prognosis, reasons
PUB105 Mesothelioma Rates in South Africa: Trends 1995-2008 
Cornelius Nattey Epidemiology & Surveillance, National Institute for Occupational Health, 
Johannesburg/South Africa
Background: Mesothelioma is a rare neoplasm which is caused by asbestos exposure. 
South Africa has mined and refined all three types of asbestos since 19th century with the 
peak of production in1940-1980s. At present asbestos use and production is banned in 
South Africa. Trend 1995-2008 in mesothelioma rate was assessed to determine burden 
of asbestos related deaths due to mesothelioma by year and gender. Methods: Death 
certificates with underlying cause of death stated as C45 were selected for the study in 
1995-2008. For each year of study, age and gender distribution was obtained from the 
national statistical releases. Mesothelioma rates, 95% confidence interval were calculated 
for each year and sex, and for age groups and sex .Poisson regression was used to test 
for trend. Results: In total 2497 cases were identified of deaths due to mesothelioma, 
1919 in men and 578 in women in the study period. There was 3:1 male to female ratio. 
The trend was stable and constant over time for both men and women cases. Mortality 
rate in men was 8-16 per million and in women 2-5 per million respectively Conclusion: If 
mortality rate remains at current estimates we can expect 2 134 cases until 2020. 
These mortality rates are much lower than expected, given the historical production 
and use of, and high exposure to, asbestos in South Africa. Possible reasons for this are 
discussed, including the effect of HIV which has been instrumental in reducing the life 
expectancy of South Africans in the last two decades. Asbestos-exposed individuals may 
not live long enough to develop mesothelioma. Competing causes of death need to be 
taken into account when constructing models to predict mesothelioma mortality rates. 
Keywords: rates, Poisson, asbestos, Mesothelioma
PUB106 Long-Term Administration of Endostar Combined with Chemotherapy 
in Hemangioendothelioma of Bone Accompanying Pulmonary Metastasis 
Ningrong Yang, Lin Wang, Chen Xue, Shukui Qin The 81St Hospital of PLA, Nanjing/China
Background: To explore the feasibility for long-term administration of rh-endostatin 
injection (YH-16,endostar) combined with chemotherapy in the treatment of 
hemangioendothelioma of bone accompanying pulmonary metastasis. Methods: One 
case of hemangioendothelioma of bone accompanying pulmonary metastasis, who 
received Endostar, 15 mg daily. Additionally, the patient was treated with TE regimen 
(paclitaxel 90mg d1, d8, d15, epirubicin 90mg d1, q4w) for 6 cycles and TP regimen 
(paclitaxel 90 mg on d1, d8, cisplatin 20 mg on d1 ~ d5, q3w) for 4 cycles. After all 
the chemotherapy, the Endostar was used as maintenance therapy (Endostar d1~14 
q8w). Efficacy evaluation was conducted according to RECIST(1.0) criteria. Results: The 
patient got partial response(PR) after the application of endostar combined with 
taxane-based chemotherapy. Long-term using Endostar as monotherapy, the patient 
got long-term disease control and good quality of life for 3 years.. There was no drug 
related adverse event during the long-term therapy of Endostar, Conclusion: Endostar 
combined with chemotherapy can help achieve a convinced therapeutic effect for 
treatment of hemangioendothelioma of bone accompanying pulmonary metastasis. 
And use of endostar as maintenance treatment after patient got the optimal efficacy 
is feasible and profitable. This treatment method is worthy of further observed. 
Keywords: Hemangioendothelioma of bone; Endostar; Anti-angiogenesis; Maintenance 
therapy
PUB107 18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids versus 
Pulmonary Hamartomas Oscar Grundberg Department of Pulmonary Medicine, 
Karolinska Univeristy Hospital, Stockholm/Sweden
Background: Radiological characterization of pulmonary tumors may be difficult and 
invasive. Needle biopsy may produce false negative results. 18F-FDG PET/CT is an established 
non-invasive procedure for lung tumor characterization and staging. Methods: In a 
retrospective analysis of 118 patients, with surgically resected pulmonary carcinoid 
tumors and hamartomas, 87 of those selected had also undergone 18F-FDG PET/CT 
preoperatively and constituted the study population. In order to better assess the tracer 
accumulation, especially in small lesions, the 18F-FDG uptake (SUV) in the tumors was 
corrected for partial volume effects (PVC) by applying recovery coefficients corresponding 
to the respective various specific tumor volumes, as extrapolated from those obtained 
from experiments in a NEMA phantom. Results: The SUVmax was higher in the pulmonary 
carcinoids (mean 3.9) than in the hamartomas (mean 1.4) (p ≤ 0.00001) and higher in 
the subgroup of peripheral carcinoids than in hamartomas (p ≤ 0.00001). The SUVmax was 
similar for the atypical and typical carcinoids, 5.0 and 3.8, respectively, because of 
the large variation in the data (p = 0.11). Conclusion: Using PET measurements of 
the18F-FDG-uptake (SUVmax) in the tumors, corrected for partial volume effects, it was 
possible to differentiate the carcinoids from the hamartomas, but the clinically more 
aggressive atypical carcinoids could not be differentiated from the typical carcinoids. 
Keywords: Pulmonary carcinoid, harmartoma, 18F-FDG PET/CT, bronchial NET
first-line chemotherapy. The primary end points was response rate (RR). The secondary 
end points were progression free survival (PFS), overall survival (OS) and safety 
profiles. Results: From August 2006 to December 2013, a total of 116 patients were 
enrolled. The median age was 64 years (range, 28-82), and ratio of males to females 
was 0.89. In total, 186 cycles of topotecan (median 2, range 1-9) and 180 cycles of 
belotecan (median 2, range 1-8) were administered. Median follow-up was 5.6 months. 
RR of belotecan and topotecan was 19.7% (12/61) and 18.2% (10/55), respectively 
(p=0.92). Median PFS and OS of belotecan and topotecan was 2.1 months (95% CI 1.43-
2.72) versus 2.3 months (1.46-3.07) and 11.2 months (10.2-12.1) versus 12.1 months 
(10.1-14.0), respectively (p=0.167, 0.659) (Figure 1). Grade 3/4 hematologic adverse 
events in belotecan and topotecan were anemia (13.1% versus 14.5% (p=1.000)), 
thrombocytopenia (3.3% versus 7.3% (p=0.421)), neutropenia (21.3% versus 43.6% 
(p=0.016)).
 
 
 
Conclusion: Belotecan showed comparable efficacy with topotecan and more favorable 
toxicity profiles in neutropenia. Keywords: second-line chemotherapy, topotecan, 
belotecan, small cell lung cancer
PUB103 Prognosis of Initial Care Patterns of Small Cell Lung Cancer in Chinese 
Patients Lan-Ying Gou, Yi-Long Wu, Jin -Ji Yang Guangdong Lung Cancer Institute, 
Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou/
China
Background: Small Cell Lung Cancer (SCLC) is a most fatal cancer, some patients 
refused to receive anticancer treatment after diagnosis. There is no any report about 
initial care patterns on prognosis of SCLC in China.
Methods: Patient characteristics and initial care patterns were investigated 
retrospectively from June 2004 to December 2012 using the database of electronic 
medical record of Guangdong General Hospital (GGH) in China. All of the patients 
were divided into anticancer treatment group, support care group and no-treatment 
group. Kaplan-meier analysis was used to estimate and compare the overall survival 
among groups. The reasons of no-treatment were analyzed. Results: From June 
2004 to December 2012, a total of 474 patients with SCLC were included in this 
retrospective study. All of the patients were divided into three groups: 405 patients 
were in anticancer treatment group (group A); 12 patients were in support care Group 
(group B) and 57 patients didn’t receive any treatment at their disease course (group 
C). The median overall survival (OS) of three groups was 15.27 months, 4.37 months 
and2.53 months, respectively (P<0.001). The reasons of the patients refused anticancer 
treatment were: afraid of toxicity and side effect of chemotherapy (31.9%), poor financial 
support (27.5%), elder age (23.2%), poor performance status (10.1%) and unknown 
(7.2%). Conclusion: The prognosis of the patients refused anticancer treatment was 
much worse than the patients received anticancer treatment even best support care. 
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PUB110 The Burden of Lung Cancer and the Various Factors Deciding the 
Treatment of Lung Cancer in the Developing World Ramesh Kandel1, Santosh 
Maharjan2, Gyan Kayastha1 1Department of Medicine, Patan Academy of Health Sciences 
(PAHS), Kathmandu/Nepal, 2Radiology, Institute of Medicine, Kathmandu/Nepal
Background: With the global rise in the prevalence, lung cancer has become an unavoidable 
reality of old age, especially in the developing world with high prevalence of chronic 
smoking. As the treatment of lung cancer is dependent on functional status, a substantial 
number of patients get excluded, due to perceived loss of functionality and disability of 
old age. In this study, co-morbidity and functional status of older lung cancer patients was 
assessed and their impact on management was observed. Methods: In a cross-sectional 
study in a tertiary medical facility in Nepal, lung cancer patients aged 65 years or more, 
were recruited before the start of treatment. Comprehensive geriatric assessment, 
functional status and co-morbidities were evaluated as per various validated scales. The 
management of patients at the cancer centre was observed. Results: Two-third of 1450 
patients (68.6%males) were between 65 and 80 years of age(mean:71.4 yrs). 80.4% of 
the patients were current smokers. The number of lung cancer patients abruptly declined 
after the age of 85. 58.3% were diagnosed in stage-4 and none in stage-1. The common 
co-morbidities were hypertension (30.8%), diabetes (15.2%) and Chronic obstructive 
pulmonary disease (14.9%). Vision problem with cataract was the commonest disability. 
42.6%were depressed. 32.7% had cognitive impairment. 55.2% were independent in 
activities of daily living (ADL). 64.5% had their ECOG status score between 0-2 (thereby 
eligibility for treatment). However, 49.4% of older cancer patients did not receive any 
form of treatment including the palliative one. In multivariable analysis, age more than 
70 year (P<0.001), ECOG status 2 or more (P<0.005) and low ADL score (P<0.004) 
were associated with ineligibility for treatment by the oncologists. Conclusion: Older 
patients with lung cancer were victims of ageism. These observations are congruent 
with the global cancer scenario. Greater effort is required for timely detection of lung 
cancer among older people along with improved criteria for selection for treatment. 
Keywords: ageism, lung cancer, functional status
PUB111 Chemotherapy at the End of Life (EOL) for Patients with Lung Cancer 
within the VA System Rafael Santana-Davila1, Michael J. Kelley2, Christina D. Williams3, 
Keith Eaton1, Jeffrey C. Whittle4 1University of Washington, Seattle/United States of 
America, 2Duke University, Durham/United States of America, 3Duke University/Va Hospital, 
Durham/NC/United States of America, 4Medical College of Wisconsin, Milwaukee/WI/United 
States of America
Background: It is well established that chemotherapy given at the EOL is not associated 
with any survival advantage, prevents access to other services such as hospice and 
is considered a measure of low quality of care. While many studies have been done to 
determine the rate of chemotherapy at EOL, little is known about the patient/physician 
characteristics of those receiving/prescribing it. In this study we used a detailed database 
of patients treated with metastatic lung cancer within the Veterans Affairs (VA) health 
system to investigate the clinical characteristics of those who receive chemotherapy at the 
EOL. Methods: Using the VA Central Cancer Registry, patients with stage IV lung cancer 
diagnosed between 2001 and 2010 were identified. For analysis, patients were included 
if chemotherapy was initiated within 4 months of diagnosis. Results: In a database of 
12,928 patients with metastatic lung cancer (68% NSCLC and 32% SCLC) that received 
chemotherapy within the VA, 2,067 (16%) patients received chemotherapy within 14 days 
of death. The majority (71.4%) of these patients was receiving first line therapy and had 
worse prognostic factors at the initiation of chemotherapy compared to patients that did 
not receive chemotherapy at EOL (Table 1). A multivariable logistic regression analysis 
identified several prognostic factors that were independently associated with receipt of 
chemotherapy at the EOL (Figure 1). The number of palliative care visits was associated 
with a reduction in the odds of having chemotherapy at the EOL.
PUB108 Dietary Intake in Lung Cancer Rosemary Poulose1, Itisha Kulshreshtha1, 
Anant Mohan2 1All India Institute of Medical Sciences, New Delhi/India, 2Pulmonary Medicine, 
All India Institute of Medical Sciences, New Delhi/India
Background: Lung cancer is associated with loss of appetite, weight loss and reduced 
dietary intake. This study aims to analyze the dietary intake in lung cancer patients and 
correlate it with body mass index (BMI), exercise capacity, and metabolism. Methods: This 
prospective observational study was carried out from 1 Feb 2011 to 31 Jan 2014. 
Patients with confirmed cytological/histological diagnosis of lung cancer were screened 
and staged according to the American Thoracic Society TNM classification. Subjects 
were recruited after obtaining informed consent. Dietary intake was calculated using 
twenty four hour dietary recall method, recommended calorie intake was estimated 
using the Harris Benedict equation and the Resting Energy Expenditure (REE) was 
calculated using the Katch-McArdle formula. Nutritional profile included assessment of 
body composition by bioelectric impedance method and anthropometric measurements 
of skin fold thicknesses. Results: A total of 148 subjects were studied (87% male). The 
mean (SD) age was 56.6(9.7) years, median pack years was 20 (range 0-120) and median 
duration of symptoms was 159 days (range 15-1080). The commonest symptoms were 
cough (80%), chest pain (68%), loss of weight (55%), hemoptysis (45%), fatigue (43%), 
shortness of breath (41%), and loss of appetite (31%). The mean (SD) energy intake 
was 1576.9(149.2) kcal/day which was significantly lower than the recommended calorie 
intake (p=0.04). The mean percentage deficit in energy intake was 13.9 and ranged from 
a deficit of 88.4% to an excess of 128.7%. Mean(SD) protein intake was 48.2(23.4) g/
day, ranging from 4.8 to 88.9 g/day. The mean protein intake per kilogram of body weight 
was 0.9(0.1) g/kg/day, which was significantly lower than recommended (p<0.01).
Dietary macronutrient composition did not differ from the general population.Six (4%) 
patients were hypometabolic, seventy three (49.3%) were having a normal metabolism, 
and sixty nine (46.6%) were hypermetabolic. Dietary intake did not differ significantly 
between underweight, normal weight or over weight patients, nor did it differ significantly 
between the normo- and hypermetabolic patients. There was no significant difference 
between patients with an adequate or higher calorie consumption and those with a 
deficient energy intake in the distance covered in the 6 minute walk test. Conclusion: 
Dietary intake of calories and protein were significantly lower than recommended, which 
may adversely affect the quality of life and survial of cancer patients.Hypermetabolism, 
although frequent, was not compensated by increased dietary intake indicating that in 
cancer, there may not be an up-regulation of dietary intake in response to increased 
energy expenditure.Measures to counteract hypermetabolism and improved dietary 
intake have been demonstrated to have a role in the survival, function and quality 
of life of cancer patients and should be further explored in interventional studies. 
Keywords: diet, hypermetaboilsm
PUB109 Evaluation of Hyponatraemia in Lung Cancer Patients: A U.K. Teaching 
Hospital Experience Ankit Jain, Mariam Jafri, Salma Alam, Sophie Mascall, Rhian 
Thomas, James Kendrick, Joyce Thompson Medical Oncology, Birmingham Heartlands 
Hospital, Birmingham/United Kingdom
Background: Hyponatraemia, defined as a serum Na of <135mEq/L, is the commonest 
electrolyte abnormality in oncology practice. Among cancer patients, it occurs most 
frequently in small cell lung cancer(SCLC) and is due to inappropriate antidiuretic 
hormone secretion (SIADH), a paraneoplastic syndrome. The incidence of SIADH in SCLC 
is 11-15%. We describe the demographics, oncological management and response of 
hyponatraemia to oncological treatment modalities in hospitalised patients with lung 
cancer in a large inner-city teaching hospital. Methods: We retrospectively analysed 
the serum sodium levels in all lung cancer patients admitted to a teaching hospital in 
the West Midlands between 2007-2013. Data was collected on baseline demographics, 
histology, tumour stage and grade of hyponatraemia. Mild hyponatraemia was defined 
as a serum sodium between 130-135mEq/L, moderate between 125-129mEq/L, and 
severe as <124mEq/L. Results: 182 (108 male; 74 female) patients with lung cancer 
and documented hyponatraemia were hospitalised between 2007-2013. The median 
age of patients on admission was 69.2 years (range 33-92 years). 119(65%) had mild, 
58(32%) moderate and 5(3%) severe hyponatraemia. 74(40%) were adenocarcinomas 
, 58(32%) squamous carcinomas, 43(24%) SCLC and 7(4%) had unspecified non small 
cell lung cancer. 89(49%) had metastatic disease at diagnosis. 18/43 (42%) small 
cell, 14/58 (33%) squamous , 23/74 (31%) adenocarcinoma patients had moderate 
to severe hyponatraemia. 132(74%) of this cohort had active oncological treatment: 
93(51%) chemotherapy, 25(14%) radiotherapy, 17(9%) surgery whilst 47(26%) had best 
supportive care. 28(15%) had a biochemical response to their treatment, 11(39%) of 
these patients were adenocarcinomas, 10(36%) squamous carcinomas and 7(25%) 
SCLC. Conclusion: Hyponatraemia in lung cancer patients is widely distributed in 
various age groups and histological subtypes as shown from our data. Among those 
admitted with hyponatraemia, severe cases (<124mEq/L) were rare. Higher rates of 
SIADH are seen in SCLC than in any other malignancy and our data confirmed that, 
proportionately, more SCLC patients had moderate - severe hyponatremia than non small 
cell lung cancer patients. Hyponatraemia does respond to active oncological treatment 
including chemotherapy, radiotherapy and surgery. Although historically, hyponatraemia 
is considered as a poor prognostic marker and has been shown to be significantly 
associated with shorter survival duration, this should not preclude active oncological 
management. Asymptomatic patients with SIADH have been managed initially by 
fluid restriction but patient compliance is usually poor. Older medications such as 
demeclocycline, urea and lithium are limited by variable efficacy, poor palatability and/or 
toxicity, thus underscoring the need for new approaches. Tolvaptan, a new vasopressin 
receptor antagonist, can improve hyponatraemia due to SIADH and allow patients to 
receive appropriate treatments or palliate symptoms. Further studies are needed to 
evaluate the prognostic value of hyponatraemia and it’s treatment in cancer patients. 
Keywords: Hyponatremia in lung cancer
S790 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
PUB112 Trends in Lung Cancer Mortality in South Africa: 1995-2008 
Cornelius Nattey Epidemiology & Surveillance, National Institute for Occupational Health, 
Johannesburg/South Africa
Background: Cancers remains a major cause of morbidity and mortality in the world 
today. The global burden of cancer is expected to continue to increase with much of 
the burden being borne by developing countries. This study presents the trends in lung 
cancer (and all respiratory cancers) mortality for the South African national population, 
and by gender. Methods: Using the country’s annual mortality and population estimate 
data from Statistics South Africa, we calculated lung cancer and all respiratory cancers 
age-adjusted mortality rates per 100 000 people for the period 1995-2008. The South 
African population structure for the year 2001 was used as the reference population. To 
determine trends in mortality, scatter plots were plotted and regression models were 
fitted to assess for linear trends in the age-adjusted cancer mortality rates for the period. 
This was done for the entire population and by gender. Results: Lung cancer caused 
61 418 deaths and other respiratory cancers, 6 445 deaths, during the study period. 
Males accounted for 70.5% of lung cancer deaths and 71.7% of all respiratory cancer 
deaths. The majority of deaths (56%) were in the 50-69 year age group. While the age-
adjusted lung cancer mortality rates for males decreased by 23.1%, the rates for females 
increased by 26.4%. Similar gender differences were observed for all respiratory 
cancers. Conclusion: The declining lung cancer mortality rate in men is welcome 
but the increasing rate in women is a public health concern and requires intervention 
Keywords: lung cancer, mortality, rates, regression
Clinical characteristics of patients
Variable at the start 
of treatment
Received Chemo-
therapy at EOL
No Chemotherapy 
at the EOL P value
Age >65 49.2% 46.2 0.0143
Anemia (Hgb<12 
g/dl) 42.6% 34% <0.0001
Hypoalbuminemia 
(serum albumin<3.5 
g/dl)
66.1% 49.8% <0.0001
Neutrophil to Lympho-
cyte ratio >5 59.6% 44.3% <0.0001
Chronic Kidney Dis-
ease (EGFR<60mg/
dl)
22.8% 15.9% <0.0001
Hypercalcemia 
(corrected serum 
calcium>10)
26% 20% <0.0001
>1 Hospitalization in 
the year preceding 
treatment
32.3% 24.3% <0.0001
>10% Weight loss 34.8% 28.7 <0.0001
Comorbidity Index >2 20.1% 15.9% <0.0001
 
 
 
Conclusion: Our results demonstrate that within the VA the majority of patients that receive 
chemotherapy at EOL do so during first line treatment, these patients have worse prognostic 
factors at the initiation of treatment that could be used to identify them. Higher frequency 
of palliative care visits was associated with lower receipt of chemotherapy at the EOL. 
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